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Abstract 
 
Neuroendocrine neoplasms (NENs) arise from cells within the diffuse 
neuroendocrine system. Five year survival may be as low as 30%.  
Chromogranin A (Cg A) is the best available NEN biomarker. Lack of 
standardisation between Cg A assays, makes direct comparison between them 
difficult. Comparison of diagnostic accuracy between four commonly used Cg A 
assays showed there was no significant difference in diagnostic accuracy when 
investigating NEN patients with/without liver metastases. Concordance between 
assays was variable and this was further examined to establish whether assays in 
combination may improve diagnostic accuracy. Cisbio and SAS were the least 
concordant and this combination was the most useful in predicting a NEN 
diagnosis.  
Calcitonin is the most sensitive and specific biomarker for medullary thyroid 
carcinoma. The study established local reference ranges for the new Diasorin
®
 
calcitonin assay and demonstrated that reference ranges quoted by the 
manufacturers would lead to increase in false positive results in the local 
population. Further, this study confirmed that the manufacturers’ recommendation 
to use diagnostic cut-offs established using the old Cisbio assay for this new assay 
needed revision. Thus, despite standardisation of antisera specificities, diagnostic 
cut-offs from one assay cannot be automatically extrapolated to another.   
None of the existing biomarkers fit the paradigm of a definitive NEN marker and 
hence the need for novel biomarkers. Circulating Cocaine and Amphetamine 
Regulated Transcript (CART) levels are elevated in NEN patients. This study 
demonstrated that circulating CART was increased in all types of NEN, particularly 
pancreatic NENs. While CART was expressed in all phaeochromocytoma tissues, 
expression in other NENs was variable. In addition to being a diagnostic marker, 
CART may also be a prognostic indicator as levels are higher in patients with 
progressive disease. Further long-term longitudinal studies are needed to fully 
assess the role of CART as a diagnostic and prognostic marker for NEN. 
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Chapter 1 : General Introduction 
 
1.1 The Diffuse Neuroendocrine System 
Neuroendocrine cells were first described in the 19
th
 century by anatomists 
studying the intestinal mucosa (1). They reported the presence of a small number of 
chromium and silver reactive cells that were morphologically different from the 
other more abundant mucosal cells. It was subsequently discovered that, unlike the 
other cells within the mucosa, these cells secreted their contents into the blood 
stream rather than the intestinal lumen (1).  
Since their discovery these cells have been variously named clear cells (due to the 
clear, faintly staining  cytoplasm on histology), argentaffin cells (due to reactivity 
to chromium and silver) and Kulchitsky cells (in honour of Nikolai Kulchitsky who 
studied these cells in considerable detail) (2). The term ‘neuroendocrine cells’ is 
now preferred as these cells function like endocrine cells and exhibit a number of 
distinct neural phenotypic features (3).  Like neurones, at the ultra-structural level, 
they are characterised by cytoplasmic, membrane-bound, dense-core secretory 
granules (diameter >80 nm). They also contain small clear vesicles (diameter 40 –
80 nm) that correspond to the synaptic vesicles of neurones (4). 
These cells were initially considered to share a common embryological origin and 
biochemical pathway. They were all thought to arise from the neural crest and have 
the ability to take up amines and decarboxylate them (hence the name APUD cells) 
(5). However, it is now known that these are a morphologically, functionally and 
embryologically diverse group of cells, some of which are derived from the neural 
crest and others from local multipotent stem cells (6). Although the mechanism 
underlying the differentiation is as yet poorly understood, a number of transcription 
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factors such as neurogenin 3 have recently been shown to govern the location-
specific development and differentiation of neuroendocrine cells (7).  At least 13 
different neuroendocrine cells have been identified in the gut alone (8).  
All neuroendocrine cells exhibit evidence of pro-hormone activity. They 
synthesise, store and secrete a wide array of hormones and/or peptides/ that mediate 
their actions via G protein coupled, tyrosine kinase or ion-gated receptors (9). The 
secretory products of neuroendocrine cells are stored in large dense core secretory 
vesicles and small synaptic-like vesicles. While as a general rule, different granules 
store individual peptides/hormones, two or more peptides/hormones may 
sometimes co-localise in the same granule (9, 10). A number of these 
peptides/hormones are true endocrine hormones (e.g. catecholamines), acting away 
from the site of their origin. Some are paracrine hormones (e.g. histamine) that act 
locally and others have a neurocrine (e.g. serotonin) function.  Neuroendocrine 
cells release these peptides by exocytosis in response to external stimuli (11). A 
number of different peptides can be secreted by a single type of neuroendocrine cell 
and it is conversely, not uncommon to find different neuroendocrine cell types 
secreting the same peptide.  
The term ‘diffuse neuroendocrine system’ was first coined in 1938 by the 
Friederich Feyrter, Professor of Pathology at the Medical Academy of Danzig, 
Poland, who described the presence of a complex system of ‘clear cells’ scattered 
throughout the gut and the pancreas (12,13). Since this original discovery in the 
gut, these cells have been shown to have a wide distribution throughout the body. 
Components of the diffuse neuroendocrine system can occur either as groups of 
cells within other endocrine glands such as C cells of the thyroid, adrenal 
medullary cells or the islet cells of the pancreas, or as single cells scattered within 
the gastrointestinal, respiratory or urogenital tracts. 
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1.2 Neuroendocrine Neoplasms 
Neuroendocrine neoplasms (NENs) are a group of neoplasms arising from cells that 
exhibit a neuroendocrine phenotype (14).  They were referred to as carcinoids in 
the past, a term derived from the word karzinoide, or "carcinoma-like". This term 
was first used by Siegfried Oberndorfer, a German pathologist, to describe their 
unique feature of behaving like benign tumours despite having a malignant 
appearance on histology (15, 16).  The term carcinoid is no longer preferred, 
although it is still sometimes used to describe serotonin secreting neuroendocrine 
neoplasms in the digestive system and the bronchopulmonary system. The term 
neuroendocrine tumour/carcinoma is now preferred (17). 
NEN account for 0.5 % of all malignancies and have an overall incidence of 5.25 
cases per 100,000 (18). The incidence has trebled in the recent years, probably as a 
result of greater awareness and better diagnostic modalities (19). Most NEN are 
sporadic. However, 1% show evidence of familial clustering and may occur as part 
of other neoplastic syndromes such as Multiple Endocrine Neoplasia (MEN 1 and 
2), neurofibromatosis type 1 and Von Hipple Lindau syndrome (19, 20). The most 
common primary sites for NEN are the gastrointestinal tract and the respiratory 
system accounting for approximately 66% and 31% of these tumours respectively 
(Figure 1-1)(21).  
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Figure 1-1: Topographic distribution of NENs 
Topographic distribution of 20,436 neuroendocrine (classical carcinoid) tumours 
derived from the Surveillance Epidemiology and End Results database 1973–2004. 
Approximately 66% of NENs are located in the digestive system (hatched bar), 
most commonly in the ileum and rectum (black bars: distribution in the different 
organs of the digestive system). Roughly thirty one percent of NENs occur in the 
bronchopulmonary system (white bar).  Reproduced from Gustafsson et al, 
Neuroendocrine tumors of the diffuse neuroendocrine system, Current opinion in 
Oncology (21). 
 
Presentation varies considerably, both in terms of symptoms and outcome. NEN 
may either be asymptomatic tumours that are discovered incidentally, or present 
with non-specific symptoms (non-functioning) or with specific hormone 
hypersecretion syndromes (functioning). As majority of NENs are asymptomatic or 
present with non-specific symptoms, diagnosis is often delayed by an average of 
five to seven years. Non-functioning NENs often present as metastatic disease.  
Prognosis is also variable. The Surveillance Epidemiology and End Results (SEER) 
database suggests that while the overall 5 year survival for NEN is 67% (22), the 
survival for pancreatic NEN varies from 97% in benign insulinomas to as low as 
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30% in clinically silent pancreatic NEN (22).  Despite a significant increase in 
incidence in the last 30 years, the 5 year survival has remained static (23), possibly 
reflecting a relatively small proportion of cancer research funding available to NEN 
research (15, 24). 
The 2010 WHO classification categorises NENs into three grades based on 
histology (Table 1-1). Grade 1 and 2 neoplasms are well to moderately 
differentiated, and have a low mitotic index. These are termed collectively as 
neuroendocrine tumours (NETs) while grade three tumours have a high mitotic 
index and are moderately to poorly differentiated and are termed neuroendocrine 
cancers (NEC) (17, 25). Well differentiated tumours express all the phenotypic 
characteristics of neuroendocrine cells on histology and may present as 
hyperfunctional syndromes depending on the hormone type secreted by the 
neoplasms. In contrast, poorly differentiated NENs usually present with fewer 
neuroendocrine phenotypic features and are unlikely to be associated with any 
specific hypersecretion syndromes (14). 
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Table 1-1: 2010 WHO grading system for neuroendocrine neoplasia.  
Mitotic count, the number of actively dividing cells per ten HPF; Ki 67 index, 
percentage of cells staining positive for the Ki 67 protein which is a marker for 
cellular proliferation; HPF, high-power field; NEC, neuroendocrine carcinoma; 
NET, neuroendocrine tumour (25)  
 
1.3 Neuroendocrine Neoplasm Markers 
A number of normal and abnormal forms of peptides and hormones secreted by 
NENs are routinely measured as markers of disease.  
1.3.1 General circulating  neuroendocrine markers 
NENs often express and secrete peptides that are common to most neuroendocrine 
cells and to cells that have undergone neuroendocrine differentiation. 
Granins 
Granins are major components of the dense core secretory vescicles and are co-
secreted with peptides and amines by the neuroendocrine cells. There are eight 
proteins within the granin family – chromogranin A (Cg A), chromogranin B 
(secretogranin I), secretogranins II – VI and VGF (26). They vary from 27 to 100 
kD and contain up to 10% acidic residues. Their functions are cell specific and 
depend on the presence of other granins, hormones and processing enzymes present 
within the cell. Of these, Cg A and B are the most well characterised and are 
routinely measured as biomarkers for NENs (27). Cg A and B are best measured in 
Classification 
Grading 
Grade 
Mitotic count 
(per 10 HPF) 
Ki 67 index 
(%) 
NET 1 <2 <2 
NET 2 2 - 20 3 - 20 
NEC 3 >20 >20 
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plasma. Fasting samples are not required (28). Samples must be centrifuged, 
plasma aliquoted and stored at -20C immediately after collection, to prevent 
peptide degradation. Patients on acid suppressive therapy should be advised to stop 
before Cg A is measured. 
Chromogranin A 
Chromogranin A (Cg A) has the widest distribution within the diffuse 
neuroendocrine system (29, 30) and is quantitatively the major constituent of the 
secretory granules in neuroendocrine cells. The human form of Cg A is an acidic 
439 amino acid protein that is preceded by an 18 amino acid signal peptide. Both 
the N and C terminals are well conserved between species. The Cg A molecule 
contains a number of mono and di-basic amino acid sites, thus implying fairly 
extensive and varied post-translational processing. A number of biologically active 
peptides like catestatin, pancreastatin and vasostatin are derived from 
chromogranin A through post translational enzymatic cleavage. Of these 
pancreastatin (detailed below) is measured as a NEN biomarker. 
A number of NENs are associated with increased circulating levels of Cg A. Cg A 
is routinely used as a marker for both diagnosis and monitoring of NENs. Cg A is 
particularly useful (i) when existing cell specific markers are either unstable, 
rapidly fluctuating or inconvenient for clinical use (ii) to confirm the 
neuroendocrine nature of a tumour and (iii) as a general marker of disease when the 
neoplastic disease involves multiple neuroendocrine tissues e.g. MEN (29). 
However, Cg A is not specific for NENs. A number of non-neoplastic conditions 
are associated with high Cg A levels including proton pump inhibitor (PPI) 
treatment (31), renal and liver impairment and hypergastrinaemic states (32). 
Nevertheless, Cg A is the most sensitive NEN marker available.   
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There are, however, a number of limitations to using Cg A. Due to the wide 
distribution of Cg A secreting cells, basal circulating concentrations are much 
higher than most peptide hormones. Therefore, an increase in Cg A levels due to a 
NEN often goes undetected until the tumour has reached a size capable of 
producing appreciably increased amounts of Cg A. Further, Cg A cannot 
differentiate between different subtypes of NEN and it is not equally expressed in 
all NENs. Some only weakly express Cg A e.g. bronchial small cell carcinoma of 
the lung (33). While most patients with metastatic foregut and midgut carcinoids 
have increased levels of Cg A, concentrations are only minimally elevated in 
patients with localised pancreatic NENs (32). Gastrinomas are associated with very 
high levels of Cg A even in patients with very limited disease (32).  
The overall diagnostic specificity and sensitivity of Cg A in NENs is 71.3 % and 
77.8% respectively (34). However, the sensitivity drops to <50% in early disease. It 
has a high negative predictive value of > 90% but the positive predictive value is 
poor, at around 50% or less depending on site of the tumour (34).  
Pancreastatin 
Pancreastatin is a 49-amino acid (Cg A 240-288) peptide produced by dibasic 
cleavage of Cg A. Pancreastatin assays that use antisera raised to the mid-molecule 
cross react strongly to Cg A and can be used to measure both pancreastatin and Cg 
A. Assays using antisera raised to the N or C terminals of pancreastatin are, 
however, specific for pancreastatin. It has been suggested that pancreastatin 
concentrations correlate with extent of liver involvement, but actual studies to 
support this are lacking (35). 
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Chromogranin B  
Chromogranin B (657 amino acid peptide) (Cg B) or GAWK (a partial sequence of 
Cg B 420-493) co-exists with Cg A in the secretory granules and bears a strong 
homology to Cg A in the terminal regions. Like Cg A, it is an acidic protein (36). 
The relative abundance of Cg A and Cg B is cell specific. Cg A is the dominant 
granin in pancreatic NENs and in ileal and appendiceal carcinoid tumours. 
However, in rectal carcinoids, where Cg A is virtually absent, Cg B is the most 
abundant granin (37). Unlike Cg A, Cg B is unaffected by renal impairment or use 
of PPI (38). It is, therefore, measured complementary to Cg A in some centres, and 
may improve diagnostic sensitivity by decreasing false positives secondary to PPI 
treatment and renal impairment (37).  
Neuron specific enolase 
α-γ and γ-γ isomers of the glycolytic enzyme phosphopyruvate hydratase, 2-
phospho-D-glycerate hydrolase occur mainly in neuronal and neuroectodermal 
tissue, and are collectively known as Neuron Specific Enolase (NSE). NSE is used 
specifically in the diagnosis and follow-up of patients with neuroblastoma and 
small cell carcinoma of lung, which are tumours that commonly express NSE (39). 
NSE is also increased in a few other NENs such as paragangliomas and 
insulinomas (40). It is, however, increased in a number of non-neuroendocrine 
neoplasms and thus is a less specific NEN diagnostic marker than Cg A. It is 
therefore not routinely measured as part of the standard NEN biomarker panel (40). 
Pancreatic polypeptide 
Pancreatic polypeptide (PP) is a 36 amino acid peptide secreted by the normal 
pancreas.    Levels are increased in 74% of gastropancreatic NENs and roughly 
50% of gut carcinoids (41). The term PPoma is used to describe tumours secreting 
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particularly high levels of PP (41, 42). Due to a significant response to food 
ingestion, PP is best measured in plasma samples taken after an overnight fast. 
Samples must be centrifuged, plasma aliquoted and stored at -20C immediately 
after collection, to prevent peptide degradation. 
Cocaine and Amphetamine Regulated Transcript (CART) 
CART was first identified as an mRNA transcript by Douglas et al in 1995 when 
studying the effects of cocaine and amphetamine on the rat brain (43). It was found 
to be upregulated following acute administration of cocaine and amphetamine. This 
initial study showed increased expression in neuroendocrine cells and neurones 
within the paraventricular, supra-optic and arcuate nuclei of the hypothalamus. 
CART has subsequently been shown to be present in the human brain with a 
similar distribution to the rat brain (44). Further studies have shown that CART is 
widely expressed in other neuroendocrine cells and neurones including those in the 
pituitary (45), adrenal medulla (45), gut (46) and pancreas (47). Electron 
microscopy studies have isolated the intracellular location of CART to cytoplasmic 
dense core vesicles (48). Although a specific receptor has not yet been identified, 
studies suggest that CART probably acts via a G protein coupled CART receptor 
(49).   
The function of CART in body weight homeostasis (50), reward and reinforcement 
pathways (51), anxiety (52), stress (53) and pancreatic islet cell function (54) has 
been extensively studied. 
In addition to normal neuroendocrine cells and neurones in the hypothalamus, 
pituitary, adrenals and pancreas, CART has been shown to be expressed by a 
number of NENs including phaeochromocytomas (55), glucagonoma (56) and 
insulinoma (54). In 2008, Bech et al conducted a preliminary study of circulating 
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plasma CART levels in patients with NENs compared to healthy normal controls 
(57). This study demonstrated higher plasma levels of CART in patients with both 
functioning and non-functioning NENs. In particular, pancreatic NENs were 
associated with very high CART levels. This raised the possibility of CART as a 
novel NEN marker. CART’s role as a prognostic marker and marker of therapeutic 
response has not yet been studied. 
1.3.2 Markers for specific NENs 
In addition to the general markers mentioned above, cell-specific hormones 
secreted by NENs may be used as a marker for diagnosis, monitoring and 
surveillance of these tumours (Table 1-2). While hypersecretion of some of the 
cell-specific hormones are associated with pathognomonic symptoms (e.g. 
hypoglycaemia secondary to hypersecretion of insulin in insulinomas) others may 
be associated with non-specific/no symptoms (e.g. hypersecretion of calcitonin by 
medullary thyroid carcinomas) or unusual symptoms due to ectopic secretion of 
hormones (e.g. growth hormone/adrenocorticotropic hormone (ACTH)/parathyroid 
hormone related peptide).  
Dynamic function tests may sometimes improve the diagnostic sensitivity of 
hormone measurements. Common examples include the pentagastrin stimulation 
test for medullary thyroid carcinoma (MTC) and the 72 hour fasting test for 
insulinomas.  
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Table 1-2: Common hypersecretion syndromes, principal hormone/peptide 
secreted, commonest location of primary and clinical manifestation 
 
 
 
 
 
 
 
 
NEN subtype Peptide/Hormone Location Clinical Features 
Insulinoma Insulin pancreas 
Features of 
hypoglycaemia – 
confusion, dizziness, 
sweating, weakness – 
alleviated by eating 
Gastrinoma Gastrin 
pancreas, 
duodenum,  
stomach 
Severe dyspeptic 
symptoms, peptic 
ulceration and diarrhoea 
Glucagonoma Glucagon pancreas 
Necrolytic migratory 
erythema, diabetes, 
weight loss, diarrhoea and 
stomatitis 
VIPoma 
Vasoactive 
Intestinal Peptide 
(VIP) 
pancreas, 
foregut 
Profuse watery diarrhoea, 
hypokalemia and 
achlorhydria 
Somatostatinoma Somatostatin 
pancreas, 
foregut 
Cholelithiasis, diarrhoea, 
weight loss, diabetes 
mellitus, steatorrhoea 
Carcinoid 
 
5HIAA 
(5 hydoxy-
indoleacetic acid) 
(24 hour urine 
levels measured) 
GI tumours 
with liver 
metastases, 
primary 
bronchial 
tumours 
Flushing, wheeze, 
breathlessness, diarrhoea, 
clinical manifestations of 
pellagra 
Medullary thyroid 
carcinoma (MTC) 
Calcitonin thyroid Non specific symptoms 
Phaeochromocytoma/ 
paraganglioma 
Catecholamines 
and metanephrines 
(24 hour urines and 
plasma levels) 
adrenal 
medulla, 
sympathetic and 
parasympathetic 
ganglia 
Headache, sweating, 
palpitations, anxiety and 
raised blood pressure 
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1.3.3 Circulating markers that are not specific to NENs 
Human chorionic gonadotropin 
The alpha subunit of the glycoprotein hormones and/or β-HCG is elevated in about 
25% of patients with NENs including carcinoids, islet cell tumours, MTC and small 
cell lung cancer. Locally invasive NENs are associated with increased β-HCG and 
alpha subunit tissue peptide expression and circulating levels (58).  β-HCG is 
therefore sometimes used as a prognostic indicator for NENs. 
Carcinoembryonic antigen 
Carcinoembryonic antigen (CEA) is an onco-foetal glycoprotein and was initially 
described as a biomarker for colorectal cancer. It has since been shown to be 
increased in a number of cancers including NENs such as MTC. American Thyroid 
Society guidelines recommend measurements of CEA in conjunction with 
calcitonin for diagnosis and monitoring of patients with MTC (59). CEA is a good 
prognostic marker as higher levels and shorter doubling times are suggestive of less 
differentiated aggressive tumours with poorer prognosis (60, 61) 
1.3.4 Tissue markers  
Diagnostic markers 
Cg A and synaptophysin are used as immunocytochemical diagnostic markers for 
NENs and are routinely used to confirm the neuroendocrine origin of a tumour. 
Synaptophysin is an integral membrane protein of the small clear vescicles and is 
diffusely expressed in all normal neuroendocrine cells and NEN cells (62). Cg A is 
expressed in the matrix of the large dense core granules and its distribution in the 
NEN cell is proportional to the density of the dense core granules (62).    
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Markers for specific NENs 
Immunohistochemistry of expression of certain cell specific hormones such as 
insulin, gastrin, serotonin in metastatic deposits of an unknown primary may aid in 
identifying the site of origin of the tumour (62). For example, serotonin expressing 
tumours mainly arise in the ileum, gastrin in the duodenum or pancreas, and those 
expressing glucagon in the pancreas. They may also be used to establish the 
functional nature of a tumour (62).     
Prognostic markers 
Ki 67 is not specific for NENs, and is expressed in all actively dividing cells. It is 
used as an immunocytochemistry (ICC) marker for cellular proliferation. It is a 
proliferation antigen, which is expressed in G1, S, G2, and
 
M phases of the mitotic 
cycle. Cells in G0 phase (resting phase) of the mitotic cycle do not express Ki 67. 
As a result, actively proliferating tumour cells have a higher expression of Ki 67 
using ICC. Ki 67 proliferation index is a measure of its expression in the cell, based 
on the number of Ki 67 positive cells on ICC. Increased expression of Ki 67 is 
associated with a poorer prognosis (63).  
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1.4 Limitations of the Currently Available NEN Biomarkers 
There are a number of analytical limitations to the measurement of NEN markers. 
Many of these peptides undergo extensive post-translational modifications and 
hence circulate as a mixture of molecularly heterogeneous forms. Several of these 
forms may contribute to the overall biological activity of the peptide. Analytical 
measurements of peptides are invariably used to estimate biological function. 
Therefore accurate estimation of biological function is only possible if all 
functionally active isoforms are recognised by the assay.  However, measurement 
of a combination of these morphologically and functionally diverse peptide forms 
in plasma can be difficult (64, 65).  
Levels of the peptide measured are dependent on the antiserum used in the assay, as 
immunoassays will only detect those peptide fragments that contain the epitope 
recognised by the antiserum. Thus, there is usually significant variation between 
methods and the results obtained using different methods are often not comparable. 
Monoclonal antibodies recognise a specific site on the peptide and hence usually 
compound the problems associated with heterogeneous molecular forms. In 
contrast, polyclonal antisera recognise a larger number of fragments. To decrease 
the risk of false negative results, the antibody used must cross-react with as many 
forms of the peptide as possible. Polyclonal antibodies raised against a combination 
of heterogeneous forms are likely to be associated with fewer false negative results. 
However, no single antiserum is capable of recognising all fragments or forms of 
the peptides under investigation, and inevitably, some tumours will present with 
tumour marker concentrations within the reference range. As assays using different 
antisera are not directly comparable, it may not always be possible to accurately 
extrapolate the clinical implications of results obtained using one assay to another. 
Consensus regarding epitopes measured may improve comparability and 
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concordance between assays. Nevertheless, it is important to note that even assays 
using antisera raised against the same epitope may not be equivalent as differences 
in affinity, avidity and cross-reactivity profiles may exist. 
Choice of calibration standard for NEN marker assays can also be challenging. In 
the absence of international standards, NEN marker assays often use different 
standards. This again leads to significant between-method differences. International 
reference preparations are available for certain peptides such as gastrin (66/138, 
non WHO reference material, National Institute of Biological Standards and 
Control, UK). However, this reference preparation is porcine and is significantly 
different to the gastrin forms present in human plasma. Using this, or a similar 
standard to calibrate assays measuring plasma gastrin in humans would not only 
make the assays inaccurate, but also make comparison between assays impossible.  
Problems associated with standardisation of human chorionic gonadotropin (HCG) 
assays were recently partially resolved by a decade long endeavour to prepare an 
international standard containing all diagnostically significant forms of HCG and 
antisera preparations that recognise all these forms (66). While the development of 
standardised antisera and robust reference standards for all assays measuring 
heterogeneous peptides is desirable, it is usually a very laborious and lengthy 
undertaking and may not always be feasible due to practical or financial 
constraints. In the absence of standardisation, a clear nomenclature, improved 
understanding of what the different assays measure, and information regarding 
differences in assay performance, concordance and diagnostic accuracy, would be 
invaluable for a laboratory seeking to introduce an assay into their repertoire (64).  
The different assays for a NEN tumour marker may be discordant in detecting the 
presence or absence of disease and the diagnostic accuracy of the assays may be 
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variable. It is the responsibility of the local clinical biochemistry departments to 
ensure that their clinicians are aware of the method differences and the risks of 
automatically extrapolating clinical decision limits, sensitivity and specificity data 
from the literature obtained by using one method to another. This is particularly 
important if these clinical decision limits are being used to screen otherwise 
asymptomatic individuals for significant prophylactic/therapeutic intervention.  
Aside from the problems associated with standardisation, none of the currently 
available markers fit the paradigm for an ideal tumour marker. An ideal tumour 
marker would be one that is secreted exclusively by the tumour cells and is useful 
(i) for screening and diagnosis of NEN (ii) as a prognostic indicator (iii) as an 
estimate of tumour burden and (iv) as a surveillance tool. None of the currently 
available markers are sensitive or specific enough to justify their use as screening 
tools for NENs in the general population. They are however routinely used for 
surveillance of patients with a genetic predisposition to NENs. Even in these 
patients, NEN markers often remain within the reference range until a tumour is 
visible on imaging, thus adding no specific diagnostic advantage over imaging 
modalities. The discovery of new markers capable of detecting the presence of a 
NEN at a size below the resolution of imaging modalities will be particularly useful 
in management of these patients.  
Ki 67 index is most commonly used as a prognostic marker for NENs (25). 
However, NEN tumour tissue is often not amenable for biopsy and analysis. None 
of the currently available circulating biomarkers can reliably predict prognosis. 
Although there is evidence to suggest that raised Cg A results are associated with 
poorer prognosis, no definite correlation between Cg A levels and survival has as 
yet been established (27). Further, none of the currently available circulating NEN 
tumour markers can reliably predict disease progression or response to therapy. 
26 
 
Discovery of new circulating NEN tumour markers capable of predicting 
prognosis, progression and response to therapy will enable more effective 
management of patients through personalised follow up and treatment plans. A 
prognostic marker and a marker for disease progression will allow streamlining of 
resources through introduction of individualised surveillance protocols.  
The work in this thesis focuses on the diagnostic accuracy of some well established 
circulating NEN markers including Cg A and calcitonin. The comparative 
diagnostic accuracy between four Cg A assays commonly used across UK and 
Europe and the appropriateness of applying diagnostic cut-offs from one calcitonin 
assay to another will be examined. The role of the novel NEN marker CART in 
diagnosis and prognosis will be explored. 
 
 
 
 
 
 
 
 
 
 
27 
 
Chapter 2 : Comparison of diagnostic accuracy 
of four Chromogranin A assays 
2.1 Introduction 
2.1.1 Chromogranin  A 
Chromogranin A (Cg A) is a soluble acidic thermostable glycoprotein first 
identified in the adrenal medulla (30). It is widely expressed in endocrine and 
neuroendocrine cells and has been localised to the dense core secretary granules 
within these cells. There is a considerable interspecies homology, particularly at the 
C and N terminal ends of the protein (67). 
Cg A is coded for by a single copy 15 kilobase gene located on chromosome 14.  
The gene contains 8 exons.  Exon I encodes  the  5’-noncoding  region  and  the 
majority  of  the  signal  peptide  coding  region.  Exon VI encodes a variable 
domain within which is the chromostatin (Cg A 124 -143) sequence.  Exon VII 
encodes another variable domain, which contains the pancreastatin (Cg A 250 – 
301) sequence. Exon VIII encodes the highly conserved carboxyl-terminal domain 
and the 3’-noncoding region. Exons II-V collectively encode the highly conserved 
amino-terminal domain (67).  The biosynthesis of Cg A is regulated by a number of 
factors including steroid hormones that activate the protein kinase A and C 
pathways (67). Base sequences lying between -55 and + 32 base pairs relative to 
the transcription initiation site contain the TATA box and the cyclic AMP response 
element, and are responsible for neuroendocrine cell-specific expression (67). 
Cg A is synthesised in the rough endoplasmic reticulum and inserted into the rough 
endoplasmic reticulum cisternae via a signal peptide. It is then transported into the 
trans golgi network (TGN) where it is sorted into secretory granules for regulated 
secretion. While the constitutive pathway is present in all cell types and allows 
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proteins to be secreted as soon as they are synthesised, secretion by the regulated 
pathway in endocrine cells allows for proteins to be synthesised and stored in the 
secretory granules until a metabolic need arises. Granulogenesis is initiated when 
the highly conserved N and C terminal sequences of the Cg A molecule bind to 
cholesterol rich domains of the TGN membrane via proteins such as secretogranin 
III in a cell specific manner to initiate the process of granulogenesis. During this 
process, Cg A molecules also chaperone a number of other pro-hormones into the 
granules by forming aggregates with these pro-hormones in the acidic calcium rich 
environment of the golgi apparatus, and then drawing them towards the newly 
forming secretory granules. The pro-hormones are cleaved by both endo and 
exopeptidases within the dense core granules to form mature hormones and then 
co-secreted with Cg A into the circulation by calcium/secretogogue stimulated 
exocytosis. Cg A thus plays an important role in granulogenesis and processing of 
hormones for secretion by the regulated secretory pathway (Figure 2-1) (67). 
The Cg A molecule itself also has a number of dibasic amino-acid pairs which are 
potential sites for cleavage by intracellular endo and exopeptidases and 
extracellular proteins such as plasmin. Indeed, it is now known that Cg A may itself 
be a pro-hormone for a number of peptides such as Vasostatin I (Cg A 1-113) and 
II (Cg A 1 – 76), Chromofugin (Cg A 44 – 66), Pancreastatin (Cg A 250 – 301), 
WE14 [Cg A 316 – 329, N terminal tryptophanyl (W) and C terminal glutamyl (E)] 
(68), Catestatin (Cg A 344 – 364), Parastatin (Cg A 347 – 419) and Chromostatin 
(Cg A 124 – 143) (Figure 2-2). Evidence for biological activity of Cg A derived 
peptides has been growing since the discovery of a role for pancreastatin (Cg A 250 
– 301) in glucose homeostasis in 1986 (69). Cg A derived peptides may play a role 
in parathyroid hormone secretion (69), carbohydrate and lipid metabolism (70, 71), 
catecholamine secretion (72), (73) inflammatory response and reproduction (74). 
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Figure 2-1: Secretory pathways and dense core granule biogenesis in (neuro) 
endocrine cells. 
Cg A and pro-hormones synthesised  in the rough endoplasmic reticulum (RER), are 
transported to the golgi complex, aggregated and bound to cholesterol-rich  membrane  
micro-domains  in  the  trans-Golgi  network (TGN) via  sorting receptors such as 
Secretogranin III (Sg III) and Carboxypeptidase E (CPE) respectively. Aggregated and 
bound Cg A and pro-hormones induce the budding  of  the TGN  membrane  to  form  the  
dense  core  granule in the regulated  secretory  pathway. Pro-hormones and Cg A  are  
cleaved by proteases within the granules to yield  biologically  active  peptides.  
Stimulation of the granules by secretagogues triggers exocytosis and secretion of 
hormones. In contrast, vesicles of the constitutive secretory pathway present in all cell 
types release their contents without stimulation. Reproduced from Koshimizu H et al, 
Chromogranin A: a new proposal for trafficking, processing and induction of granule 
biogenesis, Regulatory Peptides 160 (2010) 153–159(75) 
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Figure 2-2: Schematic representation of the structure of Cg A  
This shows the whole Cg A (1-439) molecule with 18 amino acid signal peptide 
(blue bar) and peptides (amino acid sequence) derived from Cg A. 
 
2.1.1.2 Chromogranin A as a NEN marker 
Chromogranin A (Cg A) is the best available tissue and serum marker for 
neuroendocrine neoplasms, and is routinely used for diagnosis and monitoring of 
these tumours (27, 29, 76, 77). Cg A may also be increased in a number of other 
conditions such as, liver impairment (78), pregnancy (79), hypertension (80) and 
hypergastrinemia due to any cause including treatment with PPI (81).  However, 
very high levels of Cg A are usually due to NENs or occasionally due to treatment 
with proton pump inhibitors (PPI) (82). Circulating concentrations of Cg A (38, 83, 
84), and those of the other neuroendocrine markers such as CART and Cg B (38) 
are known to increase with renal impairment. However, the extent of the effect of 
varying degrees of renal impairment on the circulating concentrations of these 
peptides is unclear. This makes the interpretation of results of circulating 
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concentrations of these biomarkers in NEN patients with renal impairment difficult.  
Approximately 8% of adults in the UK have been estimated to have chronic kidney 
disease (CKD) (85). Thus, it is likely that a small proportion of NEN patients may 
also have some degree of renal impairment. An understanding of the effects of 
varying degrees of renal impairment on concentrations of NEN biomarkers will 
enable better interpretation of results in a patient with NEN and renal impairment. I 
therefore examined the effects of renal impairment on circulating concentrations of 
Cg A and of two other neuroendocrine tumour markers, Cg B and CART, both of 
which are described and studied in greater detail in a subsequent chapter (Chapter 
4). 
The specificity for Cg A is variable depending on tumour type and burden. Even 
small gastrinomas are associated with high Cg A levels, while insulinomas of a 
similar size almost never present with Cg A levels above the reference range (86). 
Metastatic mid-gut NENs are associated with the highest levels of Cg A (86). There 
is moderate correlation between Cg A levels and tumour burden (87). A study 
looking at 128 NEN patients found that the sensitivity of Cg A was 29% for loco-
regional disease and 67% for NENs with distant metastases (86, 88). However the 
low negative predictive value of Cg A for metastases means that Cg A alone cannot 
be used as a marker for diagnosis of metastatic disease in NEN. Cg A may be 
useful in predicting recurrence following radical resection of NENs (86). However, 
its role as a prognostic marker has not been fully established (27). Clinical 
interpretation of Cg A results may be limited by the considerable heterogeneity 
between commonly available Cg A assays. The Cg A molecule undergoes 
extensive and varied post-translational processing. Such processes are often 
impaired in tumour cells. NENs may therefore release different molecular forms of 
Cg A. The diagnostic accuracy of an assay depends upon antibody specificity and 
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the molecular forms it recognises. An assay that recognises more forms is likely to 
have better diagnostic accuracy (89). Although several commercial Cg A assays are 
currently available, the forms of Cg A detected by these assays vary due to 
differences in antibody specificities and assay design. This makes direct 
comparison between assays problematic (88). Adequate information regarding 
concordance between these assays and their comparative diagnostic accuracies is 
not currently available. In the absence of standardisation and quality assurance 
schemes, a laboratory seeking to introduce a chromogranin A assay into their 
repertoire would find information regarding the comparative diagnostic accuracies 
and concordance invaluable. This information will allow laboratories to make an 
informed decision regarding choice of Cg A assay and also allow meaningful 
extrapolation of results of research studies into routine clinical practice. 
This study was designed to compare the diagnostic accuracy of the Imperial supra-
regional assay service radioimmunoassay (RIA) (SAS Hammersmith Hospital, 
Imperial College, London) and three commercial Cg A assays (Cisbio, DAKO and 
Eurodiagnostica). These assays all use different antisera. The SAS assay is a 
competitive radioimmunoassay utilising polyclonal antisera raised against the 
whole pancreastatin molecule, which is a 51-amino acid (Cg A 250-301) fragment 
produced by dibasic cleavage of the 439 amino acid Cg A peptide (57). 
Eurodiagnostica is a competitive radioimmunoassay which uses polyclonal 
antibodies raised against Cg A fragment 116-439. Cisbio is an ELISA assay and 
uses two monoclonal antibodies directed against the amino acid sequences 145–197 
and 198–245 of Cg A. In contrast, DAKO is an ELISA using two polyclonal 
antibodies directed against a 23kD C terminal fragment of Cg A  (88) (Figure 2-3). 
Raised levels of Cg A may remain undetected by an assay if the molecular form 
secreted by a particular patient is not recognised by that assay. On this basis, I 
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predicted discordance between the diagnostic results obtained when using the 
above mentioned four assays. I hypothesised that discordance between Cg A 
assays could be exploited to improve NET diagnosis. 
 
 
 
Figure 2-3: Schematic representation of the chromogranin A (Cg A) molecule 
and epitopes against which antibodies were raised for SAS, Cisbio, DAKO and 
Eurodiagnostica (ED) assays. 
Cg A is a 439 amino acid (aa) peptide. SAS is a competitive RIA and uses a 
polyclonal antibody directed against aa 250-301. Cisbio is an ELISA and uses two 
monoclonal antibodies directed against aa 145–197 and 198–245. DAKO is an 
ELISA and uses two polyclonal antibodies directed against a 23kD C terminal 
fragment of Cg A (aa sequence not specified by manufacturer).  Eurodiagnostica 
(ED) is a competitive RIA and uses a single polyclonal antibody raised to 
fragment 116-439.  
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2.2 Hypotheses and Aims  
2.2.1 Hypotheses 
I hypothesised that 
1. circulating concentrations of  NEN biomarkers increase with worsening renal 
impairment. 
2. discordance between Cg A assays exists and can be exploited for NEN diagnosis. 
3. different NEN tumour types may release different molecular forms of Cg A and 
hence the comparative diagnostic accuracy of the assays may vary with tumour 
type. 
2.2.2 Aims 
1. To examine the effects of renal impairment on circulating concentrations of Cg A 
and two other NEN biomarkers, Cg B and CART.  
2. To compare diagnostic accuracy of the Imperial supra-regional assay service 
radioimmunoassay (SAS Hammersmith Hospital, Imperial College, London) and 
three commercial Cg A assays (Cisbio, DAKO and Eurodiagnostica). 
3. To investigate the concordance between the four assays. 
4. To investigate if using a combination of assays improves NEN diagnosis. 
5. To investigate the comparative diagnostic accuracy of the assays in different 
NEN tumour types. 
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2.3 Methods 
Ethical approval for the study was obtained from Hammersmith and Queen 
Charlotte's & Chelsea Research Ethics Committee (08/H0707/143, 04/Q0406/80). 
The study was carried out at two NEN centres in London, UK (Imperial College 
Healthcare NHS Trust and Royal Free Hampstead NHS Trust).  
2.3.1 Collection of Samples 
Patients with renal impairment for examining the effects of renal impairment on 
Cg A, Cg B and CART concentrations 
Samples from 107 patients with different stages of renal impairment [patients with 
an estimated glomerular filtration rate (eGFR) of < 60 ml/min/1.73m
2
] were 
obtained and irreversibly anonymised as per Royal College of Pathology, UK 
guidelines (90). All samples were collected in an EDTA tube, spun within 15 
minutes of collection at 10,000g for 10 minutes. Plasma was then stored at -20ºC 
until analysis. Cg A, Cg B and CART concentrations were measured using an in-
house radioimmunoassay (57) (Appendix 1) at the Gut Hormone SAS, ICHNT, 
UK. 
Patients for comparing diagnostic accuracy of four Cg A assays 
The Imperial College Healthcare NHS Trust Supra-regional Assay Service (SAS) 
gut hormone laboratory is a national service for Cg A measurement. NEN samples 
for this study were selected from routine clinical samples received from Imperial 
College Healthcare NHS Trust and Royal Free Hampstead NHS Trust. These 
samples were collected as per routine protocol into plasma EDTA BD

 vacutainer 
tubes, centrifuged at 1200xg for 10 minutes within 15 minutes of collection and 
transported to and stored in the SAS laboratory at -20
◦
C until they were assayed in 
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batches. The diagnosis of NEN was confirmed using clinical investigations and 
histology.   Patients with a previous diagnosis of NEN but with no current evidence 
of residual disease on imaging or endoscopy were considered to be in clinical 
remission and excluded from the analysis. Blood samples from 125 patients with 
confirmed NENs who were not in remission were selected: Sixty mid-gut 
carcinoids (n = 62), gastro-pancreatic non-carcinoid NENs (n = 26), bronchial 
carcinoids (n = 7), phaeochromocytomas/paragangliomas (n = 7), renal NEN (n = 
2) and unknown primary (n = 21). Thirty-one of these 125 patients had no evidence 
of liver metastases. One hundred and eight of these patients (28 without liver 
metastases) had no evidence of renal impairment as determined by an eGFR of > 
60 ml/min/1.73m
2
 and/or serum creatinine levels below the upper limit of reference 
range 
Healthy volunteers 
Samples from healthy volunteers were collected following informed consent. 
Previous studies have shown that there is no significant post-prandial increase in 
plasma Cg A levels (28). Therefore, a single non-fasting sample was collected from 
one hundred and eight healthy controls (54 female and 54 male, age range 21 – 65 
years). The a priori strategy was used for selecting volunteers for sampling. This 
involved selecting a reference population from a group of healthy volunteers 
working at Imperial College Healthcare NHS Trust. Volunteers on medications 
causing hypergastrinaemia (e.g. PPIs), pregnant women and patients with renal 
impairment or liver disease were excluded from the study as Cg A may be 
increased in these patients (76). A ten ml blood sample was collected from each 
volunteer into plasma EDTA BD

 vacutainer tubes. Samples were centrifuged at 
1200xg for 10 minutes within 15 minutes of collection. Aliquots of serum were 
stored at -20
◦
C until they were assayed in batches.  
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Non-NEN cancer patients 
Forty-one patients with cancers other than NENs (non-NENs) (6 colon, 2 gall 
bladder, 1 liver, 2 rectal, 2 stomach, 7 pancreatic, 7 lung, 1 adrenal, 7 ovarian, 3 
testicular, 1 choriocarcinoma, 1 glioblastoma and 1 prostate) were recruited 
following informed consent. Patients who were pregnant, had renal disease, or were 
taking PPI were again excluded from the study as described above (76). As above, 
a single 10 ml non-fasted blood sample was collected into EDTA BD
®
 Vacutainer 
tubes. Samples were centrifuged at 1200xg for 10 minutes within 15 minutes of 
collection. Aliquots of serum were stored at -20
◦
C until they were assayed in 
batches. 
2.3.2 Measurement of Cg A 
Cg A was measured in all samples (108 healthy controls, 125 NEN patients and 41 
non-NET patients) using the Imperial SAS radioimmunoassay (SAS) and three 
different commercial assays (Cisbio, DAKO, Eurodiagnostica). Samples were 
processed and analysed following manufacturer’s recommendations for each kit 
(57, 88, 89) 
SAS RIA 
The SAS method is the in-house sensitive and specific manual RIA method 
(detailed in Appendix 1) routinely used for measuring Cg A at the Imperial College 
SAS laboratory. 
Cg A antibody for SAS assay 
The SAS assay is a competitive radioimmunoassay utilising polyclonal antisera 
raised against porcine pancreastatin amide (Peninsula, CA, USA), which is a 49-
amino acid fragment produced by dibasic cleavage of the Cg A peptide (57). It had 
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full cross reactivity with human pancreastatin (91). While antisera raised against 
the carboxy-terminal of pancreastatin are specific for pancreastatin, those raised 
against the whole molecule, cross-react with Cg A (92). The antiserum was used at 
a final dilution of 1:79000. 
Eurodiagnostica  
The Eurodiagnostica kit is a competitive manual radioimmunoassay utilising a 
single rabbit polyclonal antibody raised against human Cg A fragment 116-439 and 
an 
125
I labelled tracer. A Cg A fragment purified from the urine of patients with 
carcinoid tumours is used as standard.  The fragment contains the Cg A 116-439 
sequence and is expressed in nmol/L (88). The assay range is 0.4 – 50 nmol/L. The 
assay was performed as per standard laboratory protocol supplied with the kit. 
Cisbio 
The Cisbio assay is an ELISA. The range of the assay is 7 – 1200 ng/ml. The 
standard is recombinant human Cg A produced in E. coli (93) and the concentration 
is expressed in ng/ml. It utilises two monoclonal antibodies directed against Cg A 
amino acid sequences 145 -197 and 198 - 245. The capture antibody is fixed to the 
surface of a well, while the detection antibody is conjugated to peroxidise. Addition 
of the chromogenic substrate to the wells produces a light reaction. The intensity of 
the resulting light reaction is proportional to the concentration of Cg A present in 
the well. The light reaction is stopped by adding sulphuric acid and the absorbance 
is measured at 450nm. The assay was performed as per standard laboratory 
protocol supplied with the kit.  
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DAKO 
The DAKO assay is an ELISA. The range of the assay is 5 - 450 U/L. It uses a 
23kD C-terminal fragment as standard and two polyclonal antibodies directed 
against this fragment. The capture antibody is fixed to the surface of a well, while 
the detection antibody is conjugated to peroxidise. Addition of the chromogenic 
substrate to the wells produces a light reaction. The intensity of the resulting light 
reaction is proportional to the concentration of Cg A present in the well. The light 
reaction is stopped by adding the stop solution provided and the absorbance is 
measured at 450nm. The assay was performed as per standard laboratory protocol 
supplied with the kit. 
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2.4 Statistics 
To examine the effect of renal impairment, patients were divided into groups 
according to chronic kidney disease (CKD) stages: Stages I and II (eGFR: ≥ 60 
ml/min/1.73m
2
); Stage IIIA (eGFR: 45-59 ml/min/1.73m
2
); Stage IIIB (eGFR: 30-
44 ml/min/1.73m
2
); Stage IV (eGFR: 15-29 ml/min/1.73m
2
); Stage V (eGFR: <15 
ml/min/1.73m
2
)
 
and Cg A, Cg B and CART concentrations were analysed by 
Kruskal-Wallis one-way ANOVA using Dunn’s multiple comparison test to 
examine for significant differences between healthy volunteers and different CKD 
stages.  
The diagnostic accuracies of the assays were determined by constructing receiver-
operator-characteristic (ROC) curves using Cg A concentrations in healthy 
volunteers as a control group and Cg A concentrations in patients with NENs as the 
disease group (controls versus NENs).  The diagnostic accuracy of the assays in 
detecting NENs without liver metastases was also assessed using Cg A 
concentrations from healthy volunteers as the control group and patients with 
NENs without liver metastases as the disease group. To assess the specificity of the 
assays in diagnosing tumours of neuroendocrine origin, ROC curves were used to 
determine the changes in diagnostic accuracy when patients with non-NENs were 
included in the control group. The area under the curve (AUC) for each ROC curve 
was calculated and the AUCs compared to assess their comparative diagnostic 
accuracy (94). Spearman’s rank correlation was used to examine the concordance 
in Cg A values obtained by the four assays. The change in the likelihood of having 
a diagnosis of a NEN, with one unit increase in the value of Cg A on the log scale 
(odds ratio), was calculated for each assay using univariate logistical regression. A 
multivariate logistical regression was also performed to determine if measuring two 
or more assays in combination improved diagnostic accuracy. A backwards 
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selection procedure was employed to retain only the statistically significant 
(p<0.05) factors.  
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2.5 Results 
2.5.1 Measurement of plasma Cg A concentrations in healthy volunteers 
The values obtained for plasma Cg A concentrations in healthy controls were 
positively skewed, and thus not normally distributed.  
Cg A concentrations using the Cisbio assay trended to be higher in males when 
compared to females. However, analysis showed that there was no statistically 
significant difference (Mann-Whitney U test, p > 0.1) in circulating Cg A levels 
between male (n=54) and female volunteers (n = 54) observed when using the 
Cisbio or any of the other three assays studied (Table 2-1). Results from patients at 
extremes of age within my control population (twelve patients over 50 years of age 
and 20 patients aged 25 years and under) were compared using the Mann-Whitney 
U test to investigate the possibility of age specific differences in circulating Cg A 
concentrations. Although there is a trend towards higher levels in the older cohort 
with the DAKO assay, no significant difference was observed (p > 0.1) with either 
the DAKO or any of the other assays (Table 2-2).  
 
Assay 
Male (n = 54) 
(Median, interquartile 
range) 
Female (n = 54) 
(Median, interquartile 
range) 
SAS 28, 10 - 42 pmol/L 27, 5 – 36 pmol/L 
Cisbio 49, 34 – 76 ng/ml 40, 29 – 54 ng/ml 
DAKO 34, 13 – 60 U/L 40, 20 – 78 U/L 
Eurodiagnostica 6, 5 – 10 nmol/L 8, 5 – 20 nmol/L 
 
Table 2-1: Gender specific Cg A concentrations 
 
Concentrations are expressed as median, interquartile range in 54 female and 54 male 
volunteers. No significant differences were observed (p >0.1). 
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Table 2-2: Age related Cg A concentrations  
 
Concentrations are expressed as median, interquartile range in twelve volunteers over 
50 years and 20 patients under 25 years. No significant differences were observed (p 
>0.1) 
 
Using this cohort of healthy controls, the diagnostic cut-off values for Cg A 
recommended by the manufacturers were at the following percentiles: 95
th
 for SAS 
(cut off value 60 pmol/L), 85
th 
for Cisbio (cut off value 94 ng/ml), 45
th 
for DAKO 
(cut off value 18 U/L) and 85
th 
for Eurodiagnostica (cut off value 10 nmol/L) 
(Figure 2-4). 
 
 
 
 
 
 
 
 
Assay 
Age ( > 50 years) 
(Median, interquartile 
range) 
Age ( < 25 years) 
(Median, interquartile 
range) 
SAS 20, 6 – 37 pmol/L 32, 10 – 44 pmol/L 
Cisbio 41, 26 – 76 ng/ml 42, 34 – 59 ng/ml 
DAKO 64, 15 – 88 U/L 23, 10 – 63 U/L 
Eurodiagnostica 7, 5 – 21 nmol/L 5, 3 – 24 nmol/L 
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Figure 2-4 Plasma Cg A measured using SAS, Cisbio, DAKO and 
Eurodiagnostica assays.  
Cg A (median and inter-quartile range) measured in healthy controls (n=108), 
non-NENs (n=41) and NENs (n=125). The dotted line corresponds to the 
manufacturer’s recommended diagnostic cut-off for each assay: SAS (60pmol/L), 
Cisbio (94 µg/L i.e. 94 ng/ml), DAKO (18 U/L) and Eurodiagnostica (10 nmol/L). 
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2.5.2 Assessment of the effect of renal impairment on circulating Cg A , Cg B and 
CART concentrations 
Forty volunteers from the healthy controls described in section 2.5.1 had all three 
peptides, Cg A, Cg B and CART measured. Median (range) concentrations for the 
healthy control group were: Cg A = 29 pmol/L (22-47), Cg B = 70 pmol/L (55-
111), and CART = 56 pmol/L (22-84). Biomarker levels in healthy controls were 
compared to the 107 patients with renal impairment [CKD stage I and II (n = 17), 
stage IIIA (n = 19), stage IIIB (n = 22), stage IV (n = 20) and stage V (n = 29)]. For 
all three biomarkers, concentrations increased with decreasing eGFR, with highest 
median concentrations detected in patients with eGFR <15 (Figure 2-5).  
Forty percent of patients with eGFR ≥60ml/min/1.73m2 had increased Cg A, a 
percentage that rose to 100% with an eGFR of less than 29. The highest plasma 
concentration of Cg A measured was 489pmol/L (laboratory reference range <60 
pmol/L) (Figure 2-5).  Cg B concentrations were less affected by renal function 
than Cg A concentrations. Only 16% of patients with eGFR values between 29-16 
had increased concentrations, while 84% of patients with eGFR of <15 had raised 
Cg B concentrations.  The highest concentration of Cg B measured was 232 pmol/L 
(laboratory reference range <150 pmol/L) (Figure 2-5). Plasma CART 
concentrations were normal in patients with eGFR ≥60, but were increased in 80% 
of patients with eGFR of <15. The highest concentration of CART measured was 
494 pmol/L (laboratory reference range <125 pmol/L) (Figure 2-5). 
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Figure 2-5 : Plasma levels of Cg A, Cg B and CART increase with decreasing 
estimated glomerular filtration rate (eGFR) 
Anonymised patient samples (107) were categorised according to their eGFR 
ml/min/1.73m2 value: 90-60 (CKD stage 1+II, n=17), 45-59 (CKD stage IIIA, n=19), 30-
44 (CKD stage IIIB, n=22), 15-29 (CKD stage IV, n=20), <15 (CKD stage V, n=29), control 
indicates healthy subject group (n=40). A one-way ANOVA with Dunn’s post test 
compares CKD stage groups against healthy volunteers for each biomarker; ns=not 
significant (P>0.05); *= P<0.05; ***= P<0.001. Dashed line indicates normal upper limit 
for each biomarker. 
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2.5.3 Assessment of the accuracy of Cg A assays in NEN diagnosis 
Cg A concentration was measured in 125 samples from patients with NENs. Patient 
demographics are detailed in Table 2-3.  
 
NEN patients   
Total number 125  
NEN without renal impairment 108 
Age  
Range  27 – 89 years 
Median 65 years 
Sex  
Male 64 
Female 61 
Location of Primary tumour   
Pancreatic 26 (22 without RI) 
Mid-gut 62 (53 without RI) 
Phaeochromocytoma/paragangliomas 7 (5 without RI) 
Kidney 2 (2 without RI) 
Bronchial 7 (7 without RI) 
Unknown Primary 21 (19 without RI) 
 
 
Table 2-3: Patient Demographics. RI = renal impairment  
The AUC for ROC curves for controls vs. NENs, controls vs. NENs without liver 
metastases and controls + non-NENs vs. NENs for all four assays are detailed in 
Table 2-4. The analysis indicated that when each assay was examined separately 
(univariate analysis), Cg A levels in all four assays were positively correlated with a 
diagnosis of NEN i.e. higher Cg A levels associated with greater odds of having a 
NEN diagnosis. All four assays had good diagnostic accuracy with AUC 
significantly greater than 0.5 (AUC > 0.80, p<0.0001). There was no significant 
difference in the AUC (p > 0.05) and hence diagnostic accuracy between the 
individual assays in any of the cohorts (controls vs. NENs, controls vs. NENs 
without liver metastases and controls + non-NENs vs. NENs) studied.  
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Table 2-4: Univariate analysis of diagnostic accuracy of individual Cg A assays  
 
Each assay was examined separately for association of Cg A with NEN/NEN 
without liver metastasis occurrence (univariate analysis). The odds ratio (OR) is 
the increase in the likelihood of a NEN diagnosis with every one unit increase in Cg 
A concentration on a log scale. The higher the area under the ROC curve (AUC), 
the greater the diagnostic accuracy of the assay. Controls = healthy controls (n = 
108), NENs = all NEN patients (n = 125), non-NENs = cancers other than NENs (n 
= 41), NENs without liver metastases (n = 31). p = < 0.05 was considered 
statistically significant. 
 
However, none of the assays positively identified all patients with NENs. Further, 
not all patients had correspondingly high Cg A levels by all four assays. Consistent 
with this, the concordance between assays was variable (Table 2-5). While Cisbio 
and Eurodiagnostica were the most concordant (correlation coefficient: controls and 
NENs 0.75, controls and NENs without liver metastases 0.54, controls and non-
NENs and NENs 0.75), Cisbio and SAS assays were the least (correlation 
coefficient: controls vs. NENs 0.43, controls vs. NENs without liver metastases 
Assay OR (95% CI) p-value for OR AUC  
Controls vs. NENs 
SAS  8.9 (4.2, 19.6) <0.001 0.81  
Cisbio 3.7 (2.6, 5.2) <0.001 0.82 
DAKO 3.1 (2.3, 4.3) <0.001 0.84  
Eurodiagnostica 5.1 (3.2, 8.1) <0.001 0.81  
Controls vs. NENs without liver metastases 
SAS  6.0 (2.3, 15.5) <0.001 0.74 
Cisbio 4.2 (2.5, 7.0) <0.001 0.79  
DAKO 3.3 (1.9, 4.8) <0.001 0.78  
Eurodiagnostica   6.7 (3.2, 14.1) <0.001 0.79  
Controls  + Non-NENs vs. NENs 
SAS    10.0 (4.9, 20.4) <0.001 0.81  
Cisbio 3.1 (2.4, 4.1) <0.001 0.80  
DAKO 3.1 (2.3, 4.1) <0.001 0.83  
Eurodiagnostica 4.8 (3.2, 7.2) <0.001 0.80  
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0.22, controls + non-NENs vs. NENs 0.40). This is likely to reflect the degree of 
overlap between the epitopes used to raise antisera for Eurodiagnostica and Cisbio. 
In contrast, there is no overlap between the epitopes used to raise antisera for Cisbio 
and SAS (Figure 2-3). Interestingly, the results of a post-hoc analysis of 
concordance between assays using only healthy controls showed that there was no 
significant concordance between Cisbio and SAS, SAS and Eurodiagnostica and 
DAKO and Eurodiagnostica. Cisbio and Eurodiagnostica remained significantly 
concordant (Table 2-5). The most likely explanation for the observed differences in 
degree of concordance between assays when only healthy controls versus when 
diseased patients were studied, is the secretion of different molecular forms of Cg A 
secreted in health and disease. 
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Table 2-5: Assessment of concordance between Cg A assays 
Correlation coefficients (and associated p values) using Spearman’s correlation to 
examine the association between the four assays for Controls, NENs, NENS 
without liver metastases and non-NENs + NENs. The higher the correlation 
coefficient, the stronger the relationship between the two assays. Controls (n= 
108), NENs = all NEN patients (n = 125), non-NENs = cancers other than NENs 
(n = 41), NENs without liver metastases (n = 31). P = < 0.05 was considered 
statistically significant. 
 
Assay 1 Assay 2 
Correlation 
Coefficient 
 
p-value 
 
NENs 
SAS Cisbio 0.43 <0.001 
SAS DAKO 0.56 <0.001 
SAS Eurodiagnostica 0.46 <0.001 
Cisbio DAKO 0.70 <0.001 
Cisbio Eurodiagnostica 0.75 <0.001 
DAKO Eurodiagnostica 0.66 <0.001 
NENs without liver metastases 
SAS Cisbio 0.22 <0.001 
SAS DAKO 0.35 <0.001 
SAS Eurodiagnostica 0.29 <0.001 
Cisbio DAKO 0.50 <0.001 
Cisbio Eurodiagnostica 0.54 <0.001 
DAKO Eurodiagnostica 0.35 <0.001 
Non-NENs plus NENs 
SAS Cisbio 0.40 <0.001 
SAS DAKO 0.52 <0.001 
SAS Eurodiagnostica 0.43 <0.001 
Cisbio DAKO 0.68 <0.001 
Cisbio Eurodiagnostica 0.75 <0.001 
DAKO Eurodiagnostica 0.64 <0.001 
Controls 
SAS Cisbio 0.006 .98 
SAS DAKO 0.22 0.02 
SAS Eurodiagnostica 0.03 0.74 
Cisbio DAKO 0.31 0.001 
Cisbio Eurodiagnostica 0.41 <0.001 
DAKO Eurodiagnostica 0.12 0.22 
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The results above suggest that a single Cg A assay, irrespective of the assay used, 
may not always detect raised circulating Cg A in a NEN patient. To investigate if 
using two Cg A assays improves NEN diagnosis, a multivariate analysis was 
performed (Table 2-6). All four assays were entered into the analysis in the first 
instance. Assays that failed to remain significant on multivariate analysis (i.e. p > 
0.05) were then excluded and the analysis repeated. In controls vs. NENs, SAS, 
Cisbio and DAKO remained significant. This suggested that there was diagnostic 
benefit in using all three assays in combination. Consistent with this, the 
combination of SAS (p<0.001), Cisbio (p<0.001) and DAKO (p = 0.03) gave an 
AUC of 0.89. This was higher than any AUC achieved when using each assay 
independently (Table 2-4). Thus, using these assays in combination is likely to 
detect more patients with NENs than any other combination or single assay alone. 
The results suggest that adding Eurodiagnostica assay to this combination is 
unlikely to result in a significant increase in the number of patients. This is because 
the patients detected by the Eurodiagnostica assay would most likely have been also 
detected by one of the other three assays. However, the DAKO assay made less of a 
contribution to this improved diagnostic accuracy as suggested by the higher p 
value (p = 0.03). Similarly, in controls + non-NENs vs. NENs, the combination of 
SAS, Cisbio and DAKO Cg A assays also provided a greater diagnostic accuracy 
(AUC 0.87) (Table 2-3) compared to each of the four assays alone. Again, DAKO 
made a smaller contribution (p = 0.01) to this increased AUC.  
In NEN patients without hepatic metastases, there was no significant difference in 
diagnostic accuracy between the individual assays (univariate analysis, Table 2-4). 
However, subsequent multivariate analysis confirmed that a combination of assays 
did not improve NEN diagnosis in this patient cohort and in this analysis, Cisbio 
was the only assay significantly associated with NEN diagnosis (AUC 0.79, 
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p<0.001) (Table 2-6).  This suggests that the Cisbio assay may be most useful in 
NEN diagnosis in patients without hepatic metastases. Thus, there is unlikely to be 
any significant increase in the number of patients detected when using Cg A assays 
in combination in this patient cohort.  
 
Table 2-6: Multivariate analysis of diagnostic accuracy of Cg A assays in 
combination  
The four Cg A assays were examined together in a multivariate analysis to 
establish whether a combination of assays was better than any one individual 
assay. A backwards selection procedure was employed to retain only the 
statistically significant factors. This involves removing the non-significant factors, 
one at a time, retaining only those variables found to be statistically significant. 
Controls = healthy controls (n = 108), NENs = all NEN patients (n = 125), non-
NENs = cancers other than NENs (n = 41), NENs without liver metastases (n = 
31). OR = odds ratio, AUC = area under ROC curve, CI = confidence intervals. p 
= <0.05 is considered statistically significant. 
 
 
 
 
 
 
Assay OR (95% CI) p-value AUC 
Controls vs. NENs 
SAS 6.2 (2.5, 15.3) <0.001 
0.89 Cisbio 2.3 (1.5, 3.5) <0.001 
DAKO 1.5 (1.1, 2.2) 0.03 
Controls vs. NENs without liver metastases 
Cisbio 3.5  (2.0, 6.1) <0.001 0.79 
Controls  + Non-NENs vs. NENs 
SAS 6.9 (3.0, 15.8) <0.001 
0.87 Cisbio 1.8 (1.3, 2.6) 0.001 
DAKO 1.6 (1.1, 2.3) 0.01 
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2.5.4 Assessment of comparative diagnostic accuracy of Cg A assays in NEN 
patients without renal impairment 
The aim of the above study was to assess the diagnostic equivalence of the four 
assays rather than the exact sensitivities and specificities of each of the assays. In 
the results described in the previous section, it was assumed that Cg A measured by 
all assays would be equally affected by renal impairment and hence would not 
affect the comparative diagnostic accuracy of the assays tested.  The NEN patient 
samples were therefore not screened for renal impairment. However, following the 
completion of the study looking at the effects of renal impairment on circulating 
NEN marker concentrations (which was completed subsequent to the work 
comparing the four assays), a post-hoc analysis was carried out to investigate 
whether the inclusion of patients with renal impairment did influence these results 
or would likely impact on the comparative diagnostic accuracy of the assays when 
used in the future.  
Creatinine and eGFR results of the NEN patients at the time of sample collection 
were retrieved from electronic patient records and laboratory information systems. 
Eight patients had serum creatinine results above the reference range, two of whom 
had creatinine levels greater than 150 µmol/L. However, 17 patients, including 
these eight, had eGFR levels < 60 ml/1.73 m
2
. Results were re-analysed following 
exclusion of all individuals with eGFR values < 60 ml/1.73 m
2
. Univariate analysis 
of the diagnostic accuracy of the individual assays suggested that there was no 
significant difference between the assays (Table 2-7). 
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Table2-7: Univariate analysis of diagnostic accuracy of individual Cg A assays for 
NENs without renal impairment 
Each assay was examined separately for association of Cg A with NEN/NEN 
without liver metastasis occurrence (univariate analysis). AUC = Area under ROC 
curve. Controls = healthy controls (n = 108), NENs = all NEN patients (n = 108), 
non-NENs = cancers other than NENs (n = 41), NENs without liver metastases (n 
= 28).There was no significant difference in AUC between the assays in any of the 
groups studies. p = < 0.05 was considered statistically significant. 
 
SAS and Cisbio remained the least concordant assays on re-analysis following 
exclusion of NEN patients with renal impairment (Table 2-8). The results of 
multivariate analysis investigating the beneficial effect of using a combination of 
assays on diagnostic accuracy also remained unchanged (Table 2-9).  
 
Assay OR (95% CI) p-value for OR AUC  
Controls vs. NENs 
SAS  4.05 (2.6, 6.2) <0.001 0.80 
Cisbio 8.1 (4.1, 14.7) <0.001 0.81 
DAKO 2.0  (1.5, 2.5) <0.001 0.83 
Eurodiagnostica 2.7 (1.9, 4.0) <0.001 0.80 
Controls vs. NENs without liver metastases 
SAS  3.5 (2.1, 5.8) <0.001 0.75 
Cisbio 7.6  (4.0, 14.3) <0.001 0.80 
DAKO 3.4 (2.9, 4.9) <0.001 0.77 
Eurodiagnostica   2.6 (1.6, 4.1) <0.001 0.79 
Controls  + Non-NENs vs. NENs 
SAS    3.9  (2.7, 5.6) <0.001 0.80 
Cisbio 3.6  (2.5, 5.2) <0.001 0.78 
DAKO 2.2 (1.7, 2.7) <0.001 0.81 
Eurodiagnostica 3.12 (2.2, 4.5) <0.001 0.78 
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Table2-8: Assessment of concordance between Cg A assays for NENs without 
renal impairment  
Correlation coefficients (and associated p values) using Spearman’s correlation to 
examine the association between the four assays for NENs, NENS without liver 
metastases and non-NENs + NENs. The higher the correlation coefficient, the 
stronger the relationship between the two assays. NENs = all NEN patients (n = 
108), non-NENs = cancers other than NENs (n = 41), NENs without liver 
metastases (n = 28). P = < 0.05 was considered statistically significant. 
 
 
 
 
 
Assay 1 Assay 2 
Correlation 
Coefficient 
 
 
p-value 
 
NENs 
SAS Cisbio 0.38 <0.001 
SAS DAKO 0.52 <0.001 
SAS Eurodiagnostica 0.41 <0.001 
Cisbio DAKO 0.66 <0.001 
Cisbio Eurodiagnostica 0.71 <0.001 
DAKO Eurodiagnostica 0.60 <0.001 
NENs without liver metastases 
SAS Cisbio 0.23 0.01 
SAS DAKO 0.35 <0.001 
SAS Eurodiagnostica 0.29 <0.001 
Cisbio DAKO 0.50 <0.001 
Cisbio Eurodiagnostica 0.54 <0.001 
DAKO Eurodiagnostica 0.36 <0.001 
Non-NENs +  NENs 
SAS Cisbio 0.35 <0.001 
SAS DAKO 0.48 <0.001 
SAS Eurodiagnostica 0.38 <0.001 
Cisbio DAKO 0.65 <0.001 
Cisbio Eurodiagnostica 0.72 <0.001 
DAKO Eurodiagnostica 0.59 <0.001 
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Table2-9: Multivariate analysis of diagnostic accuracy of Cg A assays in 
combination for NEN patients without renal impairment 
The four Cg A assays were examined together in a multivariate analysis to 
establish whether a combination of assays was better than any one individual 
assay. A backwards selection procedure was employed to retain only the 
statistically significant factors. This involves removing the non-significant factors, 
one at a time, retaining only those variables found to be statistically significant. 
Controls = healthy controls (n = 108), NENs = all NEN patients (n = 108), non-
NENs = cancers other than NENs (n = 41), NENs without liver metastases (n = 
28). OR = odds ratio, AUC = area under ROC curve, CI = confidence intervals. p 
= <0.05 is considered statistically significant. 
 
 
 
 
 
 
 
 
 
Assay OR (95% CI) p-value AUC 
Controls vs. NENs 
SAS 1.03 (1.01, 1.05) 0.004 
0.89 Cisbio 1.01(1.00, 1.01) 0.004 
DAKO 1.01 (1.00, 1.02) 0.04 
Controls vs. NENs without liver metastases 
Cisbio 1.01  (1.00, 1.01) <0.001 0.78 
Controls  + Non-NENs vs. NENs 
SAS 1.03 (1.01,1.05)   <0.001 
0.87 Cisbio 1.00(1.00, 1.00)   0.006 
DAKO 1.01 (1.00, 1.02) 0.01 
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2.5.5 Comparison of diagnostic accuracy in different sub-types of NENs 
Although samples from NEN patients were not collected with the aim of comparing 
the diagnostic accuracy of individual assays in different NEN sub-types, a post-hoc 
analysis was carried out to assess if differences in the epitopes recognised by each 
of the assays resulted in differences in comparative diagnostic accuracy between 
the assays when individual NEN sub-types (without renal impairment) were 
considered separately. Optimal diagnostic cut-offs offering the best combination of 
sensitivity and specificity for each assay were determined using ROC analysis 
[SAS 43 pmol/L, Cisbio 100 ng/ml, DAKO 46 U/L and Eurodiagnostica 13 
nmol/L]. The number of patients with levels above these cut-offs in each NEN sub-
type were then determined (Table 2-10). While the numbers of all other sub-types 
were too small to make a comparison, the diagnostic accuracy for all four assays 
for mid-gut tumours were compared using ROC curve analysis and no significant 
difference in accuracy was found (p > 0.1) [AUC (95 % confidence limits) : SAS 
0.83(0.76 – 0.88), Cisbio 0.82 (0.76 – 0.88), DAKO 0.86 (0.80 – 0.91), ED 0.82 
(0.75 – 0.87)].  
Location of Primary 
Number of patients with Cg A concentrations above the 
optimal diagnostic cut-off 
NEN sub-type (total 
number of patients) 
SAS 
(43 pmol/L) 
Cisbio 
(>100 ng/ml) 
DAKO 
(> 46 U/L) 
ED 
(13 nmol/L) 
Gastro-Pancreatic (n = 22) 14 (64%) 16 (73%) 16 (73%) 14(64%) 
Mid-Gut (n=53) 39 (74%) 42 (79%) 45 (85%) 32 (60%) 
Bronchial (n=7) 4 (57%) 4(57%) 4(57%) 3(43%) 
Ph/PGs (n=5) 3 (60%) 4(80%) 3(60%) 3(60%) 
Kidney (n=2) 2 (100%) 1(50%) 1(50%) 1(50%) 
Unknown Primary (n=19) 15(79%) 14(74%) 15(79%) 14(74%) 
 
Table 2-10: Patients with elevated Cg A concentrations in each NEN sub-type 
 
Number of patients (percentage) in each NEN subtype with Cg A levels above the 
optimal diagnostic cut-off is shown. Ph/PGs = phaeochromocytomas/paragangliomas 
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2.6 Discussion 
The results of my study assessing the effect of renal impairment on concentrations 
of Cg A, CART and Cg B confirm that circulating levels increase with increasing 
renal impairment. The accuracy of GFR estimation decreases at near-normal levels 
of kidney function, and it is therefore common clinical practice to report values 
over 60 ml/ min/1.73m
2
 as eGFR as ≥ 60ml/ min/1.73m2. As a result, eGFR cannot 
be used to distinguish between individuals with normal renal function and those 
with CKD stages I (eGFR ≥ 90 ml/ min/1.73m2 but other evidence of renal disease 
present) and II (eGFR 60 - 89 ml/ min/1.73m
2
). The eGFR ≥ 60ml group in our 
study therefore likely included patients with mild renal impairment (CKD stages I 
and II).  
While there was no significant difference in circulating Cg B and CART 
concentrations, circulating Cg A concentrations were significantly increased 
(P=0.0358) in patients in the eGFR ≥60ml/min/1.73m2  compared to healthy 
volunteers. These results are interesting because they suggest that while all three 
peptides are affected to varying degrees by renal impairment, Cg A may rise with 
even relatively mild renal impairment (eGFR ≥60ml/min/1.73m2). Interestingly, no 
patients with renal impairment had Cg A or CART concentrations above 
500pmol/L or Cg B concentrations above 250pmol/L. Therefore, at these higher 
cut-offs, although the diagnostic sensitivity of these NEN markers is low (Cg A 
20% at 500 pmol/L; CART 17% at 500pmol/L; Cg B 12% at 250pmol/L), the 
diagnostic specificity for NEN diagnosis is very high (100% for all three 
biomarkers). Thus these markers are likely of some use even in patients with severe 
renal impairment, and patients with concentrations greater than these higher cut-
offs should be investigated for NENs, even in the presence of end stage renal 
impairment. 
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Cg A is the most commonly used marker for diagnosis and monitoring of NENs 
(27, 76). However, direct comparison between Cg A assays is problematic, due to 
differences in antiserum, assay design, units of measurement and recommended 
diagnostic cut-offs. There are significant differences in sensitivities and 
specificities, quoted in the literature, between Eurodiagnostica, DAKO and Cisbio 
assays (88). Comparing the percentile positions of the diagnostic cut-offs 
recommended by the manufacturers, the cut-offs fell at significantly different 
positions on the percentile score of our local reference population. While the cut-
offs for Eurodiagnostica and Cisbio both stood at the 85
th
 percentile, DAKO was 
placed much lower, at the 45
th
 percentile and SAS much higher at the 95
th
 
percentile. Unsurprisingly, DAKO appeared the most sensitive (89%) and SAS the 
most specific (95%) Cg A assay. Thus, it is likely that the apparent differences in 
the sensitivities and specificities, quoted in the literature, are due to choice of 
diagnostic cut-offs used. Any gain in increased sensitivity obtained by placing the 
cut-off at a lower percentile must be balanced against a potential increase in false 
positives as a result of decreased specificity. The trade-off between sensitivities and 
specificities for each of these assays was assessed by constructing ROC curves. The 
results suggested that it was possible to achieve comparable sensitivities and 
specificities by choosing a diagnostic cut-off stood at equivalent points on the 
percentile score; SAS cut-off 54.5 pmol/L, sensitivity 42 % and specificity 95%, 
Cisbio cut-off 127 ng/ml, sensitivity 56 % and specificity 95%, DAKO cut-off 
74.4 U/L, sensitivity 56 % and specificity 94% and Eurodiagnostica cut-off 12.6 
nmol/L, sensitivity 56 % and specificity 100%. Thus consensus regarding 
desirable sensitivities and specificities will allow establishment of more appropriate 
cut-offs.   
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It has been suggested that assays using antibodies raised against pancreastatin have 
a higher specificity for NENs with liver metastases (35). Notably, the SAS assay 
utilises polyclonal antisera raised against the whole pancreastatin molecule.  
However, comparing the diagnostic accuracy of the assays in NEN patients without 
liver metastases, there was no significant difference between the four assays. In 
NEN patients without liver metastases, all four assays individually (univariate 
analysis) demonstrated similar diagnostic accuracy. 
Interestingly, all four assays performed less well when patients with non-NEN 
cancers were included in the control group. This reflects those non-NEN cancers 
with Cg A levels above the 95
th
 percentile: 1/41 (SAS), 11/41 (Cisbio), 4/41 
(DAKO) and 5/41 (Eurodiagnostica). Evidence suggests many cancer tissues may 
undergo neuroendocrine differentiation (95). This may account for the raised Cg A 
levels in the non-NEN cancer group and thus the apparent reduction in diagnostic 
accuracy. Neuroendocrine differentiation is not routinely reported on histology of 
non-NEN cancers and thus it was not possible to confirm that this was the cause of 
elevated Cg A levels in this group.  
As described earlier, NENs release different molecular forms of Cg A (42). The 
assays described in this study all recognise different epitopes of the Cg A molecule. 
Levels of Cg A measured are thus dependent on the molecular forms detected by 
the antiserum used. Although all four assays showed comparable diagnostic 
accuracy for NENs when used independently, there were significant differences in 
concordance between assays. This suggests that the populations of NEN patients 
recognised by the four assays varied.  Therefore, negative results by one Cg A 
assay should prompt analysis by another assay, particularly if the clinical suspicion 
of NEN is high. This may be important not only for diagnosis, but also for 
subsequent follow up of patients. The assay that best detects the forms of Cg A 
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secreted by a specific patient can then be used for all further monitoring. Cisbio and 
SAS were the least concordant and the most significant diagnostic markers on 
multiple logistic regression analysis. Hence, it may be beneficial to have this 
combination in a laboratory’s repertoire as it is most likely to detect more forms of 
Cg A and hence a greater number of NEN patients than any other single or 
combination of assays. In NEN patients without liver metastases, Cisbio was the 
only Cg A assay significantly associated with NEN diagnosis in the multivariate 
analysis. Thus, Cisbio may be the preferred assay in NEN patients without hepatic 
metastases, with no additional benefit from combining any of the other three assays 
with this assay.  Thus, in a heterogeneous NEN patient population, a Cg A assay 
combination which includes the Cisbio assay may be particularly useful to improve 
diagnosis of NEN patients with and without hepatic metastases. Re-analysis 
following exclusion of NEN patients with renal impairment did not significantly 
alter these findings. It is possible that any potential impact of differences in renal 
handling of fragments recognised by the four assays was not picked up in this study 
due to a relatively small number of patients with renal impairment. Examining the 
specific fragments of Cg A increased in renal impairment alone and in NEN 
patients with renal impairment may help to determine the optimum diagnostic 
procedure for putative NEN patients with renal impairment. When patients with 
different NEN subtypes were considered separately, the percentage of mid-gut 
carcinoid patients with elevated Cg A levels was highest using the DAKO assay, 
although this was not statistically significant. Number of patients in each of the 
other sub-types, were too small to allow any definite conclusions to be drawn. 
Future studies measuring biochemical markers in larger numbers of patients with 
specific NEN subtypes are required to establish whether using these assays in 
combination improves diagnostic accuracy in all sub-types.  
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This study confirms that there is no significant difference in NEN diagnostic 
accuracy between the four assays alone. However, the lack of standardisation 
between them means that the same assay must be used for serial measurements in a 
patient to allow meaningful interpretation (76). While practical on an individual 
patient basis, interpreting changes in Cg A concentrations analysed by different 
methods between patient groups in multi-centre studies and establishing 
international guidelines is difficult. The first step towards increased comparability 
between the assays is characterisation of all the clinically significant forms of Cg 
A. Portela-Gomes et al examined the distribution of different epitopes of Cg A in 
20 NEN patients using 11 region specific antibodies (96). They found that highest 
circulating levels were found for the N terminal domain of vasostatin-I (Cg 1-17), 
the N-terminal domain of chromostatin (Cg A 116 -130), and for the C-terminal 
domain of pancreastatin (Cg A 284 -301) and WE14 (Cg A 324 – 337). These 
results would suggest that a polyclonal antibody directed against an epitope which 
includes amino acid sequence Cg A 116 – 337 would be have the best diagnostic 
accuracy as this would detect the intact Cg A molecule and also the cleaved peptide 
products chromostatin, pancreastatin and WE 14. This is likely to be the rationale 
for the use of polyclonal antisera raised against Cg A 116 – 439 by 
Eurodiagnostica, as Portela-Gomes et al provided the technical expertise for the 
assay. However, interestingly the current study shows that although concordance 
was variable, diagnostic accuracy using antisera directed against Cg A 116 – 439 
was no higher than with the SAS assay, which is likely to detect intact Cg A and 
pancreastatin but not chromostatin or WE 14, or with the Cisbio assay, which is 
likely to only detect intact Cg A.  
Most Cg A is released from the secretory granules in an intact from and only a 
small proportion is released as cleaved peptides (75). Indeed the circulating 
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concentration of intact Cg A has been shown to be a thousand fold higher than Cg 
A derived peptides (75). In addition, the proportion of unprocessed peptides 
released by neoplastic cells is usually higher compared to secretion by normal 
neuroendocrine cells (75).  Therefore the diagnostic equivalence between these 
assays may be due to comparable affinity and avidity of the assays for intact Cg A. 
Any differences in the ability to recognise individual peptides become insignificant 
due to relatively small circulating concentrations of the peptides. The differences in 
concordance between assays when only healthy controls versus diseased population 
were studied, provide further evidence for differences in circulating molecular 
forms of Cg A in health and disease. Again, the improvement in condordance when 
diseased populations were studied could be explained by the presence of a higher 
proportion of unprocessed intact peptide which is recognised by all four assays.  
While this theory of a higher proportion of intact Cg A in disease could explain 
diagnostic equivalence and relative improvement in concordance, it does not 
explain the variability in concordance. A further study looking at the differences in 
Cg A peptide signatures in health and different NEN sub-types may allow further 
characterisation of disease specific forms of Cg A. This information may then be 
used for development of more accurate Cg A assays for NEN diagnosis. Further, 
development of an external quality assurance scheme distributing real clinical 
samples will allow real-time comparison of the various assays and provide useful 
information regarding the strengths and weaknesses of each assay.  Information 
thus gathered will be invaluable when developing more robust and diagnostically 
accurate Cg A assays with more clinically appropriate antibody specificities. 
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Chapter 3 : Medullary Thyroid Carcinoma and 
calcitonin 
 
3.1 Background 
3.1.1 Medullary thyroid carcinoma (MTC) 
C cells are neuroendocrine cells that account for roughly 0.1% of the granular mass 
of the thyroid gland. They are located either singly or in groups within the thyroid 
follicles and are most numerous at the junction of the upper third and lower two 
thirds of the thyroid gland. These cells are most often found in the periphery of the 
follicular walls and are therefore also known as parafollicular cells.  They are 
responsible for the secretion of the hormone calcitonin (97).  
 Medullary thyroid carcinoma (MTC) arises from these parafollicular C cells of the 
thyroid gland. The National Cancer Institute’s Surveillance, Epidemiology, and 
End Results (SEER) program’s data for thyroid cancer cases reported between 
1992–2006, suggests that MTC accounts for about 2.5% of all thyroid cancers (98). 
The study also compared the incidence of MTC in Hispanics, Asians, Whites and 
Blacks and calculated the incidence risk ratio between men and women in each 
racial group. The incidence of MTC was found to be the highest among Hispanics. 
There was no significant difference in incidence between men and women in any 
racial group except for Whites, where women had a small but significantly 
increased risk (incidence risk ratio for women vs. men was 1.3). The gender 
disparity decreased with increasing age (99).  
The majority of MTC cases are sporadic (non-familial) with the incidence peaking 
between the fourth and sixth decades (100). Commonest clinical presentation in 
sporadic disease is a thyroid nodule and 20% of patients have evidence of 
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metastases at diagnosis (100). Twenty five percent of cases of MTC are hereditary. 
They are inherited as an autosomal dominant trait, and may be either transmitted 
alone as Familial MTC (FMTC) or as part of Multiple Endocrine Neoplasia (MEN) 
2 syndrome. The clinical manifestations associated with MEN 2 are MTC, 
phaeochromocytoma and hyperthyroidism (101). FMTC and MEN 2 result from 
one of a number of different mutations in the RET proto-oncogene, a 21 exon gene, 
which encodes a membrane tyrosine kinase receptor (102-104, 105). Presentation is 
much earlier in the hereditary forms of MTC, and varies depending on the germline 
mutation involved. De novo germ line mutations have been found in 4-10% of 
patients with MEN2A and FMTC and in most cases of MEN2B (100). Interestingly 
de novo mutations are most often found on the allele inherited from the father 
(106). Apart from this, somatic mutations, limited to the tumour cells are found in 
roughly 30% of sporadic MTC (107).  
MTC is a well differentiated thyroid tumour and tumour cells maintain the physical 
and functional features of the parent parafollicular cells. Hence in a majority of 
cases, the tumour cells continue to secrete calcitonin and elevated calcitonin levels 
are highly suggestive of disease. Prognosis for early disease is good, with a 10-year 
survival of 100% for localised disease (108). Unfortunately, since MTC is 
frequently associated with non-specific symptoms, patients often present with 
distant metastatic disease, which has a five year survival of just 40% (109). Early 
diagnosis allows complete resection and improves survival (110). Therefore 
relatives of index cases with known RET mutations are offered genetic testing and 
are offered prophylactic total thyroidectomy. Relatives who are either mutation 
negative or decline surgery should be followed up with annual basal and stimulated 
calcitonin levels (100). 
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Further, since almost all patients with clinically detectable MTC have raised 
circulating calcitonin levels and the majority (75%) of MTC cases are sporadic, a 
number of prospective studies recommend routine measurement of plasma 
calcitonin in all patients presenting with a thyroid nodule  (111,112, 113). It has 
been suggested that serum calcitonin was a better predictor of MTC than fine 
needle aspiration cytology and the patients detected thus, had a better prognosis due 
to earlier detection (113, 112) 
3.1.2 Calcitonin 
Calcitonin, is a 32-amino acid linear polypeptide secreted by parafollicular C cells 
(114). It is encoded by the CALC1 gene located on chromosome 11p. By the 
mechanism of alternate splicing, the CALC1 gene can form 2 distinct mRNAs; the 
calcitonin mRNA and calcitonin Gene Related Peptide (CGRP) mRNA. While 
calcitonin mRNA is found exclusively in thyroid tissue, CGRP mRNA is widely 
expressed in the dorsal and ventral horns of the spinal cord and in the 
hypothalamus, preoptic area, ventromedial thalamus, medial amygdala, 
hippocampus, superior colliculus, lateral lemniscus and dentate gyrus nervous 
system (115, 116). 
Mature calcitonin is derived from post translational modification of a 141 amino 
acid precursor, preprocalcitonin. Preprocalcitonin first undergoes cleavage of a 
signal peptide to form procalcitonin, a prohormone consisting of 116 amino-acid 
residues. Procalcitonin contains within it, a 57 amino acid peptide PAS -57 in its 
amino terminal end and a 21 amino acid peptide, calcitonin carboxyterminal 
peptide-1 (CCP-1 or Katacalcin), at its carboxy terminal end. The immature 
calcitonin peptide consisting of 33 amino-acids is located centrally within the 
procalcitonin molecule. The mature, active, 32 amino-acid calcitonin is produced 
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from immature calcitonin by the enzyme peptidylglycine-amidating mono-oxidase 
(PAM) (117) 
Mature calcitonin has an N-terminal disulphide bond linking the cystine residues at 
position 1 and 7, a methionine residue at position 8 and a C-terminal proline-amide, 
all of which are necessary for biological activity. The physiological role of 
calcitonin is incompletely understood. Calcitonin binds to osteoclasts, and 
homozygous calcitonin knock-out mice have increased bone turnover, suggesting 
an inhibitory role for calcitonin in bone turnover (118). In patients with increased 
bone turnover, calcitonin transiently lowers bone turnover and lowers circulating 
calcium levels (119). However in healthy humans, even large doses of calcitonin 
have little impact on serum calcium levels (120). Receptors for calcitonin are 
expressed by lymphocytes, placenta, central nervous system, testes and skeletal 
muscle (121). This suggests that calcitonin has several functions other than in bone.  
Calcitonin is the best available marker for both diagnosis and post-operative 
surveillance of MTC. However, a number of other non-C-cell related conditions 
including renal impairment, hypergastrinaemia, thyroid disease, pancreatic disease 
and the presence of heterophilic antibodies (122) are also associated with raised 
calcitonin levels. Further, calcitonin levels are higher in males than in females and 
are positively correlated with age and BMI (122). Cigarette smoking may be 
associated with elevated calcitonin levels (122). Food ingestion has been reported 
to have little effect on plasma calcitonin (123).  
Measurement of stimulated calcitonin using provocative agents such as intravenous 
pentagastrin, a synthetic analogue of gastrin (124) improves diagnostic specificity 
since increased levels of stimulated calcitonin only occur in conditions associated 
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with C-cell derived hypercalcitoninaemia (125). Patients with MTC show an 
exaggerated calcitonin response to pentagastrin stimulation (126).  
3.1.3 MTC and Calcitonin 
Survival and cure rates in MTC are highly dependent on staging at diagnosis. There 
is a strong relationship between calcitonin doubling times in MTC patients and 
MTC recurrence and survival (125). Multiple forms of circulating immune-reactive 
calcitonin (icalcitonin), including precursors, dimers and glycosylated forms, have 
been identified in both healthy controls and in patients with MTC (127). Much of 
icalcitonin comprises larger forms rather than the monomeric molecule (127). The 
heterogeneity of the circulating calcitonin molecule results in large differences in 
both sensitivity and specificity of the different commercial calcitonin assays, 
making both measurement and interpretation of calcitonin levels complicated. The 
different calcitonin assays are not directly comparable. In fact, reference ranges are 
assay dependent and the values quoted by manufacturers of the individual 
calcitonin assays vary considerably, ranging from < 5.5 ng/L to < 13 ng/L in 
females and < 10 ng/L in men to < 30ng/L in males (122). As a result, it is 
imperative reference ranges are individually established for each calcitonin assay.  
In most centres, a basal calcitonin of less than 10 ng/L, is considered to be normal 
(111,126,128,129). Patients with a basal calcitonin concentration >10 ng/L are 
recommended to undergo a pentagastrin stimulation test (PGT) to exclude the 
presence of MTC (126).  Stimulated peak calcitonin concentrations of >100 ng/L 
have been reported to support a diagnosis of C-cell disease, either C-cell 
hyperplasia or MTC (111). Stimulated levels >1000 ng/L have a 100% positive 
predictive value for MTC (111,126,128,130,129). These diagnostic limits were 
established using data from studies using the manual Cisbio immunoradiometric 
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calcitonin assay (111, 131) and were subsequently validated for the automated 
Nichols
®
 immunochemiluminometric calcitonin assay (129). 
The Nichols
®
 calcitonin assay was suddenly withdrawn in 2007. The DiaSorin 
Liaison
®
 assay, an automated immunochemiluminetric assay, is now used by many 
centres as an alternative to the Nichols
®
 assay for high throughput automated 
calcitonin measurements. Bieglmayer et al have shown that the DiaSorin
®
 
calcitonin assay is positively biased when compared to the Nichols
®
 assay (132). 
This was reflected in the higher upper limit of the reference range quoted by 
DiaSorin
®
 when compared to the Nichols
®
 assay (reference range - Nichols
®
: 
males < 11.5 ng/L and females < 4.8 ng/L; DiaSorin
®
: males < 18.6 ng/L and 
females <5.5 ng/L). In my clinical practice, I found a significant increase in the 
number of female patients with ‘borderline elevated’ basal calcitonin levels using 
the DiaSorin
®
 assay manufacturer’s reference range of <5.5ng/L for females (133). 
Moreover, the manufacturers of the DiaSorin
®
 assay currently continue to 
recommend a basal calcitonin concentration of > 10 ng/L as the diagnostic limit for 
further investigation for MTC, despite the upper limit of reference range for males 
being much higher (134). Therefore it remains unclear whether the manufacturers 
recommend that male patients with basal calcitonin levels greater than 10 ng/L, but 
below 18.6ng/L using the DiaSorin
®
 assay, undergo further investigation. In view 
of the higher reference ranges for the DiaSorin
®
 assay, when compared to the 
Cisbio assay, it may be inappropriate to extend this recommended diagnostic cut-
off of < 10 ng/L to the new DiaSorin
®
 assay. In addition, there is no published data 
on recommended diagnostic limits for calcitonin response following pentagastrin 
stimulation when using the DiaSorin
®
 assay.  
The functional sensitivity or the limit of quantification, relates to the total error 
considered acceptable for an assay, and can be determined by taking into account 
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the biological variability, analytical co-efficient of variation and precision required. 
It is the lowest value at which the specifications for total error/ total percentage co-
efficient of variance (cv) can be fulfilled (135). The acceptable total error/cv for 
calcitonin is considered to be 20% (136). The manufacturers quote the functional 
sensitivity to be 8ng/L. This implies that calcitonin values below 8 ng/L must be 
reported as <8ng/L, rather than numerical values. It is interesting that the upper 
limit of the reference range for females using the DiaSorin
®
  assay is quoted by the 
manufacturers as <5.5 ng/L, which is below the functional sensitivity of the assay. 
These discrepancies and a paucity of published data regarding the DiaSorin
®
 
Liaison calcitonin assay, led me to conduct a study to evaluate the functional 
sensitivity of the assay and examine basal and stimulated calcitonin concentrations 
in healthy individuals using this assay. 
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3.2 Hypothesis and Aims 
3.2.1 Hypothesis 
I hypothesise that the manufacturer’s recommended range for measuring basal 
serum calcitonin in healthy females, using the DiaSorin
® 
calcitonin assay, is 
incorrect. In addition, the use of a basal serum calcitonin value of > 10 ng/L as a 
diagnostic cut-off for further investigation for MTC needs revision. 
 3.2.2 Aims 
1. To establish the functional sensitivity of the DiaSorin®  assay for calcitonin 
2. To establish reference ranges for the DiaSorin® assay for calcitonin in 
healthy controls 
3. To investigate the stimulated calcitonin levels following a PGT in healthy 
volunteers using the DiaSorin
®
 assay for calcitonin 
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3.3 Methods  
Local ethical approval was obtained (COREC number 07/Q0406/18) and all 
participants gave informed consent.  
3.3.1 Establishing the functional sensitivity and reference ranges for the assay 
Ninety samples from patients with calcitonin levels < 10 ng/L were measured in 
duplicate. The samples were assayed in multiple runs. The mean of the two results 
obtained for each sample was calculated and this was then used to calculate the 
standard deviation and cv. The lowest value at which a cv of 20% was achieved, 
was established as the functional sensitivity of the assay. 
The a priori strategy was used for selecting volunteers for sampling for 
establishment of reference ranges. This involved selecting a reference population 
from a group of healthy volunteers working at Imperial College Healthcare NHS 
Trust.  
Volunteers on medications causing hypergastrinaemia (e.g. PPIs), pregnant women 
and patients with a history of pernicious anaemia, thyroid disease or family history 
of MTC, were excluded from the study. In order to ensure that no participants with 
abnormal renal or thyroid function were included in the study, creatinine, fT4 and 
TSH was also measured in all samples.  
A single non-fasting 5 ml blood sample was taken from each volunteer and 
collected into plain serum BD

 vacutainer tubes. Ten female and 12 male 
volunteers also underwent a PGT and in their case, the sample used for calculating 
reference ranges was the baseline (t = 0) sample of the PGT.  
Samples were allowed to clot and centrifuged at 1200xg for 10 minutes within 20 
minutes of collection. Aliquots of serum were stored at -20
◦
C until they were 
assayed in batches.  
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3.3.2 Collection of samples for the pentagastrin stimulation tests 
The test was performed in the non-fasting state. A 22G intravenous cannula was 
placed in the antecubital fossa and 5 ml baseline blood sample for calcitonin was 
taken at t = 0. All t=0 samples were drawn at the point of insertion of a 20 G 
venflon. A single IV bolus of pentagastrin (250mcg/ml) at a dose of 0.5mcg/kg was 
given. Further 5 ml blood samples were then collected at 1, 2, 3, 5, and 10 minutes 
into plain serum BD vacutainer

 tubes. Samples were allowed to clot and 
centrifuged at 1200xg for 10 minutes within 20 minutes of collection. Aliquots of 
serum were then stored at -20
o
C and assayed in batches. 
3.3.3 Assay details 
Calcitonin was measured using the automated DiaSorin
®
 Liaison assay, which is a 
direct, two-site, sandwich type immunoluminometric assay using directly coated 
magnetic microparticles. It uses a primary monoclonal antibody conjugated to 
isoluminol (label) and a second capture monoclonal antibody coated to magnetic 
microparticles. The reported detection limit of this assay is 1ng/L and the range is 
1-2000 ng/L (134). The functional sensitivity (defined as the concentration with a 
cv
 
not to exceed 20%) is reported by the manufacturer to be 8 ng/L.  
Free T4 was measured using the Abbott Architect automated competitive 
immunochemiluminescent assay and TSH was measured using an automated 2-step 
Abbott Architect immunochemiluminescent assay. Creatinine was measured using 
the Abbott Architect automated enzymatic colourimetric assay (Abbott 
Laboratories, Illinois, USA). 
 
 
 
74 
 
3.4 Statistics 
No assumptions were made regarding the type of distribution of the serum 
calcitonin values. The sample size calculations were, therefore, made for estimation 
of reference range by a nonparametric method. Assuming that the 2.5
th
 and 97.5
th
 
percentiles would be used as the lower and upper limits of the reference range 
respectively, the minimal sample size was calculated to be 40, using the formula 
100/ where  equals 2.5(135). Knowing that the serum calcitonin values are 
significantly different in males and females, volunteers were divided into two 
separate groups based on gender, and 40 volunteers were recruited into to each 
group (135). 
The data for calcitonin did not adhere to a Gaussian distribution. A rank based non-
parametric method, as recommended by the International Federation of Clinical 
Chemistry, was used to calculate reference ranges (137).  Serum calcitonin values 
were ranked in ascending order of magnitude. The 5
th
 and 95
th
 percentile, and the 
median calcitonin values were calculated. The 5
th
 and 95
th
 percentiles were used as 
the lower and upper limit of the reference range respectively.   
Peak stimulated calcitonin levels are expressed as median and range. 
Recommendations for reference limits for peak calcitonin were not made due to the 
small sample size. 
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3.5 Results  
3.5.1 Assessment of basal serum calcitonin in healthy volunteers 
The functional sensitivity of the assay was found to be 4 ng/L. Eighty-three healthy 
volunteers, 43 females (age range 18- 59 yrs, mean 32 yrs) and 40 males (age range 
22-72 yrs, mean 39 yrs) were recruited into the study. From this cohort, ten women 
(age range 27-36 yrs, mean 31.8 yrs) and 12 men (age range 25-48 yrs, mean 33.4 
yrs) also underwent a pentagastrin stimulation test.  The reference ranges for basal 
calcitonin are expressed as ‘< the 95th percentile’, since the values obtained for the 
5
th
 percentile in both males and females were lower than the functional sensitivity 
of the assay (4 ng/L). The 95
th
 percentile and hence the upper limit of the reference 
range for basal calcitonin was 21.9 ng/L for males (n = 40) and 11.1 ng/L for 
females (n = 43) (Figure 3-1). The median calcitonin value was 9.75 ng/L for males 
and 5.7 ng/L for females. Therefore, 13% of healthy male volunteers had basal 
calcitonin concentrations exceeding the manufacturer’s recommended upper limit 
of reference range of 18.6 ng/L. At least half (54%) of healthy females had basal 
calcitonin values above the manufacturer’s recommended upper limit of reference 
range of 5.5 ng/L. Using a basal calcitonin cut-off level of 10 ng/L to indicate the 
need for further assessment with PGT (126, 129), 48% of healthy males and 19 % 
of healthy females had values above this cut-off.  
Circulating calcitonin levels in volunteers in the first quartile of the age range were 
compared with those in the last quartile [female: 22 – 27 years (first quartile), 36 – 
59 (last quartile); male: 22 – 28 years (first quartile), 47 – 72 (last quartile)]. No 
significant differences in circulating calcitonin levels were found.  
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Figure 3-1: Basal serum calcitonin in healthy subjects 
Basal calcitonin concentrations in males (n=40) and females (n=43). The solid line 
indicates the current diagnostic limit of 10 ng/L, above which further investigation 
for C cell disease is suggested. The dashed line indicates the upper limit of the 
manufacturer’s reference range for males (18.6 ng/L) and the dotted line indicates 
the upper limit of manufacturer’s reference range for females (5.5 ng/L).  
 
To investigate the effects of different cannula sizes and anticipatory stress prior to a 
PGT, I compared basal calcitonin levels (t=0 sample) in volunteers who underwent 
PGT test (group 1) and in those who only donated a one-off basal sample (Group 2) 
(Table 3-1). There was no statistical difference between the two groups (p = 0.88 
for males, p=0.14 for females). There was no significant change in the median 
basal calcitonin levels (p = 0.68 for males and 0.28 for females) when only samples 
from patients in group 2 were considered compared to the whole group (groups 
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1+2), thus suggesting that the in-dwelling cannula/anticipatory stress of having a 
PGT did not affect serum calcitonin levels. 
 
Table 3-1: Comparison of basal serum calcitonin levels in subjects with and 
without an indwelling cannula 
Median concentrations of basal serum calcitonin levels in group 1 (t=0 sample 
taken from indwelling cannula in volunteers who underwent PGT) and group 2 
(volunteers who had a random blood sample only). Total subjects (groups 1+2). 
 
3.5.3 Assessment of basal and peak calcitonin concentrations during a PGT  
In males (n = 12), the range of basal calcitonin values was 4.1 – 19.6 ng/L (median 
9.9 ng/L). Following iv pentagastrin, the range of peak stimulated calcitonin value 
was 19.5 – 110 ng/L (median 28.2 ng/L) (Figure 3-2A). The range of basal 
calcitonin in females (n = 10) was <4 – 14.3 ng/L (median 10.2 ng/L), and the 
range of peak stimulated calcitonin was < 4 to 38.6 ng/L (median 11 ng/L) (Figure 
3-2B).  
 
 
 
 
 
 
 
 
 Group 1 Group 2 Total subjects 
Basal 
serum 
calcitonin 
Male 
(n=10) 
Female 
(n=12) 
Male 
(n=30) 
Female 
(n=31) 
Male 
(n=40) 
Female 
(n=43) 
Median 
(ng/L) 
9.9 6.2 9.6 5.7 9.6 5.7 
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A       Males 
 
 
 
 
 
 
 
 
 
B  Females 
 
 
 
 
 
 
 
 
 
Figure 3-2:Basal and peak calcitonin concentrations following pentagastrin 
stimulation 
Basal and peak calcitonin concentrations following pentagastrin stimulation in A: 
males (n=12) and B: females (n=10).   
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3.6 Discussion 
This study shows that although the upper limit of the reference interval in healthy 
males (21.9 ng/L) is similar to that recommended by the manufacturers of the 
DiaSorin
® 
calcitonin assay (18.6 ng/L), the upper limit for healthy females (11.1 
ng/L) is double the recommended value (5.5 ng/L). Thirteen percent of healthy 
male and 54% of healthy female volunteers had basal calcitonin concentrations 
exceeding the manufacturer’s recommended upper limit of reference range. 
Consequently, in the Imperial College Healthcare NHS Trust Supra-regional Assay 
and Advisory Service Laboratory, reference ranges for basal calcitonin measured 
by the DiaSorin
®
 assay have been revised to < 21.9 ng/L in men and < 11.1 ng/L in 
females. Circulating calcitonin levels were similar in volunteers in the first quartile 
of the age range compared with those in the last quartile. However, this data was 
not collected with the aim of establishing age related changes in circulating 
calcitonin levels and hence there were no volunteers in a paediatric age group. 
Furthermore, there were only three female and seven male volunteers over 50 years 
of age. A larger study including paediatric age groups and more patients over 50 
years would be needed to conclusively establish whether there are any age specific 
changes in circulating calcitonin.  
Using a basal calcitonin diagnostic limit of 10 ng/L to indicate the need for further 
assessment with PGT (126,129), 48% of healthy males and 19 % of healthy 
females had a basal calcitonin > 10 ng/L.  
Previous studies of pentagastrin stimulation in healthy volunteers using the Cisbio 
calcitonin assay show peak calcitonin levels below 50ng/L (126, 131, 138). In this 
study, 18% of individuals had a peak calcitonin value above this limit. A stimulated 
peak calcitonin concentration of >100 ng/L using the Cisbio assay has been shown 
to support a diagnosis of C-cell hyperplasia/MTC (126,128-130). In the current 
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study, one male healthy volunteer had a peak stimulated calcitonin value > 100 
ng/L (110 ng/L). Of note, his basal calcitonin level was 16.6ng/L, which is well 
within the manufacturer’s reference limits.  
The basal and stimulated diagnostic cut-offs for plasma calcitonin in MTC, were 
based on measurements by the Cisbio assay and later validated for the Nicholls 
assay (111,126,128,130, 129). The calibrator (WHO 89/620) used in these two 
assays is identical to that used in the DiaSorin
®
 assay, raising expectation that the 
levels of calcitonin obtained by the DiaSorin
® 
assay, and hence the diagnostic cut-
offs would be comparable. This presumption is likely to be the basis for 
extrapolating the cut-offs using Cisbio and Nicholls assays to the DiaSorin
®
 assay.  
However, my data does not support using the diagnostic cut-offs for the Cisbio and 
Nicholl’s assays for the DiaSorin® assay.  
Earlier assays for calcitonin were one site polyclonal assays which had cross 
reactivity with a number of molecular forms of calcitonin including precursors like 
procalcitonin and CCP-1 (139). In order to improve homogeneity between assays, 
the newer assays two site immunoassays including Cisbio were designed to be 
specific for the mature calcitonin fragments (139). However, despite the 
recommendation that new assays for calcitonin are specific for the mature form, 
antibody specificities vary and cross-reactivities for the various other molecular 
forms including precursors like pro-calcitonin still exist (140, 132). Despite the use 
of the same international calibrant, the cross-reactivity profiles for the different 
assays are likely to be different and it is these differences that probably account for 
the discrepancies in values obtained for plasma calcitonin. My results suggest that 
further studies assessing the cross reactivity profile of the DiaSorin
®
 calcitonin 
assay may be helpful in establishing assay appropriate diagnostic cut-offs. 
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The recommendation by National Association of Clinical Biochemists (USA) that 
assays specific for the mature form of calcitonin be used, is in itself surprising as it 
is contrary to its recommendations for other cancers like prostate cancer and 
gestational trophoblastic tumours (139). It is known that patients with MTC secrete 
many molecular forms of calcitonin (127). Experience from study of other cancers, 
including other NENs, suggests that tumours are often associated with impaired 
post-translational processes, and hence secrete a larger proportion of unprocessed 
precursor molecules. Therefore, the more molecular forms an assay measuring a 
biomarker detects, the better the diagnostic accuracy is likely to be (141). A future 
study comparing the diagnostic accuracy of older calcitonin assays involving 
polyclonal antibodies detecting more molecular forms of calcitonin with newer 
more specific assays would be interesting. 
 The current study disputes the validity of applying a single diagnostic limit for 
basal and stimulated calcitonin for both males and females. Postmortem studies 
have shown that men have twice the number of C cells compared to females (122). 
This is reflected in my data as the upper limit of the reference range in males is 
almost double that in females. Previous studies do not have different diagnostic 
limits for peak calcitonin concentrations in males and females following 
stimulation. In my study, the median stimulated peak calcitonin level following 
pentagastrin stimulation in males was twice that observed in females. Using a 
single diagnostic cut-off for both men and women may result in increased false 
positives in men and increased false negatives in women. This could result in 
unnecessary further investigations and interventions in men and potentially missed 
diagnosis at an early curable stage of MTC in women. My results suggest a role for 
gender specific diagnostic cut-offs.  
In conclusion, these results suggest revision of reference ranges for serum 
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calcitonin in males and females when using the DiaSorin
®
 assay. This study 
suggests that the current diagnostic limits of > 10 ng/L and > 100ng/L for basal and 
stimulated calcitonin concentrations are too low when using the DiaSorin
®
 assay. 
Further work is also necessary to determine the normal calcitonin response 
following pentagastrin stimulation when using this DiaSorin
®
 assay.  
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Chapter 4 : Cocaine and Amphetamine 
Regulated Transcript (CART) in Neuroendocrine 
Neoplasms (NENs) 
4.1 Introduction 
4.1.1 CART 
CART was first identified as an mRNA transcript by Douglas et al in 1995 when 
studying the effects of cocaine and amphetamine on the rat brain (43). CART 
mRNA was upregulated following acute administration of cocaine and 
amphetamine. This initial study showed increased expression in NE cells and 
neurones within the paraventricular, supra-optic and arcuate nuclei of the 
hypothalamus. The peptide CART has subsequently been shown to be present in a 
similar distribution in the human brain compared to the rat brain (44).  
The 2 kB human CART gene maps to chromosome 5q13 – 14 and is composed of 
three exons and two introns. Alternate splicing in the rat results in two different 
pre-pro-hormones 116 or 129 amino acids in length, referred to as rsCART and 
rlCART respectively (43). Splicing occurs within exon 2 of rlCART and results in 
a transcript that is missing 39 nucleotides. The difference in functional significance 
and regulation of these two forms is not yet known. However, the rsCART appears 
to be the more abundant form. This phenomenon of alternate splicing has not been 
observed in man, where only the short 116 aa transcript exists (44).  
Further studies have shown that CART is widely expressed in other NE cells and 
neurones including those in the pituitary (45), adrenal medulla (45), gut (46) and 
pancreas (47). Electron microscopy studies have isolated the intracellular location 
of CART to the dense core vesicles in the cytoplasm (48).  
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The pre-pro-hormone carries a 27 amino acid hydrophobic amino terminal domain, 
which is cleaved before its entry into the regulated secretory pathway (142).   The 
resulting 102aa/89 aa pro-hormone then undergoes further pro-hormone convertase 
mediated processing in the Golgi bodies to form smaller peptides. Two of these 
fragments, 55–102 and 62–102, have been shown to be bioactive (142). These have 
also been shown to be the two major circulating forms of the peptide (143). 
Although a specific receptor has not yet been identified, studies suggest that CART 
probably acts via a G protein coupled CART receptor (49). The cAMP/PKA/CREB 
pathway has been identified as important mediator of CART gene expression.   
The function of CART in body weight homeostasis (50), reward and reinforcement 
pathways, anxiety (52), stress (53) and pancreatic islet cell function (54) has been 
extensively studied. 
4.1.2 CART in NENs 
In addition to normal NE cells and neurones in the hypothalamus, pituitary, 
adrenals and pancreas, CART has been shown to be expressed by a number of 
NENs such as phaeochromocytoma (55), glucagonoma (56)and insulinoma (54).  
In 2008, Bech et al conducted a preliminary study of plasma CART in patients with 
NENs compared to healthy normal controls (57). This study demonstrated higher 
plasma CART in patients with NENs, raising the possibility of its role as a NEN 
marker. In addition, this study also established that in humans, circulating CART 
levels did not exhibit diurnal variation, were not affected by food and that there 
were no significant age or sex related differences between males and females (57, 
personal communication Dr Paul Bech 2010).  
Bech et al calculated plasma CART reference ranges using mean +/- 2 SD values 
measured in 29 healthy volunteers (57). For the introduction of CART as a NEN 
marker, it may be more valuable to use a diagnostic cut-off based on acceptable 
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true and false positive rates, rather than reference limits. Constructing a receiver 
operator characteristic (ROC) curve of the plasma biomarker levels in controls 
verses NEN patients will give an indication of the robustness of CART as a NEN 
marker. In addition, it would be interesting to establish whether tumour burden (i.e. 
metastatic versus non-metastatic disease), and aggressiveness (as determined by the 
Ki 67 index) correlates with plasma CART concentrations. This will help to 
determine whether CART can be used to assess prognosis. A comparative study 
looking at circulating CART levels in patients in clinical remission and those with 
persistent disease will help establish its role as a surveillance marker.  
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4.2 Hypothesis and Aims 
4.2.1 Hypothesis 
CART is a sensitive and specific diagnostic, prognostic and surveillance marker for 
NENs. 
4.2.2 Aims 
Preliminary studies suggest a possible role for CART as a NEN biomarker. The 
aim of my study was to examine the utility of CART when compared to Cg A and 
Cg B; 
(i) as a diagnostic biomarker by assessing its ability to correctly identify 
NENs. 
(ii) as a prognostic indicator by correlating plasma CART levels to  
a. site of primary tumour 
b. disease progression 
c. tumour burden (metastases) 
d. metastatic potential of tumour (Ki 67 index). 
(iii) as a surveillance marker in NENs by studying the difference in plasma 
CART levels in those patients who are in clinical remission and those 
who are not. 
(iv) as a marker of response to therapy. 
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4.3 Methods 
4.3.1 Collection of control samples  
Local ethical approval was obtained (COREC number 08/H0707/143) and all 
participants gave informed consent.  
The a priori strategy was used for selecting volunteers for sampling. This involved 
selecting a reference population from a group of healthy volunteers working at 
Imperial College Healthcare NHS Trust and patients attending out-patient clinics. 
Patients chosen from the out-patient clinics were those who had no evidence of 
malignancy or renal impairment. 
Two hundred and sixteen samples were collected for measurement of plasma 
CART and one hundred and eight samples were collected for measurement of Cg 
A. A single non-fasting 5 ml blood sample was taken from each volunteer and 
collected into EDTA BD

 vacutainer tubes. Samples were centrifuged at 1200xg 
for 10 minutes within 15 minutes of collection. Aliquots of plasma were stored at -
20
◦
C until they were assayed in batches. Forty of these volunteers had CART, Cg A 
and Cg B measured. Results obtained from these 40 healthy controls were used to 
compare diagnostic utility of the three biomarkers in NENs. 
4.3.2 Collection of patient samples  
The Imperial College Healthcare NHS Trust offers a supra regional assay service 
(SAS) for the measurement of gut hormones. The SAS receives in excess of 200 
samples from patients with known and suspected NENs per week. Included in 
these, are samples from two major London centres for NENs, Imperial College 
Healthcare NHS Trust and the Royal Free Hampstead NHS Trust. Plasma CART 
Cg A and Cg B was measured in 489 patients with NENs. Aliquots for analysis 
were sourced from clinical samples sent from these two centres. In order to 
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eliminate bias, all samples received from these two centres on randomly selected 
days were included in the study. Aliquots of plasma were stored at -20
◦
C until they 
were assayed in batches.  
4.3.3 Data collection 
I obtained clinical data for these 489 patients. This information was gathered from 
patient case notes and hospital and laboratory information systems. Data were 
recorded anonymously in excel spreadsheets using numeric and binary codes. 
Information gathered included; 
1. Source of primary tumour (pancreatic, gut, 
phaeochromocytoma/paragangliomas, non-gastro-entero-pancreatic and 
unknown primary). 
2. Evidence of remission of disease. 
3. Presence of metastases.  
4. Progressive or stable disease.  
5. Ki 67 index.  
6. Plasma Cg A and Cg B levels. 
7. Tumour burden 
8. Renal function including serum creatinine levels and eGFR obtained from 
electronic patient records and laboratory IT systems 
Source of primary tumour was established from imaging reports and patient letters. 
Patients were considered to be in remission if there was no clinical, biochemical or 
radiological evidence of residual disease. 
Presence or absence of metastases was established from imaging reports and patient 
letters. 
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Patients were classified as progressive or stable based on the Response Evaluation 
Criteria in Solid Tumours (RECIST) (144). The criteria rely on the uni-dimensional 
measurements of tumour lesions. Up to a maximum of 10 target lesions (maximum 
of 5 per organ) measuring ≥ 10 mm are chosen. The sum of the longest diameter of 
all the target lesions is noted. An increase of ≥ 20% between serial staging scans is 
considered to be indicative of progressive disease. 
Ki 67 index was collated from histology reports of excised/biopsied tumours. 
Plasma Cg A and Cg B levels were retrieved from the hospital and laboratory 
patient information systems. 
Tumour burden was assessed by a single radiologist. Tumour burden in the liver 
was expressed as percentage of liver occupied by tumour. Tumour burden for all 
other lesions including the primary was expressed in terms of the sum of the 
longest diameter of all visible lesions (145). 
I also carried out a longitudinal study measuring serial plasma CART levels in 53 
patients to assess the utility of CART as a marker of response to therapy 
4.3.5 Assays 
Cg A, Cg B and CART were measured using an in-house manual RIA (Appendix 
1). 
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4.4 Statistics  
Plasma CART in controls and patients with NEN was compared using non 
parametric Kruskal-Wallis test.  
Diagnostic utility of plasma CART was assessed by constructing a ROC curve of 
controls vs. NENs patients who were not in remission. Multiple logistic regression 
analysis was used to compare the diagnostic utility of CART, Cg B and the current 
gold standard Cg A. The comparative and combined diagnostic utility of these three 
biomarkers in the different NEN sub-types (pancreatic, gut, non-GEP, 
phaeochromocytoma/paragangliomas and unknown primaries) was also compared 
using multiple logistic regression.  
Univariate and multivariate logistic regression analysis was used to investigate (i) 
metastatic and non-metastatic disease (ii) progressive and stable disease and (iii) 
metastatic progressive and metastatic stable disease (iv)remission and non-
remission. ROC curves were also used to compare the sensitivity and specificity of 
CART and Cg A as surveillance markers.  
Spearman’s rank correlation was used to assess the correlation between plasma 
CART, Cg A and Cg B levels and tumour burden.  
A p value of <0.05 was considered statistically significant. 
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4.5 Results 
Plasma CART was measured in 489 NEN patients and 216 controls.  
4.5.1 Patient Population 
Patient demographics are detailed in Table 4-1. 
NEN patients   
Total number 489 (423
$
) (345*) 
With renal impairment 53 
Renal function not available 32 
In remission 66 (59*) 
Age  
Range  19 – 101 years 
Median 60 years 
Sex  
Male 209 
Female 195 
Location of Primary tumour   
Pancreatic 151(136
$
)(108*)[RI:18, RF n/a:12, Rem:13] 
Mid-gut 205(172
$
)(131*)[RI:24, RF n/a:16, Rem:34] 
Rectal 7 (4
$
)(3*) [RI:1, RF n/a:0, Rem:3] 
Phaeochromocytoma/paragangliomas 41 (41
$
)(36*) [RI:4, RF n/a:1, Rem:0] 
Non-GEP 29 (29
$
)(28*) [RI:1, RF n/a:1, Rem:9] 
Unknown Primary 48 (48
$
)(39*) [RI:5, RF n/a:4, Rem:0] 
 
Table 4-1: Patient demographics 
RI: renal impairment (serum creatinine within the reference range and/or eGFR ≥ 
60 ml/min/1.73m
2
), RF n/a: NEN patients for whom details of renal function was 
not available, Rem: NEN patients in remission, *: NEN patients with renal function 
within the reference range and not in remission, 
$
: Number of patients not in 
remission before exclusion of patients with renal impairment.  
 
4.5.2 Plasma CART in NEN patients (including those with renal impairment) 
4.5.2.1 Plasma CART in NEN patients  
CART levels in 423 patients who were not in remission were compared to levels in 
216 healthy controls. Plasma CART was significantly higher in all NEN groups 
compared to controls: median, inter-quartile range;[controls] 51, 36 – 67 pmol/L; 
[all NENs] 91, 56 – 248 pmol/L(p<0.0001 vs. controls) ;[pancreatic NENs] 91, 58 - 
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347 pmol/L (p<0.0001 vs. controls), [gut carcinoids] 80,  52 - 157 pmol/L 
(p<0.0001 vs. controls), [phaeochromocytomas/paragangliomas]  122, 66 - 395 
pmol/L (p<0.0001 vs. controls) [non- gastro-entero-pancreatic NENs]  152, 55 - 
1000 pmol/L (p<0.0001 vs. controls) and [NENs with unknown primary] 109, 59 - 
288 pmol/L (p<0.0001 vs. controls) (Figure 4-1).  
Plasma Cg A levels were also significantly higher in all NEN groups when 
compared to healthy controls: median, inter-quartile range;[controls] 33, 26 – 41 
pmol/L; [all NENs] 72, 44 – 314 pmol/L(p<0.0001 vs. controls); [pancreatic NENs] 
55, 41 - 143 pmol/L (p<0.0001 vs. controls), [gut carcinoids] 129, 53 - 540 pmol/L 
(p<0.0001 vs. controls), [phaeochromocytomas/paragangliomas]  45, 33 - 68 
pmol/L (p<0.05 vs. controls), [non- gastro-entero-pancreatic NENs]  80, 40 - 696 
pmol/L (p<0.0001 vs. controls) and [NENs with unknown primary] 185, 55 - 700 
pmol/L (p<0.0001 vs. controls) (Figure 4-1).  
Similarly, plasma Cg B were significantly higher in all NEN groups when 
compared to healthy controls: median, inter-quartile range;[controls] 70, 63 – 81 
pmol/L; [all NENs] 124, 84 – 193 pmol/L(p<0.0001 vs. controls); [pancreatic 
NENs] 117, 74 - 183 pmol/L (p<0.0001 vs. controls), [gut carcinoids] 128, 89 - 191 
pmol/L (p<0.0001 vs. controls), [phaeochromocytomas/paragangliomas] 124, 78 - 
169 pmol/L (p<0.0001 vs. controls) [non- gastro-entero-pancreatic NENs]  121, 74 
- 220 pmol/L (p<0.0001 vs. controls) and [NENs with unknown primary] 157, 107 
- 239 pmol/L (p<0.0001 vs. controls) (Figure 4-1). 
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Figure 4-1: Plasma CART, Cg A and Cg B in healthy controls and patients with 
active NENs  
Plasma levels in controls [CART n=216, Cg A n = 108, Cg B n = 40], all NENs 
(n= 423), pancreatic NENs (Panc) [n=136], gut carcinoids (Gut) [n= 172], 
phaechromocytoma/paragangliomas (Ph/PGs) [n= 41], non-
gastroenteropancreatic NENs (Non-GEP) [n= 29] and NENs with unknown 
primaries (UnPr) [n= 48], *** = p<0.0001 vs. controls, * = p <0.05. Values are 
median, inter-quartile range (shown in red). 
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4.5.2.2 Diagnostic cut-off for CART 
A ROC curve was constructed for CART [controls: n = 216; NENs: n = 423; AUC 
(95% CI):0.77 (0.73 – 0.80)]. The 95th percentile value for CART obtained from 
analysis of plasma CART levels in 216 healthy controls was 82 pmol/L (sensitivity 
54%, specificity 96%). However, the cut-off corresponding with the highest sum of 
sensitivity and specificity offers the best compromise between correct and incorrect 
classification of patients and hence is considered the optimal diagnostic cut-off. 
The optimal diagnostic cut-off value obtained for CART in this study was 78 
pmol/L, (sensitivity 59%, specificity of 92%). By contrast 46 pmol/L is the optimal 
diagnostic cut-off for SAS Cg A (sensitivity of 72%, specificity 86%) [controls: n = 
108; NENs: n = 423; AUC (95% CI):0.86 (0.83 – 0.89)]. The diagnostic cut-off 
used in routine clinical practice for the Cg A assay is 60 pmol/L (sensitivity of 
55%, specificity 95%). Similarly, 94pmol/L was the optimal diagnostic cut-off for 
SAS Cg B (sensitivity of 63%, specificity 97%) [controls: n = 40; NENs: n = 423; 
AUC (95% CI):0.79 (0.74 – 0.84)]. The diagnostic cut-off used in routine clinical 
practice for the Cg B assay is 150 pmol/L (sensitivity of <50%, specificity 100%).  
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4.5.2.3 Utility of CART as a diagnostic marker in NEN disease  
Area under ROC curve (AUC) for plasma CART, Cg A and B as a diagnostic 
marker for controls  vs. all NENs, and for controls vs. each of the NEN subtypes 
described in Figure 4-1 was determined and compared (Figure 4-2 and Tables 4-2 
& 4-3). The control group consisted of 40 healthy controls on whom values for all 
three biomarkers were available. The AUC for all three biomarkers for diagnosis of 
all NENs and for all NEN subtypes was significantly higher than 0.5 (p<0.0001), 
thus suggesting that all three biomarkers are useful as diagnostic markers for all 
NENs (Figure 4-2).   
CART was the biomarker with the highest AUC for 
phaeochromocytoma/paragangliomas. For all NENs and for all other NEN sub-
types Cg A had the best diagnostic accuracy (Figure 4-2 and Table 4-2 & Table 4-
3).  
Multiple logistic regression analysis was carried out to assess if measuring the 
biomarkers in combination detects a greater number of patients with NENs and 
hence improves diagnostic accuracy (Table 4-4). Measuring all three biomarkers in 
combination resulted in significant improvement in diagnostic accuracy in patients 
with pancreatic NENs and phaeochromocytoma/paragangliomas. Measuring CART 
in addition to Cg A and Cg B offered no significant benefit in any of the other sub-
types of NENs. Measuring a combination of Cg A and B significantly improved 
diagnostic accuracy in patients with Gut NENs. There was no significant benefit in 
measuring any markers in addition to Cg A in patients with non GEP NENs or in 
NENs with unknown primary. 
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Figure 4-2: CART, Cg A and Cg B as diagnostic markers 
ROC curves for CART (blue), Cg A (brown) and Cg B (orange) as diagnostic 
markers for all NENs and each of the NEN sub-types. Values for area under ROC 
curve (AUC) and results of comparison of AUC between the biomarkers are 
detailed in tables 4-2 & 4-3.  
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Biomarker AUC SE 95% CI 
Controls (n =40) vs. all NENs (n = 423) 
CART 0.74 0.32 0.699 to 0.781 
Cg A 0.85 0.25 0.809 to 0.878 
Cg B 0.83 0.02 0.790 to 0.861 
Controls (n =40) vs. Pancreatic NENs (n =136) 
CART 0.74 0.04 0.66 – 0.80 
Cg A 0.89 0.03 0.84 – 0.94 
Cg B 0.79 0.03 0.72 – 0.85 
Controls (n =40)  vs. Gut NENs (n = 172) 
CART 0.69 0.04 0.62 – 0.75 
Cg A 0.95 0.02 0.90 – 0.97 
Cg B 0.85 0.03 0.79- 0.90 
Controls (n =40) vs. Non-GEP NENs (n = 29) 
CART 0.73 0.06 0.61 – 0.83 
Cg A 0.88 0.54 0.78 – 0.95 
Cg B 0.81 0.06 0.70 - 0.89 
Controls (n =40) vs. phaeochromocytoma/paragangliomas (n = 41) 
CART 0.80 0.05 0.70 – 0.88 
Cg A 0.78 0.05 0.68 – 0.87 
Cg B 0.78 0.06 0.67 – 0.86 
Controls (n =40) vs. NENs with unknown primary (n = 48) 
CART 0.77 0.05 0.66 – 0.85 
Cg A 0.97 0.02 0.91 – 0.98 
Cg B 0.92 0.03 0.84 – 0.97 
 
Table 4-2: Cg A, Cg B and CART as diagnostic markers 
Shows the area under ROC curve (AUC) (detailed in figure 4.2), SE (standard 
error) and 95% confidence limits for Cg A, Cg B and CART for controls vs. all 
NENs, pancreatic NENs, gut carcinoids, non-GEP carcinoids, 
phaeochromocytomas/paragangliomas and NENs with unknown primary. 
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Table 4-3: Comparison of CART, Cg A, Cg B as diagnostic markers 
Area under ROC curve (AUC) for controls vs. all NENs, and all NEN sub-types 
(detailed in Figure 4-2) for CART, Cg A and Cg B as diagnostic markers are 
compared. The difference in AUC was considered statistically significant if p < 
0.05. The marker with the greater AUC is detailed in bold. 
 
 
 
 
 
 
 
 
Biomarkers p value 
Controls vs. all NENs 
CART vs. Cg A 0.009 
CART vs. Cg B 0.03 
Cg A vs. Cg B 0.51 
Controls vs. Pancreatic NENs 
CART vs. Cg A 0.0004 
CART vs. Cg B 0.29 
Cg A vs. Cg B 0.005 
Control vs. Gut NENs 
CART vs. Cg A <0.0001 
CART vs. Cg B 0.0001 
Cg A vs. Cg B 0.002 
Controls vs. Non-GEP NENs 
CART vs. Cg A 0.007 
CART vs. Cg B 0.19 
Cg A vs. Cg B 0.18 
Controls vs.  phaeochromocytoma/paragangliomas 
CART vs. Cg A 0.85 
CART vs. Cg B 0.79 
Cg A vs. Cg B 0.89 
Controls vs. NENs with unknown primary 
CART vs. Cg A 0.0001 
CART vs. Cg B 0.01 
Cg A vs. Cg B 0.04 
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Biomarker (AUC ) P value 
Combined AUC for significant 
biomarkers 
Controls vs. all NENs 
CART (0.74) 0.09 
0.94 Cg A (0.85) <0.0001 
Cg B (0.83) 0.003 
Controls vs. Pancreatic NENs 
CART (0.74) 0.02 
0.95 Cg A (0.89) <0.0001 
Cg B (0.79) 0.006 
Controls vs. Gut NENs 
CART (0.69) 0.46 
0.96 Cg A (0.95) <0.0001 
Cg B (0.85) 0.01 
Controls vs. phaeochromocytoma/paragangliomas 
CART (0.80) 0.0004 
0.95 Cg A (0.78) 0.004 
Cg B (0.78) 0.001 
Controls vs. Non-GEP NENs 
CART(0.73) 0.77 
0.89 Cg A (0.88) 0.01 
Cg B (0.81) 0.29 
Controls vs. NENs with unknown primary 
CART (0.77) 0.45 
0.98 Cg A (0.97) 0.005 
Cg B (0.92) 0.11 
 
Table 4-4: Combined utility of CART, Cg A and Cg B as diagnostic markers for 
NENs 
The combined utility of Cg A, Cg B and CART as diagnostic markers for NENs was 
assessed using multivariate analysis with backward selection. Using a combination 
of those markers that have a p value < 0.05 significantly improves diagnostic 
accuracy compared to any one single biomarker in isolation. The AUC for each 
marker alone and the combined AUC for all significant markers is shown. 
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4.5.2.4 Plasma CART as a prognostic indicator in NEN disease 
4.5.2.4.1 Plasma CART in stable compared to progressive disease 
Clinical data was available on 411 patients (131 pancreatic NENs, 162 gut 
carcinoids, 29 non-GEP carcinoids, 48 NENs with unknown primary and 41 
phaeochromocytomas/paragangliomas). Two hundred and sixty seven patients had 
stable disease (87 pancreatic NENs, 117 gut carcinoids, 15 non-GEP carcinoids, 22 
NENs with unknown primary and 26 phaeochromocytomas/paragangliomas) and 
144 had progressive disease (44 pancreatic NENs, 45 gut carcinoids, 14 non-GEP 
carcinoids, 26 NENs with unknown primary and 15 
phaeochromocytomas/paragangliomas).  
Of the three biomarkers, CART was the most useful biomarker in distinguishing 
stable from progressive NENs. It had the highest AUC for pancreatic NENs, 
phaeochromocytoma/paragangliomas and NENs with unknown primary, while Cg 
A had the highest AUC for gut NENs (Figure 4-3 and Table 4-5 & 4-6).  
A multiple logistic regression analysis was carried out to assess if using a 
combination of biomarkers improved accuracy in distinguishing stable from 
progressive disease (Table 4-7). There was no significant advantage to using any 
other biomarker in addition to CART in Gut NENs, 
phaeochromocytoma/paragangliomas or NENs with unknown primary. Using Cg A 
in addition to CART significantly improved accuracy in pancreatic NENs.  There 
was no significant advantage in using a combination of biomarkers to distinguish 
between stable and progressive Non-GEP NENs, with all three markers 
individually having comparable utility. 
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Figure 4-3: CART, Cg A and Cg B as markers of disease progression 
ROC curves for CART (blue), Cg A (brown) and Cg B (orange) as markers of progressive 
disease for all NENs and each of the NEN sub-types. Values for area under ROC curve 
(AUC) and results of comparison of AUC between the biomarkers are detailed in tables 4-
5 & 4-6. 
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Biomarker AUC SE 95% CI 
All NENs (n = 411, stable n = 267, progressive n = 144) 
CART 0.78 0.03 0.72 – 0.81 
Cg A 0.72 0.03 0.67 – 0.76 
Cg B 0.72 0.03 0.67 – 0.76 
Pancreatic NENs (n =131, stable n = 87, progressive n = 44) 
CART 0.87 0.03 0.80 – 0.92 
Cg A 0.80 0.05 0.71 – 0.86 
Cg B 0.73 0.05 0.64 – 0.80 
Gut NENs (n = 162, stable n = 117, progressive n = 45 ) 
CART 0.66 0.05 0.58 – 0.73 
Cg A 0.69 0.05 0.62 – 0.76 
Cg B 0.71 0.05 0.63 – 0.78 
Non-GEP NENs (n = 29, stable n = 15, progressive n = 14) 
CART 0.68 0.1 0.46 – 0.84 
Cg A 0.71 0.1 0.51 – 0.86 
Cg B 0.69 0.1 0.49 – 0.84 
Phaeochromocytoma/paragangliomas (n = 41, stable n = 26, progressive n = 15) 
CART 0.89 0.06 0.76 – 0.96 
Cg A 0.83 0.06 0.68 – 0.93 
Cg B 0.78 0.07 0.63 – 0.89 
NENs with unknown primary (n = 48, stable n = 22, progressive n = 26) 
CART 0.74 0.07 0.59 – 0.84 
Cg A 0.68 0.08 0.53 – 0.80 
Cg B 0.65 0.08 0.50 – 0.78 
 
Table 4-5: CART, Cg A and Cg B as markers of progressive NENs 
Shows the area under ROC curve (AUC) (detailed in figure 4-3), SE (standard 
error) and 95% confidence limits for Cg A, Cg B and CART for progressive vs. 
stable (all NENs, pancreatic NENs, gut carcinoids, non-GEP carcinoids, 
phaeochromocytomas/paragangliomas and NENs with unknown primary). 
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Biomarker p value 
All NENs 
CART vs. Cg A 0.14 
CART vs. Cg B 0.07 
Cg A vs. Cg B 0.90 
Pancreatic NENs 
CART vs. Cg A 0.18 
CART vs. Cg B 0.006 
Cg A vs. Cg B 0.24 
Gut NENs 
CART vs. Cg A 0.52 
CART vs. Cg B 0.27 
Cg A vs. Cg B 0.73 
Phaeochromocytoma/paragangliomas 
CART vs. Cg A 0.35 
CART vs. Cg B 0.11 
Cg A vs. Cg B 0.46 
Non-GEP NENs 
CART vs. Cg A 0.7 
CART vs. Cg B 1.0 
Cg A vs. Cg B 0.8 
NENs with unknown primary 
CART vs. Cg A 0.55 
CART vs. Cg B 0.29 
Cg A vs. Cg B 0.73 
 
Table 4-6: Comparison of CART, Cg A, Cg B as markers of NEN disease 
progression 
Area under ROC curve (AUC) for stable vs. progressive NENs for all NENs, and 
all NEN sub-types (detailed in Figure 4-3) for CART, Cg A and Cg B are 
compared. The difference in AUC was considered statistically significant if p < 
0.05. The marker with the greater AUC is detailed in bold. 
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Biomarker P value 
Combined AUC for 
significant biomarkers 
All NENs 
CART(0.78) <0.0001 
0.80 Cg A(0.72) 0.0005 
Cg B(0.72) 0.03 
Pancreatic NENs 
CART(0.87) 0.0006 
0.91 Cg A(0.80) 0.002 
Cg B(0.73) 0.21 
Gut NENs 
CART(0.66) 0.04 
0.67 Cg A(0.69) 0.08 
Cg B(0.71) 0.09 
Non-GEP NENs 
CART(0.68) 0.83 
n/a Cg A(0.71) 0.23 
Cg B(0.69) 0.44 
Phaeochromocytoma/paragangliomas 
CART(0.89) 0.02 
0.89 Cg A(0.83) 0.65 
Cg B(0.78) 0.41 
NENs with unknown primary 
CART(0.74) 0.04 
0.74 Cg A(0.68) 0.26 
Cg B(0.65) 0.95 
 
Table 4-7: Combined utility of CART, Cg A and Cg B as markers of NEN disease 
progression 
The combined utility of Cg A, Cg B and CART as markers of NEN disease 
progression was assessed using multivariate analysis with backward selection. 
Using a combination of those markers that have a p values < 0.05 significantly 
improved diagnostic accuracy compared to any one single biomarker in isolation. 
The AUC for each marker alone and the combined AUC for all significant markers 
is shown. Using a combination of markers did not improve the discrimination 
between stable and progressive non-GEP NENs (n/a).  
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4.5.2.4.2 Plasma CART levels in metastatic compared to non-metastatic disease 
Clinical data was available for 416 patients (132 pancreatic NENs, 166 gut 
carcinoids, 29 non-GEP carcinoids, 48 NENs with unknown primary and 41 
phaeochromocytomas/paragangliomas). 350 out of 416 patients (100 pancreatic 
NENs, 158 gut carcinoids, 29 non-GEP carcinoids, 48 NENs with unknown 
primary and 20 phaeochromocytomas/paragangliomas) had metastatic disease as 
confirmed by staging imaging studies.  
Cg A had significantly higher AUC when all NENs were considered (Figure 4-4, 
Table 4-8 & 4-9). There was no significant difference in AUC between the three 
biomarkers in any of the NEN sub-types (Figure 4-4, Table 4-8 & 4-9).  
A multiple logistic regression analysis was carried out to assess the combined 
utility of the three markers in distinguishing metastatic from non-metastatic disease 
(Table 4-10). While both Cg B and Cg A in combination were useful for all NENs, 
CART was the only marker with significant ability to distinguish between 
metastatic and non-metastatic pancreatic NENs and 
phaeochromocytomas/paragangliomas. 
 Despite the high AUC when considered individually, there was no significant 
advantage to measuring any of the markers in combination on multivariate analysis 
in patients with phaeochromocytoma/paragangliomas, non-GEP NENs or gut 
carcinoids. This may be related to the wide 95% confidence intervals for the AUCs 
and the small numbers of non-metastatic patients in these NEN sub-types.   
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Figure 4-4: CART, Cg A and Cg B as markers of metastatic NENs 
ROC curves for CART (blue), Cg A (brown) and Cg B (orange) as markers of metastatic 
disease for all NENs and each of the NEN sub-types. Values for area under ROC curve 
(AUC) and results of comparison of AUC between the biomarkers are detailed in tables 4-
8 & 4-9. 
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Biomarker AUC SE 95% CI 
All NENs (n = 416, metastatic n = 350, non-metastatic n = 66) 
CART 0.65 0.03 0.60 – 0.70 
Cg A 0.74 0.03 0.70 – 0.79 
Cg B 0.69 0.04 0.64 – 0.74 
Pancreatic NENs (n =132, metastatic n = 100, non-metastatic n = 32) 
CART 0.74 0.05 0.65 – 0.81 
Cg A 0.67 0.05 0.59 – 0.75 
Cg B 0.67 0.06 0.58 – 0.75 
Gut NENs (n = 166, metastatic n = 158, non-metastatic n = 8) 
CART 0.69 0.07 0.61 – 0.76 
Cg A 0.72 0.07 0.65 – 0.79 
Cg B 0.72 0.07 0.64 – 0.79 
Non-GEP NENs (n = 29, metastatic n = 24, non-metastatic n = 5) 
CART 0.89 0.06 0.72 – 0.98 
Cg A 0.88 0.07 0.70 – 0.97 
Cg B 0.80 0.09 0.62 – 0.93 
Phaeochromocytoma/paragangliomas (n = 41, metastatic n = 20, non-metastatic n = 21) 
CART 0.88 0.05 0.74 – 0.96 
Cg A 0.82 0.07 0.67 – 0.92 
Cg B 0.82 0.07 0.67 – 0.92 
 
Table 4-8: CART, Cg A and Cg B as markers of metastatic NENs 
Shows the area under ROC curve (AUC)(detailed in figure 4-4), SE (standard 
error) and 95% confidence limits for Cg A, Cg B and CART for non-metastatic vs. 
metastatic (all NENs, pancreatic NENs, gut carcinoids, non-GEP carcinoids, 
phaeochromocytomas/paragangliomas). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
108 
 
Biomarker  p value 
All NENs 
CART vs. Cg A 0.02 
CART vs. Cg B 0.28 
Cg A vs. Cg B 0.08 
Pancreatic NENs 
CART vs. Cg A 0.30 
CART vs. Cg B 0.24 
Cg A vs. Cg B 0.88 
Gut NENs 
CART vs. Cg A 0.71 
CART vs. Cg B 0.74 
Cg A vs. Cg B 0.94 
phaeochromocytoma/paragangliomas 
CART vs. Cg A 0.35 
CART vs. Cg B 0.11 
Cg A vs. Cg B 0.46 
Non-GEP NENs 
CART vs. Cg A 0.78 
CART vs. Cg B 0.25 
Cg A vs. Cg B 0.41 
 
Table 4-9: Comparison of CART, Cg A, Cg B as markers of metastatic NEN 
disease 
Area under ROC curve (AUC) for metastatic vs. non-metastatic NENs for all 
NENs, and all NEN sub-types (detailed in Figure 4-4) for CART, Cg A and Cg B 
are compared. The difference in AUC was considered statistically significant if p < 
0.05. The marker with the greater AUC is detailed in bold. 
 
 
 
 
 
 
 
 
 
 
 
109 
 
Biomarker (AUC) P value 
Combined AUC for significant 
biomarkers 
All NENs 
CART (0.65) 0.36 
0.74 Cg A (0.74) 0.02 
Cg B (0.69) 0.003 
Pancreatic NENs 
CART (0.74) 0.04 
0.74 Cg A (0.67) 0.53 
Cg B (0.67) 0.33 
Gut NENs 
CART (0.69) 0.35 
n/a Cg A (0.72) 0.24 
Cg B (0.72) 0.76 
Phaeochromocytoma/paragangliomas 
CART (0.88) 0.02 
0.88 Cg A (0.82) 0.65 
Cg B (0.82) 0.41 
Non-GEP NENs 
CART (0.88) 0.47 
n/a Cg A (0.82) 0.52 
Cg B (0.82) 0.97 
 
Table 4-10: Combined utility of CART, Cg A and Cg B as markers of metastatic 
NEN disease 
The combined utility of Cg A, Cg B and CART as markers of metastatic NEN 
disease was assessed using multivariate analysis with backward selection. Using a 
combination of those markers that have a p values < 0.05 significantly improved 
diagnostic accuracy compared to any one single biomarker in isolation. The AUC 
for each marker alone and the combined AUC for all significant markers is shown. 
No combination of markers was useful in distinguishing metastatic from non-
metastatic gut NENs and Non-GEP NENs.  
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4.5.2.4.3 Plasma CART levels metastatic stable vs. metastatic progressive 
disease 
Clinical data was available for 343 patients (98 pancreatic NENs, 154 gut 
carcinoids, 24 non-GEP carcinoids, 48 NENs with unknown primary and 19 
phaeochromocytomas/paragangliomas). 142 out of 343 patients (43 pancreatic 
NENs, 45 gut carcinoids, 14 non-GEP carcinoids, 26 NENs with unknown primary 
and 14 phaeochromocytomas/paragangliomas) had metastatic progressive disease 
as diagnosed by staging imaging studies.  
ROC curves for all three biomarkers are shown in Figure 4-5 & Table 4-11. 
Comparison of ROC curves (Table 4-12) showed that AUC for CART was 
significantly better than AUC for Cg A and Cg B for metastatic stable vs. 
metastatic progressive NENs when all NENs were considered together. There was 
no significant difference in the AUCs of the three biomarkers for any of the 
subtypes when considered separately. 
A multiple logistic regression analysis was carried out to assess the combined 
utility of the three markers in distinguishing metastatic stable from metastatic 
progressive disease (Table 4-13). While CART, Cg A and Cg B in combination 
were useful when all NENs were considered, CART and Cg A were both useful in 
pancreatic NENs. CART was the only useful marker in gut carcinoids and NENs 
with unknown primaries. There was no significant advantage to measuring any 
combination of markers in patients with non-GEP NENs or 
phaeochromocytoma/paragangliomas. Again, this may be due to the small n 
numbers in these two groups and the wide confidence intervals. 
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Figure 4-5: CART, Cg A and Cg B as markers of metastatic progressive NENs 
ROC curves for CART (blue), Cg A (brown) and Cg B (orange) as markers of 
metastatic progressive disease for all NENs and each of the NEN sub-types. Values 
for area under ROC curve (AUC) and results of comparison of AUC between the 
biomarkers are detailed in tables 4-11 & 4-12. 
 
 
 
 
112 
 
Biomarker AUC SE 95% CI 
All NENs (n = 343, met st n = 201, met-pr n = 142) 
CART 0.75 0.03 0.70 – 0.79 
Cg A 0.66 0.03 0.60 – 0.71 
Cg B 0.69 0.03 0.64 – 0.74 
Pancreatic NENs (n = 98, met-st n = 55, met-pr n = 43) 
CART 0.84 0.04 0.75 – 0.91 
Cg A 0.78 0.05 0.69 – 0.86 
Cg B 0.71 0.05 0.61 – 0.80 
Gut NENs (n = 154, met-st n = 109, non-met-pr n = 45) 
CART 0.65 0.05 0.57 – 0.72 
Cg A 0.69 0.05 0.60 – 0.76 
Cg B 0.70 0.05 0.62 – 0.77 
Non-GEP NENs (n = 29, met-st n = 10, met-pr n = 14) 
CART 0.59 0.11 0.42 – 0.83 
Cg A 0.64 0.11 0.41 – 0.82 
Cg B 0.63 0.11 0.38 – 0.79 
Phaeochromocytoma/paragangliomas (n = 19, met-st n = 5, met-pr n = 14) 
CART 0.87 0.09 0.64 – 0.98 
Cg A 0.57 0.19 0.33 – 0.79 
Cg B 0.64 0.15 0.39 – 0.84 
Unknown primary (n = 48, met-st n = 22, met-pr n = 26) 
CART 0.74 0.07 0.59 – 0.85 
Cg A 0.68 0.08 0.53 – 0.80 
Cg B 0.65 0.08 0.49 – 0.78 
 
Table 4-11: CART, Cg A and Cg B as markers of metastatic progressive NENs  
Shows the area under ROC curve (AUC)(detailed in Figure 4-5), SE (standard 
error) and 95% confidence limits for Cg A, Cg B and CART for metastatic 
progressive vs. metastatic stable (all NENs, pancreatic NENs, gut carcinoids, non-
GEP carcinoids, phaeochromocytomas/paragangliomas and NENs with unknown 
primary). 
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Biomarkers p value 
All NENs 
CART vs. Cg A 0.01 
CART vs. Cg B 0.04 
Cg A vs. Cg B 0.33 
Pancreatic NENs 
CART vs. Cg A 0.38 
CART vs. Cg B 0.03 
Cg A vs. Cg B 0.28 
Gut NENs 
CART vs. Cg A 0.52 
CART vs. Cg B 0.28 
Cg A vs. Cg B 0.74 
Phaeochromocytoma/paragangliomas 
CART vs. Cg A 0.13 
CART vs. Cg B 0.09 
Cg A vs. Cg B 0.57 
Non-GEP NENs 
CART vs. Cg A 0.54 
CART vs. Cg B 0.68 
Cg A vs. Cg B 0.88 
Unknown primary 
CART vs. Cg A 0.55 
CART vs. Cg B 0.29 
Cg A vs. Cg B 0.73 
 
Table 4-12: Comparison of CART, Cg A, Cg B as markers of metastatic 
progressive NEN disease 
Area under ROC curve (AUC) for metastatic progressive vs. metastatic stable 
NENs for all NENs, and all NEN sub-types (detailed in Figure 4-5) for CART, Cg A 
and Cg B are compared. The difference in AUC was considered statistically 
significant if p < 0.05. The marker with the greater AUC is detailed in bold.  
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Biomarker (AUC) P value 
Combined AUC for 
significant markers  
All NENs 
CART (0.75) <0.0001 
0.78 Cg A (0.66) 0.008 
Cg B (0.69) 0.03 
Pancreatic NENs 
CART (0.84) 0.02 
0.90 Cg A (0.78) 0.01 
Cg B (0.71) 0.14 
Gut NENs 
CART (0.65) 0.04 
0.65 Cg A (0.69) 0.1 
Cg B (0.70) 0.1 
Phaeochromocytoma/paragangliomas 
CART (0.87) 0.32 
n/a Cg A (0.57) 0.60 
Cg B (0.64) 0.17 
Non-GEP NENs 
CART (0.59) 0.64 
n/a Cg A (0.64) 0.49 
Cg B (0.63) 0.22 
Unknown primary 
CART (0.74) 0.04 
0.74 Cg A (0.68) 0.27 
Cg B (0.65) 0.95 
 
Table 4-13: Combined utility of CART, Cg A and Cg B as markers of metastatic 
progressive NEN disease 
The combined utility of Cg A, Cg B and CART as markers of metastatic progressive 
NEN disease was assessed using multivariate analysis with backward selection. 
Using a combination of those markers that have a p values < 0.05 significantly 
improved diagnostic accuracy compared to any one single biomarker in isolation. 
The AUC for each marker alone and the combined AUC for all significant markers 
is shown. No combination of markers was useful in distinguishing metastatic 
progressive disease from metastatic stable disease in 
phaeochromocytoma/paragangliomas and Non-GEP NENs.  
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4.5.2.4.4 Correlation of plasma CART with Ki 67 index 
Rindi et al proposed a grading system for NENs based on the Ki 67 index: grade 1 
(≤ 2%), grade 2 (3 – 20%) and grade 3 (>20%)(25). The Ki 67 index was available 
on 161 patients. Based on the Ki 67 index scores, 65 tumours were classified grade 
1, 72 tumours grade 2 and 24 tumours grade 3. While there was no significant 
difference in Cg A levels between the three grades, both Cg B (p = 0.01) and 
CART (p = 0.007) levels were significantly higher in patients classified as grade 2 
compared to grade 1 (Table 4-14). However, there was no significant difference in 
CART and Cg A levels between grade 1 and grade 3 tumours. 
 
 
Table 4-14: Correlation of plasma CART with NEN Ki 67 index 
Plasma CART in G1 (grade 1:Ki 67 ≤ 2%) [n=65], G2 (grade 2: Ki 67 3- 20%) 
[n=72] and G3 (grade 3:Ki 67 ≥ 20%) [n=24].Values are expressed as median, 
inter-quartile range (IQR). * p<0.05 Cg B and CART grade 2 vs. grade.  
 
 
 
 
 
 
 
 
 
 
Cg A pmol/L 
median, IQR 
Cg B pmol/L 
median, IQR 
CART pmol/L 
median, IQR 
Grade 1 61, 43 - 230 93, 64 - 153 71, 46 - 154 
Grade 2 83, 45 - 356 211, 129 – 758
* 
106, 63 – 526
* 
Grade 3 59, 41 - 567 113, 80 - 146 64, 46 - 239 
116 
 
4.5.2.5 Correlation of CART with tumour burden 
Tumour burden data was available for 18 patients with 
phaeochromocytoma/paragangliomas. Tumour burden was calculated as the sum of 
the largest diameters of all lesions visible on imaging (range 0 – 87 mm). There 
was no significant correlation between tumour burden and circulating CART levels.  
Data for percentage of liver involvement was available in 66 patients with all NENs 
(range 0 – 90%, median 5%). Plasma levels of all three biomarkers were 
significantly correlated with percentage of liver involvement; CART (range 1 – 
5700 pmol/L, r = 0.46, p = 0.0001); Cg A (16 – 1000 pmol/L, r = 0.61, p <0.0001); 
Cg B (26 – 758 pmol/L, r = 0.37, p= 0.003).  
4.5.2.6 Utility of CART as a marker of response to therapy 
Longitudinal data was collected for fourteen patients with 
phaeochromocytoma/paragangliomas.  The tumour was completely excised in all 
14 of these patients. Of the 14 patients, at least pre-operative and 1 month post-
operative CART levels were available for eleven patients (Figure 4-6). Pre-
operative CART levels were above the reference range (78 pmol/L) in 10/11 
patients. Plasma CART was below reference range in 9/10 patients at 1 month post- 
surgery and in 6/6 of the patients at 12 months.  
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Figure 4-6: Serial plasma CART measurements in patients with 
phaeochromocytomas/paragangliomas 
Baseline (n = 11), one month (n = 11) and 12 month (n = 6) post operative plasma 
CART levels in patients with complete excision of 
phaeochromocytomas/paragangliomas. CART levels for each patient are shown in 
a different colour. 
 
CART was measured at serial intervals over a period of 12 months of were 
available in 34 patients with NENs (15 gut carcinoids, 12 pancreatic NENs and 6 
Non-GEP NENs). Six patients (2 gut NENs, 4 pancreatic NENs) died within 12 
months of follow-up. While 4/6 patients had baseline CART levels above the 
diagnostic cut-off, pre-death levels in all patients were above the diagnostic cut-off 
(Figure 4-7). 4/34 patients remained in remission following excision of a localised 
NEN (4/4 pancreatic NENs). All four patients had a baseline CART level below the 
diagnostic cut-off and plasma CART remained below the diagnostic cut-off 
consistent with their clinical remission (Figure 4-8). A further 24 patients have 
been followed up for a period of at least 12 months. Correlation of changes in 
plasma CART levels with response to therapy will be analysed once the patients 
have had their staging scans. 
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Figure 4-7: Serial plasma CART measurements in NEN patients who died within 
12 months of follow-up.  
Baseline + pre-death plasma CART levels in 6 patients [2 gut NENs (patient with 
no renal impairment:black line, patient with renal impairment: green line), 4 
pancreatic NENs(red)]. Dashed line denotes upper limit of reference range (78 
pmol/L). 
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Figure 4-8: Serial plasma CART measurements in pancreatic NEN patients in 
remission following complete excision of tumour.  
Plasma CART at baseline and at last follow-up of 4 pancreatic NEN patients in 
clinical remission. 
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4.5.2.7 Plasma CART as a surveillance marker in NEN disease 
Data was available on 489 patients of whom 66 were in clinical remission. A 
diagnosis of clinical remission was made on the basis of absence of both clinical 
signs and symptoms and radiological evidence of disease. Plasma Cg A, Cg B and 
CART were significantly lower in patients in clinical remission when compared to 
those with clinical evidence of disease (p<0.0001) (Table 4-15).  
 
Table 4-15: Plasma CART as a surveillance marker 
Plasma CART, Cg A and Cg B levels [median, inter-quartile range (IQR), all in 
pmol/L] in healthy controls, NEN patients in remission and NEN patients with 
active disease.*** p<0.0001 controls and patients in remission vs. patients with 
active disease. 
 
AUC (standard error, 95% confidence limits) for CART [0.75, 0.03 (0.70 – 0.79)], 
Cg A [0.77, 0.03 (0.73 – 0.80)] and Cg B [0.80, 0.02 (0.76 – 0.83)] for 
distinguishing between patients in remission and ongoing/active disease were 
compared. There was no significant difference in the AUCs of any of the three 
biomarkers. A multiple logistic regression analysis was carried out to assess if 
measuring a combination of biomarkers improves accuracy in distinguishing 
patients in remission from those with active disease. Using a combination of CART 
and Cg B was useful in identifying patients in remission (combined AUC 0.83). 
There was no significant advantage to measuring Cg A in addition to CART and 
Cg B. 
 
Cg A pmol/L 
median, IQR 
Cg B pmol/L 
median, IQR 
CART pmol/L 
median, IQR 
 controls 34, 26 - 41 70, 63 - 81 52, 36 - 67 
remission 42, 34 - 51 67, 58 - 94 54, 39 -73 
active disease 74, 45 – 315
*** 
126, 84 – 197
*** 
92, 56 – 259
*** 
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4.5.3 CART as a NEN biomarker in patients without renal impairment 
Following completion of the study of the effects of renal impairment on circulating 
NEN marker concentrations (section 2.5.2), a post-hoc analysis was performed to 
assess whether renal impairment influenced the diagnostic accuracy of CART alone 
and when compared to Cg A and Cg B.  
Creatinine and eGFR results of the NEN study patients from the time of sample 
collection were retrieved from electronic patient records and laboratory information 
systems. All patients with serum creatinine above the reference range and or eGFR 
< 60 ml/1.73 m
2
 and those for whom details of renal function were not available 
were excluded and results were re-analysed using 345 NEN patients without any 
renal impairment (Table 4-1).  
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4.5.3.1 Plasma CART in NEN patients without renal impairment 
Consistent with previous results (section 4.5.2.1) plasma CART remained 
significantly higher in all NEN groups compared to controls: median, inter-quartile 
range;[controls] 51, 36 – 67 pmol/L; [All NENs] 84, 54 - 225 pmol/L (p<0.0001 vs. 
controls), [pancreatic NENs] 87, 56 - 328 pmol/L (p<0.0001 vs. controls) [gut 
carcinoids] 77,  51 - 140 pmol/L (p<0.0001 vs. controls)], 
[phaeochromocytomas/paragangliomas 114, 66 - 360 pmol/L (p<0.0001 vs. 
controls), [non- gastro-entero-pancreatic NENs]  124, 54 - 1000 pmol/L (p<0.0001 
vs. controls) and [NENs with unknown primary] 106, 54 – 224 pmol/L (p<0.0001 
vs. controls) (Figure 4-9). 
Similarly plasma Cg A levels were also significantly higher in all NEN groups 
except phaeochromocytoma/paragangliomas when compared to healthy controls: 
median, inter-quartile range; [controls] 33, 26 – 41 pmol/L; [all NENs] 65, 42 – 
263 pmol/L; [pancreatic NENs] 52, 40 - 115 pmol/L (p<0.0001 vs. controls), [gut 
carcinoids] 107, 52 - 421 pmol/L (p<0.0001 vs. 
controls),[phaeochromocytoma/paraganglioma] 41, 31 - 61 pmol/L (p >0.05 vs. 
controls), [non- gastro-entero-pancreatic NENs] 48, 37 - 348 pmol/L (p<0.0001 vs. 
controls) and [NENs with unknown primary] 199, 54 - 679 pmol/L (p<0.0001 vs. 
controls) (Figure 4-9).  
Similarly, plasma Cg B remained significantly higher in all NEN groups when 
compared to healthy controls: median, inter-quartile range;[controls] 70, 63 – 81 
pmol/L; [all NENs] 125, 84 – 193 pmol/L; [pancreatic NENs] 117, 74 - 183 pmol/L 
(p<0.0001 vs. controls); [gut carcinoids] 128, 89 - 191 pmol/L (p<0.0001 vs. 
controls), [non- gastro-entero-pancreatic NENs]  121, 74 - 220 pmol/L (p<0.0001 
vs. controls) and [NENs with unknown primary] 157, 107 - 239 pmol/L (p<0.0001 
vs. controls) (Figure 4-9). 
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Figure: 4-9: Plasma CART, Cg A and Cg B in healthy controls and patients with 
active NENs and without renal impairment 
Plasma levels in controls [CART:n=216, Cg A: n = 108, Cg B: n = 40], all NENs 
(n= 345), pancreatic NENs (Panc) [n=108], gut carcinoids (Gut) [n= 131], 
phaechromocytoma/paragangliomas (Ph/PGs) [n= 36], non-
gastroenteropancreatic NENs (Non-GEP) [n= 28] and NENs with unknown 
primaries (UnPr) [n= 39], *** = p<0.0001 vs. controls, *=p<0.05. Values are 
median, inter-quartile range (shown in red). 
123 
 
4.5.3.2 Diagnostic cut-off for CART in NEN patients without renal impairment 
Similar to results described in section 4.5.2.2, a ROC curve was constructed for 
CART [controls: n = 216; NENs: n = 345 (NENs with no evidence of renal 
impairment). The optimal diagnostic cut-off for CART (78 pmol/L) and specificity 
at this cut-off (92%) remained the same as in the previous analysis but the 
sensitivity dropped from 59% to 56%. There was no significant change in area 
under ROC curves [AUC (95% CI) 0.76 (0.72 – 0.79) in NEN patients without 
renal impairment vs. 0.77 (0.73 – 0.80) in all NEN patients before excluding 
patients with renal impairment]. Similarly, the optimal diagnostic cut-off for the 
SAS Cg A assay (46 pmol/L) and the specificity (86%) remained the same 
compared to the previous analysis, but the sensitivity dropped from 72% to 69% 
[controls: n = 108; NENs: n = 345].  There was no significant change in area under 
ROC curves [AUC (95% CI): 0.85 (0.81 – 0.88) in NEN patients without renal 
impairment vs. 0.86 (0.83 – 0.89) in all NEN patients before excluding patients 
with renal impairment]. The optimal diagnostic cut-off for the SAS Cg B assay 
changed to 89 pmol/L from 94 pmol/L sensitivity increased from 63% to 70% and 
specificity changed from 97% to 95% [controls: n = 40; NENs: n = 345]. There was 
no significant change in area under ROC curves [AUC (95% CI): 0.82 (0.78 – 
0.86) in NEN patients without renal impairment vs. 0.79 (0.74 – 0.84) in all NEN 
patients before excluding patients with renal impairment] (Figure 4.10). 
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4.5.3.3 CART as a diagnostic marker in NEN patients without renal impairment 
Consistent with results described in section 4.5.2.3 CART had the highest AUC for 
phaeochromocytomas/paragangliomas. Cg A remained the most robust biomarker, 
with significantly better diagnostic accuracy than CART for all other NEN sub-
types (Figure 4-10, Table 4-16 and Table 4-17). In contrast to results described in 
the previous section (4.5.2.3), where the combination of CART, Cg A and Cg B 
made a significant improvement in diagnostic accuracy in pancreatic NENs - 
analysis of NEN patients without renal impairment showed that although the 
combination of Cg A and Cg B improved diagnosis for all NENs, gut NENs, 
pancreatic NENs and phaeochromocytomas, there was no advantage to using 
CART as an additional biomarker for any of the NEN subtypes (Table 4 -18).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
125 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-10: CART, Cg A and Cg B as markers of NEN diagnosis in patients 
without renal impairment 
ROC curves for CART (blue), Cg A (brown) and Cg B (orange) as diagnostic markers for 
all NENs and each of the NEN sub-types. Values for area under ROC curve (AUC) and 
results of comparison of AUC between the biomarkers are detailed in tables 4-16 & 4-17. 
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Biomarker AUC SE 95% CI 
Controls (n =40) vs. all NENs (n = 345) 
CART 0.71 0.03 0.66 to 0.75 
Cg A 0.90 0.02 0.87 to 0.93 
Cg B 0.81 0.02 0.77 to 0.86 
Controls (n =40) vs. Pancreatic NENs (n =108) 
CART 0.72 0.04 0.64 – 0.79 
Cg A 0.88 0.03 0.81 – 0.92 
Cg B 0.77 0.04 0.70 – 0.84 
Controls (n =40)  vs. Gut NENs (n = 132) 
CART 0.65 0.04 0.57 – 0.72 
Cg A 0.94 0.02 0.90 – 0.97 
Cg B 0.84 0.03 0.79- 0.89 
Controls (n =40) vs. Non-GEP NENs (n = 28) 
CART 0.72 0.07 0.60 – 0.83 
Cg A 0.88 0.04 0.78 – 0.95 
Cg B 0.80 0.06 0.69 - 0.89 
Controls (n =40) vs. phaeochromocytoma/paragangliomas (n = 36) 
CART 0.80 0.05 0.69 – 0.88 
Cg A 0.77 0.06 0.64 – 0.85 
Cg B 0.75 0.06 0.64 – 0.84 
Controls (n =40) vs. NENs with unknown primary (n = 39) 
CART 0.73 0.06 0.61 – 0.82 
Cg A 0.97 0.02 0.91 – 0.99 
Cg B 0.92 0.04 0.84 – 0.97 
 
Table 4-16: Cg A, Cg B and CART as diagnostic markers in NEN patients 
without renal impairment 
Shows the area under ROC curve (AUC) (detailed in figure 4-10), SE (standard 
error) and 95% confidence limits for Cg A, Cg B and CART for controls vs. all 
NENs, pancreatic NENs, gut carcinoids, non-GEP carcinoids, 
phaeochromocytomas/paragangliomas and NENs with unknown primary. 
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Table 4-17: Comparison of CART, Cg A, Cg B as diagnostic markers in NEN 
patients without renal impairment 
Area under ROC curve (AUC) for controls vs. all NENs, and all NEN sub-types 
(detailed in figure 4-10) for CART, Cg A and Cg B as diagnostic markers are 
compared. The difference in AUC was considered statistically significant if p < 
0.05. The marker with the greater AUC is detailed in bold. 
 
 
 
 
 
 
 
 
Biomarkers p value 
Controls vs. all NENs 
CART vs. Cg A <0.0001 
CART vs. Cg B 0.004 
Cg A vs. Cg B 0.001 
Controls vs. Pancreatic NENs 
CART vs. Cg A 0.001 
CART vs. Cg B 0.30 
Cg A vs. Cg B 0.02 
Control vs. Gut NENs 
CART vs. Cg A <0.0001 
CART vs. Cg B 0.0001 
Cg A vs. Cg B 0.001 
Controls vs. Non-GEP NENs 
CART vs. Cg A 0.008 
CART vs. Cg B 0.21 
Cg A vs. Cg B 0.19 
Controls vs.  phaeochromocytoma/paragangliomas 
CART vs. Cg A 0.32 
CART vs. Cg B 0.61 
Cg A vs. Cg B 0.58 
Controls vs. NENs with unknown primary 
CART vs. Cg A 0.0001 
CART vs. Cg B 0.008 
Cg A vs. Cg B 0.1 
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Biomarker (AUC ) P value 
Combined AUC for significant 
biomarkers 
Controls vs. all NENs 
CART (0.71) 0.33 
0.93 Cg A (0.90) <0.0001 
Cg B (0.81) 0.008 
Controls vs. Pancreatic NENs 
CART (0.72) 0.33 
0.91 Cg A (0.88) <0.0001 
Cg B (0.77) 0.009 
Controls vs. Gut NENs 
CART (0.65) 0.44 
0.96 Cg A (0.94) <0.0001 
Cg B (0.84) 0.009 
Controls vs. Non-GEP NENs 
CART(0.72) 0.77 
0.89 Cg A (0.88) 0.02 
Cg B (0.80) 0.29 
Controls vs. phaeochromocytoma/paragangliomas 
CART (0.80) 0.15 
0.81 Cg A (0.77) 0.04 
Cg B (0.75) 0.04 
Controls vs. NENs with unknown primary 
CART (0.73) 0.42 
0.97 Cg A (0.97) 0.01 
Cg B (0.92) 0.1 
 
Table 4-18: Combined utility of CART, Cg A and Cg B as diagnostic markers for 
NENs in patients without renal impairment 
The combined utility of Cg A, Cg B and CART as diagnostic markers for NENs was 
assessed using multivariate analysis with backward selection. Using a combination 
of those markers with p value < 0.05 significantly improves diagnostic accuracy 
compared to any one single biomarker in isolation. The AUC for each marker 
alone and the combined AUC for all significant markers is shown.  
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4.5.3.4 Plasma CART as a prognostic indicator in NEN disease patients without 
renal impairment 
4.5.3.4.1 Plasma CART in stable vs. progressive disease 
Consistent with the results described in section 4.5.2.4.1, CART remained the most 
useful biomarker in distinguishing between stable and progressive disease 
particularly in pancreatic NEN disease (Table 4-19, Figure 4-11). For all NENs, the 
AUC for CART was significantly higher than for Cg A (Table 4-20). CART also 
remained the most significant marker on multivariate analysis for all NENs and 
pancreatic NENs. Although CART had the highest AUC for 
phaeochromocytomas/paragangliomas and NENs with unknown primary, no 
marker was significant on multivariate analysis in distinguishing progressive from 
stable disease in gut NENs, phaeochromocytomas/paragangliomas, non-GEP NENs 
and NEN with unknown primary (Table 4-21). This is in contrast to previous 
results (section 4.5.2.4.1) where CART was significant in distinguishing 
progressive from stable disease in gut NENs (p = 0.04), 
phaeochromocytomas/paragangliomas (p = 0.02) and NEN with unknown primary 
(p = 0.04). 
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Figure 4-11: CART, Cg A and Cg B as markers of disease progression in NEN 
patients without renal impairment 
ROC curves for CART (blue), Cg A (brown) and Cg B (orange) as markers of progressive 
disease for all NENs and each of the NEN sub-types. Values for area under ROC curve 
(AUC) and results of comparison of AUC between the biomarkers are detailed in tables 4-
19 & 4-20. 
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Biomarker AUC SE 95% CI 
All NENs (n = 334, stable n = 228, progressive n = 106) 
CART 0.76 0.03 0.71 – 0.81 
Cg A 0.68 0.03 0.63 – 0.73 
Cg B 0.72 0.03 0.67 – 0.77 
Pancreatic NENs (n =108, stable n = 73, progressive n = 35) 
CART 0.84 0.04 0.76 – 0.91 
Cg A 0.74 0.06 0.65 – 0.82 
Cg B 0.73 0.05 0.63 – 0.81 
Gut NENs (n = 126, stable n = 99, progressive n = 27 ) 
CART 0.61 0.07 0.52 – 0.69 
Cg A 0.62 0.06 0.53 – 0.71 
Cg B 0.70 0.06 0.61 – 0.78 
Non-GEP NENs (n = 28, stable n = 14, progressive n = 14) 
CART 0.69 0.1 0.48 – 0.84 
Cg A 0.71 0.1 0.51 – 0.89 
Cg B 0.69 0.1 0.49 – 0.85 
Phaeochromocytoma/paragangliomas (n = 36, stable n = 24, progressive n = 12 ) 
CART 0.91 0.07 0.76 – 0.98 
Cg A 0.88 0.06 0.73 – 0.96 
Cg B 0.84 0.07 0.67 – 0.94 
NENs with unknown primary (n = 39, stable n = 20, progressive n = 19) 
CART 0.74 0.08 0.58 – 0.87 
Cg A 0.70 0.09 0.53 – 0.83 
Cg B 0.67 0.09 0.51 – 0.82 
 
Table 4-19: CART, Cg A and Cg B as markers of progressive NENs in patients 
without renal impairment 
Area under ROC curve (AUC) (detailed in figure 4-11), SE (standard error) and 
95% confidence limits for Cg A, Cg B and CART for progressive vs. stable (all 
NENs, pancreatic NENs, gut carcinoids, non-GEP carcinoids, 
phaeochromocytomas/paragangliomas and NENs with unknown primary). 
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Biomarker p value 
All NENs 
CART vs. Cg A 0.04 
CART vs. Cg B 0.23 
Cg A vs. Cg B 0.20 
Pancreatic NENs 
CART vs. Cg A 0.11 
CART vs. Cg B 0.05 
Cg A vs. Cg B 0.86 
Gut NENs 
CART vs. Cg A 0.86 
CART vs. Cg B 0.27 
Cg A vs. Cg B 0.73 
Phaeochromocytoma/paragangliomas 
CART vs. Cg A 0.68 
CART vs. Cg B 0.15 
Cg A vs. Cg B 0.20 
Non-GEP NENs 
CART vs. Cg A 0.7 
CART vs. Cg B 0.9 
Cg A vs. Cg B 0.8 
NENs with unknown primary 
CART vs. Cg A 0.55 
CART vs. Cg B 0.29 
Cg A vs. Cg B 0.73 
 
Table 4-20: Comparison of CART, Cg A, Cg B as markers of NEN disease 
progression in patients without renal impairment 
Area under ROC curve (AUC) for stable vs. progressive NENs for all NENs, and 
all NEN sub-types (detailed in Figure 4-11) for CART, Cg A and Cg B are 
compared. The difference in AUC was considered statistically significant if p < 
0.05. The marker with the greater AUC is detailed in bold.  
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Biomarker P value 
Combined AUC for 
significant biomarkers 
All NENs 
CART(0.76) <0.0001 
0.80 Cg A(0.68) 0.11 
Cg B(0.72) 0.01 
Pancreatic NENs 
CART(0.84) 0.004 
0.88 Cg A(0.74) 0.02 
Cg B(0.73) 0.17 
Gut NENs 
CART(0.61) 0.09 
n/a Cg A(0.62) 0.92 
Cg B(0.70) 0.05 
Non-GEP NENs 
CART(0.69) 0.75 
n/a Cg A(0.71) 0.23 
Cg B(0.69) 0.40 
Phaeochromocytoma/paragangliomas 
CART(0.91) 0.09 
n/a Cg A(0.88) 0.52 
Cg B(0.84) 0.76 
NENs with unknown primary 
CART(0.74) 0.10 
n/a Cg A(0.70) 0.48 
Cg B(0.67) 0.95 
 
Table 4-21: Combined utility of CART, Cg A and Cg B as markers of NEN 
disease progression in patients without renal impairment 
The combined utility of Cg A, Cg B and CART as markers of NEN disease 
progression was assessed using multivariate analysis with backward selection. 
Using a combination of those markers with p value < 0.05 significantly improved 
diagnostic accuracy compared to any one single biomarker in isolation. The AUC 
for each marker alone and the combined AUC for all significant markers is shown. 
No combination of markers was useful in distinguishing stable from progressive 
Gut NENs, non-GEP NENs, phaeochromocytomas/paragangliomas or NENs with 
unknown primaries (n/a).  
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4.5.3.4.2 Plasma CART in metastatic vs. non-metastatic disease in NEN patients 
without renal impairment 
Consistent with previous results (section 4.5.2.4.2), CART provided the highest 
diagnostic accuracy in distinguishing non-metastatic from metastatic pancreatic 
NENs (Figure 4-12, Table 4-22, Table 4-23). CART also remained the only 
significant marker able to distinguish between non-metastatic and metastatic 
pancreatic NENs on multivariate analysis (Table 4-24). Similarly, Cg A remained 
the most useful biomarker, with significantly higher AUC than CART and Cg B, 
for all NENs. In contrast to previous results (section 4.5.2.4.2), although CART 
was the biomarker with the highest AUC in phaeochromocytomas/paragangliomas, 
it was not significant on multivariate analysis. This may be related to small 
numbers and wide 95% confidence limits. 
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Figure 4-12: CART, Cg A and Cg B as markers of metastatic NENs in patients 
without renal impairment 
ROC curves for CART (blue), Cg A (brown) and Cg B (orange) as markers of metastatic 
disease for all NENs and each of the NEN sub-types. Values for area under ROC curve 
(AUC) and results of comparison of AUC between the biomarkers are detailed in tables 4-
22 & 4-23. 
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Biomarker AUC SE 95% CI 
All NENs (n = 338, metastatic n = 274, non-metastatic n = 64) 
CART 0.66 0.04 0.60 – 0.71 
Cg A 0.75 0.03 0.70 – 0.79 
Cg B 0.67 0.04 0.62 – 0.72 
Pancreatic NENs (n =108, metastatic n = 80, non-metastatic n = 28) 
CART 0.77 0.05 0.68 – 0.84 
Cg A 0.65 0.06 0.55 – 0.74 
Cg B 0.66 0.06 0.56 – 0.75 
Gut NENs (n = 130, metastatic n = 122, non-metastatic n = 8) 
CART 0.67 0.09 0.59 – 0.75 
Cg A 0.68 0.08 0.59 – 0.76 
Cg B 0.67 0.08 0.58 – 0.75 
Phaeochromocytoma/paragangliomas (n = 36, metastatic n = 17, non-metastatic n = 19) 
CART 0.89 0.06 0.74 – 0.97 
Cg A 0.78 0.08 0.61 – 0.90 
Cg B 0.81 0.08 0.65 – 0.92 
Non-GEP NENs (n = 28, metastatic n = 23, non-metastatic n = 5) 
CART 0.70 0.13 0.49 – 0.85 
Cg A 0.66 0.14 0.46 – 0.83 
Cg B 0.60 0.14 0.39 – 0.77 
 
Table 4-22: CART, Cg A and Cg B as markers of metastatic NENs in patients 
without renal impairment 
Area under ROC curve (AUC) (detailed in figure 4-12), SE (standard error) and 
95% confidence limits for Cg A, Cg B and CART for non-metastatic vs. metastatic 
(all NENs, pancreatic NENs, gut carcinoids, non-GEP carcinoids, 
phaeochromocytomas/paragangliomas and NENs with unknown primary).  
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Biomarker  p value 
All NENs 
CART vs. Cg A 0.02 
CART vs. Cg B 0.70 
Cg A vs. Cg B 0.01 
Pancreatic NENs 
CART vs. Cg A 0.06 
CART vs. Cg B 0.07 
Cg A vs. Cg B 0.85 
Gut NENs 
CART vs. Cg A 0.97 
CART vs. Cg B 0.94 
Cg A vs. Cg B 0.90 
phaeochromocytoma/paragangliomas 
CART vs. Cg A 0.33 
CART vs. Cg B 0.16 
Cg A vs. Cg B 0.64 
Non-GEP NENs 
CART vs. Cg A 0.57 
CART vs. Cg B 0.11 
Cg A vs. Cg B 0.37 
 
Table 4-23: Comparison of CART, Cg A, Cg B as markers of metastatic NEN 
disease in patients without renal impairment 
Area under ROC curve (AUC) for metastatic vs. non-metastatic NENs for all 
NENs, and all NEN sub-types (detailed in Figure 4-12), for CART, Cg A and Cg B 
are compared. The difference in AUC was considered statistically significant if p < 
0.05. The marker with the greater AUC is detailed in bold. 
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Biomarker (AUC) P value 
Combined AUC for significant 
biomarkers 
All NENs 
CART (0.65) 0.46 
0.73 Cg A (0.74) 0.01 
Cg B (0.69) 0.02 
Pancreatic NENs 
CART (0.74) 0.02 
0.77 Cg A (0.67) 0.87 
Cg B (0.67) 0.87 
Gut NENs 
CART (0.69) 0.32 
n/a Cg A (0.72) 0.26 
Cg B (0.72) 0.93 
Phaeochromocytoma/paragangliomas 
CART (0.88) 0.08 
n/a Cg A (0.82) 0.79 
Cg B (0.82) 0.26 
Non-GEP NENs 
CART (0.88) 0.47 
n/a Cg A (0.82) 0.52 
Cg B (0.82) 0.97 
 
Table 4-24: Combined utility of CART, Cg A and Cg B as markers of metastatic 
NEN disease in patients without renal impairment 
The combined utility of Cg A, Cg B and CART as markers of metastatic NEN 
disease was assessed using multivariate analysis with backward selection. Using a 
combination of those markers with p value < 0.05 significantly improved 
diagnostic accuracy compared to any one single biomarker in isolation. The AUC 
for each marker alone and the combined AUC for all significant markers is shown. 
No combination of markers was useful in distinguishing metastatic from non-
metastatic gut NENs, phaeochromocytoma/paragangliomas and Non-GEP NENs.  
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4.5.3.4.3 Plasma CART in metastatic stable vs. metastatic progressive disease in 
NEN patients without renal impairment 
ROC curves for all three biomarkers are shown in Figure 4-13 & Tables 4-25. 
Consistent with previous results (section 4.5.2.4.3), the AUC for CART remained 
significantly greater than AUC for Cg A for metastatic stable vs. metastatic 
progressive NENs when all NENs were considered together (Table 4-26). 
Similarly, there was no significant difference in the AUCs of the three biomarkers 
for any of the individual NEN subtypes. 
In contrast to previous results (section 4.5.2.4.3), measuring Cg A in addition to 
CART and Cg B did not significantly improve the ability to distinguish metastatic 
progressive from metastatic stable disease (Table 4-27). Further, CART was no 
longer significant on multivariate analysis when pancreatic NENs were considered.  
There was no significant advantage to measuring any of the markers in 
combination in patients with non-GEP NENs, gut NENs or 
phaeochromocytoma/paragangliomas. This may be due to the small n numbers in 
these two groups and the wide confidence intervals. 
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Figure 4-13: CART, Cg A and Cg B as markers of metastatic progressive NENs 
in patients without renal impairment 
ROC curves for CART (blue), Cg A (brown) and Cg B (orange) as markers of 
metastatic progressive disease for all NENs and each of the NEN sub-types. Values 
for area under ROC curve (AUC) and results of comparison of AUC between the 
biomarkers are detailed in tables 4-25 & 4-26. 
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Biomarker AUC SE 95% CI 
All NENs (n = 271, met st n = 167, met-pr n = 104) 
CART 0.74 0.03 0.69 – 0.79 
Cg A 0.63 0.04 0.57– 0.69 
Cg B 0.70 0.03 0.64 – 0.75 
Pancreatic NENs (n = 79, met-st n = 45, met-pr n = 34) 
CART 0.80 0.05 0.69 – 0.88 
Cg A 0.73 0.06 0.62 – 0.82 
Cg B 0.71 0.06 0.60 – 0.81 
Gut NENs (n = 122, met-st n = 95, non-met-pr n = 27) 
CART 0.59 0.07 0.50 – 0.68 
Cg A 0.61 0.06 0.52 – 0.70 
Cg B 0.68 0.06 0.59 – 0.76 
Non-GEP NENs (n = 21, met-st n = 13, met-pr n = 8) 
CART 0.61 0.13 0.41 – 0.83 
Cg A 0.64 0.13 0.42 – 0.85 
Cg B 0.65 0.12 0.37 – 0.81 
Phaeochromocytoma/paragangliomas (n = 17, met-st n = 5, met-pr n = 12) 
CART 0.85 0.11 0.60 – 0.97 
Cg A 0.67 0.15 0.40 – 0.87 
Cg B 0.81 0.13 0.55 – 0.96 
Unknown primary (n = 39, met-st n = 20, met-pr n = 19) 
CART 0.74 0.08 0.58 – 0.87 
Cg A 0.70 0.09 0.53 – 0.83 
Cg B 0.68 0.09 0.51 – 0.82 
 
Table 4-25: CART, Cg A and Cg B as markers of metastatic progressive NENs in 
patients without renal impairment  
Area under ROC curve (AUC)(detailed in Figure 4-13), SE (standard error) and 
95% confidence limits for Cg A, Cg B and CART for metastatic progressive vs. 
metastatic stable (all NENs, pancreatic NENs, gut carcinoids, non-GEP 
carcinoids, phaeochromocytomas/paragangliomas and NENs with unknown 
primary). 
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Biomarkers p value 
All NENs 
CART vs. Cg A 0.009 
CART vs. Cg B 0.05 
Cg A vs. Cg B 0.22 
Pancreatic NENs 
CART vs. Cg A 0.33 
CART vs. Cg B 0.17 
Cg A vs. Cg B 0.78 
Gut NENs 
CART vs. Cg A 0.80 
CART vs. Cg B 0.15 
Cg A vs. Cg B 0.25 
Phaeochromocytoma/paragangliomas 
CART vs. Cg A 0.17 
CART vs. Cg B 0.30 
Cg A vs. Cg B 0.61 
Non-GEP NENs 
CART vs. Cg A 0.69 
CART vs. Cg B 0.61 
Cg A vs. Cg B 0.93 
Unknown primary 
CART vs. Cg A 0.69 
CART vs. Cg B 0.52 
Cg A vs. Cg B 0.82 
 
Table 4-26: Comparison of CART, Cg A, Cg B as markers of metastatic 
progressive NEN disease in patients without renal impairment 
Area under ROC curve (AUC) for metastatic progressive vs. metastatic stable 
NENs for all NENs, and all NEN sub-types (detailed in Figure 4-13) for CART, Cg 
A and Cg B are compared. The difference in AUC was considered statistically 
significant if p < 0.05. The marker with the greater AUC is detailed in bold. 
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Biomarker (AUC) P value 
Combined AUC for 
significant markers  
All NENs 
CART (0.75) <0.0001 
0.78 Cg A (0.66) 0.28 
Cg B (0.69) 0.03 
Pancreatic NENs 
CART (0.84) 0.12 
0.73 Cg A (0.78) 0.03 
Cg B (0.71) 0.15 
Gut NENs 
CART (0.65) 0.14 
n/a Cg A (0.69) 0.82 
Cg B (0.70) 0.09 
Phaeochromocytoma/paragangliomas 
CART (0.87) 0.27 
n/a Cg A (0.57) 0.37 
Cg B (0.64) 0.94 
Non-GEP NENs 
CART (0.59) 0.60 
n/a Cg A (0.64) 0.46 
Cg B (0.63) 0.22 
Unknown primary 
CART (0.74) 0.10 
n/a Cg A (0.68) 0.48 
Cg B (0.65) 0.95 
 
Table 4-27: Combined utility of CART, Cg A and Cg B as markers of metastatic 
progressive NEN disease in patients without renal impairment 
The combined utility of Cg A, Cg B and CART as markers of metastatic progressive 
NEN disease was assessed using multivariate analysis with backward selection. 
Using a combination of those markers with p value < 0.05 significantly improved 
diagnostic accuracy compared to any one single biomarker in isolation. The AUC 
for each marker alone and the combined AUC for all significant markers is shown. 
None of the markers were useful in distinguishing metastatic progressive disease 
from metastatic stable disease in gut NENs, phaeochromocytoma/paragangliomas, 
Non-GEP NENs and NENs with unknown primaries.  
 
 
 
 
 
 
 
144 
 
4.5.3.4.4 Correlation of plasma CART with Ki 67 index 
Rindi et al proposed a grading system for NENs based on the Ki 67 index: grade 1 
(≤ 2%), grade 2 (3 – 20%) and grade 3 (>20%)(25). The Ki 67 index was available 
on 118 NEN patients without renal impairment. Based on the Ki 67 index scores, 
48 tumours were classified grade 1, 55 tumours grade 2 and 16 tumours grade 3. 
Consistent with previous results (section 4.5.2.4.4) , while there was no significant 
difference in Cg A levels between the three grades of tumour, both Cg B (p < 0.05) 
and CART (p < 0.05) levels were significantly higher in patients with grade 2 
compared to grade 1 tumours (Table 4-28). Similar to previous results, there was no 
significant difference in CART and Cg A levels between grade 1 and grade 3 
tumours. 
 
Table 4-28: Correlation of plasma CART with NEN Ki 67 index in patients 
without renal impairment 
Plasma CART in G1 (grade 1: Ki 67 ≤ 2%) [n=48], G2 (grade 2: Ki 67 3- 20%) 
[n=55] and G3 (grade 3: Ki 67 ≥ 20%) [n=16].Values are expressed as median, 
inter-quartile range (IQR). *p<0.05 grade 2 vs. grade 1.  
 
 
 
 
 
 
Cg A pmol/L 
median, IQR 
Cg B pmol/L 
median, IQR 
CART pmol/L 
median, IQR 
Grade 1 61, 25 - 180 94, 64 - 174 71, 49 - 156 
Grade 2         101, 44 - 362 137, 96 – 251
* 
106, 69 – 644
* 
Grade 3 47, 39 - 356 115, 80 - 171 64, 48 - 270 
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4.5.3.5 Correlation of CART with tumour burden in NEN patients without renal 
impairment 
None of the 18 patients with phaeochromocytoma/paragangliomas in whom tumour 
burden data was available had any renal impairment (ref section 4.5.2.5). There 
was no significant correlation between tumour burden and circulating CART levels.  
Data for percentage of liver involvement was available in 57 patients with all NENs 
without renal impairment (range 0 – 90%, median 5%). Plasma levels of all three 
biomarkers were significantly correlated with percentage of liver involvement; 
CART (range 1 – 5700 pmol/L, r = 0.41, p = 0.0001); Cg A (16 – 1000 pmol/L, r = 
0.57, p <0.0001); Cg B (26 – 758 pmol/L, r = 0.40, p= 0.003) (ref section 4.5.2.5).  
4.5.3.6 Utility of CART as a marker of response to therapy 
None of the fourteen patients with phaeochromocytoma/paragangliomas for whom 
longitudinal data was collected had renal impairment section (4.5.2.6, figure 4-6).   
Similarly none of the four patients in remission (section 4.5.2.6, figure 4-8) in 
whom plasma CART levels remained below the reference range on surveillance 
had renal impairment.   
Six patients (2 gut NENs, 4 pancreatic NENs) died within 12 months of follow-up. 
4/6 patients had baseline CART levels above the diagnostic cut-off, pre-death 
levels in all patients were above the diagnostic cut-off (section 4.5.2.6, figure 4-7). 
One of the patients with gut NEN had deterioration in renal impairment during 
follow-up (highlighted in green in figure 4-7). 
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4.5.3.7 Plasma CART as a surveillance marker in NEN disease without renal 
impairment 
Consistent with previous results (section 4.5.2.7), plasma Cg A, Cg B and CART 
were significantly lower in patients in clinical remission when compared to those 
with clinical evidence of disease (p<0.0001) (Table 4-29).  
 
Table 4-29: Plasma CART as a surveillance marker in patients without renal 
impairment 
Plasma CART, Cg A and Cg B levels [median, inter-quartile range (IQR), all in 
pmol/L] in healthy controls, NEN patients in remission and NEN patients with 
active disease. *** = p<0.0001. 
 
AUC (standard error, 95% confidence limits) for CART [0.74, 0.04 (0.70 – 0.79)], 
Cg A [0.72, 0.04 (0.67 – 0.76)] and Cg B [0.79, 0.03 (0.74 – 0.83)] for 
distinguishing between patients in remission and ongoing/active disease were 
compared. As described previously (section 4.5.2.7), there was no significant 
difference in the AUCs of any of the three biomarkers. Similarly, following 
multiple logistic regression analysis there was no significant advantage to 
measuring either Cg A in addition to CART or Cg B. 
 
 
 
 
 
 
 
Cg A pmol/L 
median, IQR 
Cg B pmol/L 
median, IQR 
CART pmol/L 
median, IQR 
 controls 34, 26 - 41 70, 63 - 81 52, 36 - 67 
remission 43, 34 - 55 67, 60 - 99 53, 38 -74 
active disease 65, 42 – 263
*** 
121, 82 – 184
*** 
84, 54 – 225
*** 
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4.6 Discussion  
None of the existing clinical biomarkers for NENs are sufficiently sensitive or 
specific to be used as a single definitive NEN biomarker. Bech et al proposed a 
possible role for CART as a NEN biomarker (57).The aim of the work described in 
this chapter was to further evaluate the utility of CART as a diagnostic, prognostic 
and surveillance marker in NENs. 
CART mRNA expression studies have demonstrated extensive CART expression 
in all sub-types (α, β, δ, gastrin and ghrelin) of pancreatic islet cells of rats and 
humans during the foetal stages of development (54). This expression was almost 
entirely absent in the postnatal period, being isolated only to a few scattered 
somatostatin secreting cells (54). However, CART expression has been 
demonstrated in certain types of adult pancreatic NENs including insulinomas and 
glucagonomas (146), thus implying onco-foetal expression. In contrast, although a 
number of neurones in the gut myentric plexus express CART, no CART mRNA 
expression has been found in any mid- or hindgut NE cells (46).  
Plasma CART, Cg A and Cg B were significantly higher in patients with NENs 
when compared to healthy controls. The results from this study show that Cg A is 
the most accurate NEN diagnostic marker for all NEN sub-types except for 
phaeochromocytoma/paragangliomas where CART was the most effective 
diagnostic marker. Multivariate analysis of all NEN patients with active disease 
revealed that using a combination of all three markers significantly improved 
diagnosis in patients with pancreatic NENs and 
phaeochromocytomas/paragangliomas. There was no significant advantage to using 
CART in addition to Cg A and Cg B in gut NENs. Furthermore, there was no 
advantage to measuring any other biomarker in addition to Cg A in non-GEP NENs 
and in patients with NENs with unknown primary. Thus, Cg A is the most useful 
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diagnostic marker for NEN disease. Measurement of CART in addition to Cg A is 
particularly useful in patients with phaeochromocytomas/paragangliomas and 
pancreatic NENs. After exclusion of patients with renal impairment, Cg A 
remained the most useful marker, with no significant advantage to measuring 
CART in addition to Cg A for NEN diagnosis. Measuring Cg B in addition to Cg A 
was useful in patients with pancreatic NENs, gut NENs, phaeochromocytomas and 
NENs with unknown primary. Interestingly, ROC analysis continues to suggest that 
Cg A is a useful diagnostic biomarker in phaeochromocytomas/paragangliomas 
despite the levels of Cg A in phaeochromocytomas/paragangliomas no longer being 
significantly different from controls (section 4.5.3.1). It is possible that the results 
in section 4.5.3.1 may have failed to reach significance due to small numbers. 
The rate of growth and malignancy in NENs is variable, ranging from indolent, 
slow growing to aggressive rapidly growing tumours. Intervention is dependent on 
tumour behaviour. Minimal intervention can be advocated for stable, slowly 
growing tumours and aggressive therapy for progressive ones (86). Currently, the 
distinction between stable and progressive disease is made using serial imaging or 
on the Ki 67 index. A circulating diagnostic maker capable of making this 
distinction would allow earlier intervention. This work assessed the comparative 
utility of Cg A, Cg B and CART as prognostic markers by comparing their ability 
to distinguish between stable and progressive NENs, metastatic and non-metastatic 
NENs and metastatic progressive and metastatic stable NENs.  
CART was the most useful marker for distinguishing between stable and 
progressive NENs. Multivariate analysis when all active NENs were included 
showed that using a combination of all three markers significantly improved ability 
to distinguish between stable and progressive NENs when all NENs were 
considered. Using a combination of Cg A and CART significantly improves 
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diagnostic accuracy for progressive disease in pancreatic NENs. CART has the 
highest diagnostic accuracy for detecting progressive disease in gut carcinoids and 
phaeochromocytomas/paragangliomas and there was no advantage to using Cg A 
or Cg B in addition. None of the three markers are useful in detecting progressive 
disease in non-GEP NENs and NENs with unknown primary. Following exclusion 
of patients with renal impairment, plasma CART remained the most useful marker 
for progressive disease on multivariate analysis. It was particularly useful when all 
NENs were considered together and in pancreatic NENs. Although CART 
remained the marker with the highest AUC for progressive disease in patients with 
phaeochromocytomas/paragangliomas and NENs with unknown primaries, it failed 
to be significant on multivariate analysis. Small patient numbers may account for 
the lack of significance despite high AUCs. A study with larger patient numbers 
will be useful. 
CART was the most useful marker in detecting metastatic pancreatic NENs and 
phaeochromocytomas/paragangliomas. None of the three markers were particularly 
useful in detecting metastatic non-GEP NENs and gut NENs.  
When results from all patients with active NENs were analysed, CART was most 
useful in detecting metastatic progressive NENs in all NENs, pancreatic NENs, 
phaeochromocytomas/paragangliomas and NENs with unknown primary. CART 
and Cg A in combination significantly improved ability to distinguish between 
metastatic stable and metastatic progressive pancreatic NENs. CART was the only 
marker able to distinguish between metastatic stable and metastatic progressive gut 
NENs and NENs with unknown primary. Following exclusion of patients with 
renal impairment, plasma CART remained the marker with the highest AUC for 
metastatic progressive disease in all NENs, pancreatic NENs, 
phaeochromocytomas/paragangliomas and NENs with unknown primary, with a 
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significantly higher AUC than Cg A for all NENs. On multivariate analysis, CART 
remained the most significant marker for metastatic progressive disease in all 
NENs. However, it was not superior to Cg A or Cg B for individual NEN sub-
types. 
Plasma Cg A, Cg B and CART levels were correlated with the best available 
prognostic indicator Ki 67. There was no significant correlation between plasma Cg 
A and the Ki 67 index of NENs. Cg B and CART levels were significantly higher 
in grade 2 (Ki 67 3 -20%) compared to grade 1 (<2%) (p < 0.05). CART and Cg B 
levels were lower in grade 3 NENs (>20%). Grade 1 and 2 NENs are more likely to 
be well differentiated NENs that retain most of the morphological features of 
neuroendocrine cells including secretory granules (17). Thus, higher CART levels 
in grade 2 NENs may reflect either higher tumour burden or more aggressive 
tumour behaviour. In contrast grade 3 tumours are less well differentiated and often 
lack secretory granules (17). Therefore these tumours may be unable to synthesise 
or store CART or chromogranins. This may explain the trend towards decreasing 
levels of Cg B and CART in these tumours. The results of this work suggest that 
none of the biomarkers can be reliably used to predict the proliferative behaviour of 
NENs. However, the results should be interpreted with caution since the Ki 67 
index in the samples studied was usually determined on the tissue sample taken at 
initial biopsy or tumour resection. In most cases, paired blood samples for plasma 
CART, Cg A and Cg B at the time of biopsy/tumour resection were not available. It 
is not uncommon for NENs to change behaviour during the course of the disease 
(147). Differences in tumour behaviour between the two different sampling time 
points may have a bearing on the results of this analysis.  
This work has shown that CART is the most useful prognostic marker of the three 
biomarkers in detecting progressive disease particularly in patients with pancreatic 
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NENs. Consistent with this, all pancreatic NEN patients who died within 12 
months of follow-up either had very high levels of CART at baseline, or showed a 
rapid rise in CART levels prior to death. This reiterates its role as a prognostic 
marker particularly in pancreatic NENs. It will be interesting to further review the 
role of CART as a prognostic marker in pancreatic NENs and by collecting further 
longitudinal data on these patients. 
Multivariate analysis revealed that using a combination of CART and Cg B 
significantly improved ability to distinguish between patients in clinical remission 
and those with active disease. Patients were classified as being in clinical remission 
based on a lack of symptoms and absence of disease on imaging studies. However, 
this does not unequivocally rule out the presence of residual/recurrent disease 
which may be asymptomatic and below the resolution of currently available 
imaging. This is a potential cause of misclassification of a NEN patient into the 
‘clinical remission’ category, thus decreasing the accuracy of the analysis.  Long 
term surveillance of patients in clinical remission will provide more useful 
information regarding utility of these biomarkers in detecting recurrent disease.  
The results of this work suggest that CART is a useful prognostic marker 
particularly when used in combination with Cg A and Cg B. High CART levels 
may be reflective of either tumour burden or tumour behaviour. In patients with 
phaeochromocytomas/paragangliomas, there was no correlation between tumour 
burden and circulating levels of CART or Cg A or Cg B. The high CART levels in 
these patients with progressive phaeochromocytoma/paragangliomas may therefore 
reflect tumour behaviour. In contrast, in patients with all other NENs sub-types, all 
three biomarkers were significantly correlated with percentage of liver 
involvement, with Cg A having the best correlation. The discrepancy may be a 
reflection of the challenges associated with accurate estimation of tumour load, 
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particularly in relation to three dimensional tumour volume, extra-hepatic tumour 
load and tumour load due to lesions below the resolution of the imaging modality. 
91% of the patients with localised phaeochromocytomas/paragangliomas who 
underwent complete excision of the tumours had pre-operative circulating CART 
levels above the reference range. These levels fell to within reference range after 
surgery. Future work correlating the size of the excised tumour with pre-operative 
CART levels in these patients may provide more information regarding the 
association between tumour burden and circulating CART levels.  
In conclusion, the combination of Cg A and Cg B provides greatest diagnostic 
accuracy. However, CART is a particularly useful prognostic marker in NEN 
patients with progressive and metastatic disease, especially in patients with 
pancreatic NENs. Results showing changes in plasma CART levels in patients 
before and after resection of phaeochromocytomas, suggest that CART may be a 
valuable surveillance marker in patients with these tumours to highlight recurrent 
disease. Interestingly, rising plasma CART may be associated with a poorer 
prognosis in pancreatic NENs. 
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Chapter 5 : CART peptide tissue expression in 
NEN patients 
5.1 Introduction  
5.1.1 NEN histology 
The 2010 WHO classification broadly divides NENs into well differentiated NETs 
and the poorly differentiated NECs (25). NETs are characterised by typical 
monomorphic medium sized eosinophilic cells with abundant granular cytoplasm. 
The nuclei of these cells are generally regular and mitoses are rare. They may 
occasionally present with atypical clear cells with irregular nuclei. These 
appearances are suggestive of a poorer prognosis (148).   
The general architecture of NETs is variable. These may be solid insular tumours 
composed of small to medium sized nests of cells, trabecular tumours made of 
layers of cells arranged like ribbons, or glandular tumours which have a glandular 
appearance due to either true gland formation or the presence of pseudo-glands. It 
is not uncommon for NENs to have a complex architecture combining the features 
of two or more of the above patterns (149, 150). The architectural patterns vary 
according to location of tumour. While glandular tumours are more commonly seen 
in ampullary tumours, the insular solid pattern is often associated with appendicular 
NETs and the trabecular pattern with rectal NETs (148).  
In contrast to NETs, the histological picture in NECs is very different. The cells are 
atypical, with many NECs exhibiting features of more aggressive epithelial 
neoplasms. The cells are irregular with atypical nuclei and numerous mitoses. The 
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cytoplasm in these cells is much less abundant, sometimes restricted to a thin 
perinuclear rim (149, 148). 
Although the above mentioned features are typical of NENs, histological diagnosis 
is not always straightforward. Other cancers, such as exocrine pancreatic epithelial 
neoplasms, adenocarcinoma of the ampullary region or gastrointestinal stromal 
tumours (GIST), may have a very similar microscopic morphology. NECs may also 
be associated with a non-NEN component such as adenocarcinoma or squamous 
carcinoma (151). Thus immunocytochemistry (IHC) confirmation of 
neuroendocrine origin of a tumour is essential (148,149).  
5.1.2 IHC diagnostic markers 
IHC diagnostic markers are routinely used in the diagnosis of patients with 
suspected NEN. The granular proteins Cg A and synaptophysin are two most 
commonly used (42, 76). While synaptophysin is expressed in granular 
membranes, Cg A is found in the matrix of the dense core secretory granules (62). 
The intensity of staining of these markers is variable (152). NECs often lack or 
only stain weakly for Cg A (153). The loss of Cg A staining usually indicates 
absence of the endocrine granules, de-differentiation and worse prognosis (153). 
The presence and intensity of Cg A staining also varies with location of tumour. 
Rectal tumours are poorly staining for Cg A (154). Synaptophysin is a more 
sensitive, but less specific neuroendocrine marker. Immunostaining for 
synaptophysin is often retained even in the absence of endocrine granules.  
A diagnosis of NEN, particularly in the presence of atypical histology needs IHC 
confirmation by at least two IHC markers (148). As Cg A is often absent, 
particularly in NECs, other neuroendocrine cell specific cytosolic components such 
as neuron-specific-enolase (NSE), protein-gene-product 9.5 or the membrane 
molecule CD56 N-CAM are sometimes used for NEN diagnosis confirmation(148). 
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However, the 2009 ENETs consensus guidelines on standards of care in 
neuroendocrine tumours do not recommend the routine use of these markers, as 
both the markers and the antibodies used to detect them, lack diagnostic specificity 
(62).  
5.1.3 Markers of tumour localisation  
Since the majority of NENs present with metastatic disease (21), liver and lymph 
node biopsy specimens are often the first (and may be the only) diagnostic 
specimen available to the histopathologist. The most common diagnostic challenge 
for a histopathologist in this situation is localisation of the primary tumour. An 
origin-specific marker would be very helpful in these situations. CDX2 and TTF1 
have been reported as being suggestive of intestinal and pulmonary NENs 
respectively (155,156). However, the specificity and hence the utility of these 
markers is questionable. 
5.1.4 Prognostic markers 
Prognostic markers are important for guiding therapy and management. More 
aggressive tumours, with markers of poor prognosis require more intensive therapy 
and surveillance.  
Recent recommendations for histology reporting of NENs include detailed 
description of angio-lymphatic invasion, perineural invasion, necrosis, capsular 
infiltration and local invasion. All of these features are markers of aggressive 
tumour behaviour (76,148), and hence indicators of poor prognosis. However, the 
interpretation of these markers is subjective, and may vary according to the 
experience of the histopathologist. 
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5.1.4.1 Ki 67 index 
Ki 67 is the most widely used NEN prognostic marker and the only marker 
recommended for routine diagnostic use. It was first identified using a monoclonal 
antibody generated by immunising mice with the nuclei of a Hodgkin lymphoma 
cell line L428 (157). Ki 67 is a 359 kB protein which derives its name from the city 
where the original work was done (Kiel, Germany) and the number (67) of the 
clone of the original 96-well plate (158). Interestingly Ki 67-like IR is only present 
in the nuclei of actively dividing cells in the G1, S and G2 phases. Cells in the G0 
phase do not exhibit Ki 67 IR. Ki 67 can therefore be used to determine the 
proportion of actively dividing cells in a particular cell population (159). This 
property has led to Ki 67 being extensively used as a proliferation and prognostic 
marker in cancers, including NENs (158,160). The Ki 67 index of a cell population 
is expressed as the percentage of cells in the population that express Ki 67-IR.  
The new WHO 2010 classification grades NENs based on the Ki 67 index (161). 
Although this is currently the best available proliferative marker, there are a 
number of limitations to its use as a prognostic marker. A cell with a short inter-
mitotic phase has more proliferative potential than one with a longer one (158). 
While Ki 67 identifies cells that are actively dividing, it gives no indication of the 
duration of the inter-mitotic cycle of the cell population (158, 160). Further, Ki 67 
staining is found in both normal and neoplastic cells. Hence, presence of normal 
actively proliferating cells may result in overestimation of the Ki 67 index (162).  
The reported prognostic significance of Ki 67 in the different studies published 
varies depending on whether 2%, 5%, 10% or 20% used as the prognostic cut-off 
(160). There is also a lack of uniformity in the way the Ki 67 is determined. The 
lack of automated, reproducible scoring system further undermines the utility of Ki 
67 as a prognostic marker (163). In addition, NENs may be composed of 
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heterogeneous populations of cells, thus the Ki 67 determined by analysing one 
part of the neoplasm, may not be representative of the whole NEN. It is not 
uncommon for NENs to change behaviour during the course of the disease. Ki 67 
determined at one time point may, therefore, may not be truly representative of 
tumour behaviour at a different time point (147).  
The previous chapter has demonstrated that circulating CART levels are elevated in 
patients with NENs, particularly in patients with progressive NENs. This suggests a 
role for CART as a diagnostic and prognostic NEN marker. This chapter focuses on 
the comparison of CART-IR in NEN tissues with expression of the diagnostic 
marker Cg A and the prognostic marker Ki 67.  
5.1.5 CART peptide IR in the diffuse neuroendocrine system 
CART-IR has been demonstrated in a number of normal neuroendocrine tissues 
including the peripheral nervous system (164), adrenal medulla (164), C-cells of 
the thyroid (165) and the pituitary glands (166). 
5.1.5.1 CART peptide IR in the adrenal glands and the peripheral nervous system 
CART IR is present in sympathetic pre-ganglion neurones but not in neurones 
which innervate the pre- and para- vertebral sympathetic ganglions and the adrenal 
medulla (164). Parasympathetic pre-ganglionic neurones are CART negative (164). 
While sympathetic ganglions are also CART-IR negative, the chromaffin cells in 
the adrenal medulla display CART-IR (166). Evidence for distribution of CART-IR 
within the different chromaffin cell populations within the adrenal medulla is 
conflicting. While some studies report CART-IR localises exclusively to adrenergic 
cells co-expressing phenylethanolamine-N- methyltransferase (PNMT), the enzyme 
needed for conversion of noradrenaline to adrenaline, other studies report CART-
IR co-localises mainly with NPY in noradrenergic neurones CART-IR nerve cell 
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bodies (167) and fibres have been demonstrated in the adrenal cortex, and CART is 
reported to modulate glucocorticoid secretion (168).   
5.1.5.2 Gastro-entero-pancreatic expression of CART peptide IR 
In the adult rat, CART-IR is limited to pancreatic neurones and delta cells of the 
islets of Langerhans (169). However, CART-IR is much more extensive in foetal 
pancreatic islets, with CART-IR being demonstrated in almost all cell types 
including delta, beta, alpha, PP and gastrin cells but not in ghrelin islet cells (169). 
Interestingly, CART-IR is completely absent in all but the pancreatic delta cells by 
postnatal day 10 (170, 56). Similarly CART-IR in adult mice is limited to 
pancreatic delta cells. In contrast to rats, CART-IR is not present in either beta or 
delta pancreatic cells in foetal mice, although a small proportion of PP and ghrelin 
cells display CART-IR (169). Similarly although CART-IR has been detected in 
the human foetal pancreas, no CART expression has been observed in the adult 
human pancreas (54).  This abundance of CART-IR in the foetal pancreas suggests 
a developmental role for CART.  
CART is expressed in the myentric and submucous ganglia and in the nerve fibres 
in the gut mucosa and submucosa (46). Nerve fibres to smooth muscles, blood 
vessels and submucosa also express CART (46). In addition, CART is expressed by 
gastrin producing G cells in the pyloric antrum of rats (46). Interestingly, there is 
no corresponding expression of CART in human pyloric G cells (171). In fact, the 
endocrine cells of human intestine are completely devoid of CART expression 
(171).  
Apart from the peripheral nervous system and gut, CART expression has been 
demonstrated in a number of neuroendocrine cells in the pituitary gland, thyroid 
gland, and central nervous system. 
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5.1.6 CART peptide IR in NENs 
Studies of CART-IR in NEN tumour tissues are limited. CART-IR has been 
described in human insulinomas (54). This study suggested that well-differentiated 
insulinomas demonstrated higher CART-IR than poorly differentiated insulinomas. 
However, details including the total number of insulinomas studied and the 
proportion of CART positive insulinomas are not available in this study, limiting 
the interpretation of these results. The same group has recently evaluated CART-IR 
in three insulinomas, one gastrinoma, one PP producing tumour and four non-
functioning tumours (172). Only 30% of these tumours strongly expressed CART-
IR. It is also unclear from this study which sub-types of pancreatic NEN tumours 
displayed CART-IR. CART-IR has also been demonstrated in ileal, rectal and 
gastric carcinoids and medullary thyroid carcinomas (172). CART binds to rat 
adrenal phaeochromocytomas cells in vitro. However, CART-IR in 
phaeochromocytomas has not been studied (55).  
5.1.7 High throughput technique for characterisation of CART-IR by IHC in NENs 
Sections of NEN tissues cut from conventional histology paraffin blocks are 
routinely used in clinical practice to study peptide marker expression by IHC.  
While this is the optimal method for diagnostic IHC in an individual patient, a lack 
of adequate amounts of tissue, inter-assay variation and costs, limits its utility as a 
method for validation of diagnostic/prognostic markers of neoplasia. Tissue assays 
using a tissue microarray (TMA) allows simultaneous IHC, visualisation and 
characterisation of peptide expression in tissues from several hundred patients in a 
single assay. 
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5.1.7.1 TMAs 
A TMA is a paraffin block that contains up to a thousand separate tissue cores 
assembled in an array fashion to allow multiplex histological analysis (173, 174). It 
is constructed by relocating tissue cores from conventional paraffin blocks onto 
donor paraffin blocks so that tissues from multiple blocks or patients can be viewed 
on the same slide.  
TMAs allow amplification of tissue available for analysis. A conventional 
histology section is 3 - 5 mm thick and after the initial diagnostic assays, each 
archived block may on average be sectioned 50 -100 times to yield material for a 
maximum of 100 assays. If this same block is processed for TMA, each paraffin 
block is likely to yield multiple cores (up to 200 – 300 times or more depending on 
the size of the specimen in the block). Once constructed, the thickness of the 
sections can be optimised to maximise the number of sections obtained from each 
TMA block. This technique amplifies the amount of material available for analysis 
by up to 10,000 fold.  Thus, TMA allows analysis using a huge number of tissue 
markers.  
Like conventional paraffin blocks, TMA blocks can be used for a wide range of 
techniques including IHC. TMAs have the advantage of allowing a number of 
tissues to be assayed in a single assay thus eliminating inter-assay and intra-assay 
variations by keeping reagent concentrations, incubation times, temperature, wash 
conditions and antigen retrieval consistent for all the samples studied.  
The amount of reagent needed to analyse a whole cohort of tissue samples is much 
smaller on a TMA when compared to conventional histology slides. This gives the 
TMA a significant economical advantage over conventional TMA blocks. 
Furthermore, once the cores are taken, the conventional paraffin blocks can be 
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returned to the donating institution or to the patient and still be useful for diagnostic 
analysis, if needed. 
The type of TMA used varies with the research question. A consecutive cases TMA 
includes all available cases and is ideal for studying the frequency of expression of 
a novel biomarker (175). Further information regarding the prognostic significance 
of these markers can be studied using outcome based TMAs where the cases with 
the longest clinical follow-up and the best documented outcome measures are used 
to construct the array. Progression based TMAs and tumour grade TMAs will have 
cores that represent the entire spectrum of disease, ranging from healthy controls to 
dysplastic tumours that have the worst prognosis. These TMAs can be used to 
study expression of markers throughout the spectrum of tumour differentiation. 
Despite the clear advantages listed above, TMAs are prone to a number of 
limitations. Some limitations particularly in relation to tissue and antibody quality 
are similar to those experienced by conventional histology slides. Unlike 
conventional histology slides, the technical skills required to build a TMA are 
considerably greater (175). Since TMAs allow development of large cohorts of 
tissues, the archived material used is often old and may have been subject to 
variations in processing techniques which may confound results (175). Since 
TMAs examine only a small fraction of the tissue, there were initial concerns that 
TMAs are unsuitable for assessing biomarkers that are heterogeneous in 
distribution. However, subsequent analysis, by multiple groups, confirmed strong 
correlation between TMA histo-spots and conventional slides. 
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5.2 Hypothesis and Aims 
5.2.1 Hypothesis 
CART is expressed in normal neuroendocrine cells and circulating levels of CART 
are increased in patients with NENs, particularly in patients with progressive 
NENs. I hypothesised that CART is expressed in NEN tissues and that it may have 
a role as a prognostic marker for NENs. 
5.2.2 Aims 
1. To optimise an IHC technique for CART using an in-house monoclonal 
CART antibody. 
2. To construct TMAs to study CART-IR in 
phaeochromocytomas/paragangliomas and pancreatic NENs 
3. To compare CART-IR with other diagnostic and prognostic NEN markers.   
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5.3 Methods  
An in-house monoclonal mouse CART antibody was used for all IHC studies 
(176). 
5.3.1 Optimisation of CART IHC assay 
Since the adrenal medulla is known to express CART-IR (164), this mouse 
monoclonal CART antibody was optimised using normal human adrenal medulla 
tissue. Paraffin blocks of normal adrenal medulla tissue were obtained from the 
histopathology department of ICHNT. Two micrometre thick sections were cut 
from the blocks using a microtome and mounted onto glass slides and used for IHC 
assay optimisation. Experiments were set up for optimisation of antigen retrieval, 
optimal antibody concentration and antibody and chromogen incubation times. 
All slides for IHC were de-waxed and rehydrated by immersing in three changes of 
xylene, three changes of industrial methylated spirit 99% (74 OP) and one change 
of 70 % industrial methylated spirit for two minutes each. Some cells contain 
endogenous peroxidases which may interact with the chromogen used for staining 
and result in non-specific staining. Non-specific binding with peroxidases was 
minimised by immersing the slides in 0.6% hydrogen peroxide solution (2 ml of 
30% H2O2 per 100 ml of tap water) for 15 minutes. The slides were then processed 
for optimisation of antigen retrieval. 
5.3.1.1 Antigen retrieval 
Optimisation for assay with and without antigen retrieval was carried out by 
assaying samples with and without heat mediated antigen retrieval. 
IHC expression of many antigens can be significantly improved by the pre-
treatment with the antigen retrieval reagent that break the protein cross-links formed 
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by formalin fixation and thereby uncover hidden antigenic sites (177). Heat 
mediated antigen retrieval is most the commonly used antigen retrieval method 
routinely used in the histopathology laboratory.  
Sections at all antibody concentrations (described below) were assayed in two 
groups. During antigen retrieval optimisation, slides were assayed using all 
antibody concentrations with and without prior heat mediated antigen retrieval. 
For heat mediated antigen retrieval, slides were transferred onto a plastic rack and 
placed in a plastic container holding 700 ml of 0.01 M Citrate buffer (3.8g of citric 
acid in 2L of distilled water, pH to 6.0 with 2M sodium hydroxide). The container 
was loosely covered with a plastic lid and heated in an 800 W microwave for 10 
minutes. The container was removed from the microwave and placed under slow 
running cold tap water until cooled. The slides were then rinsed thoroughly in cold 
tap water and immersed into phosphate buffer solution.  
5.3.1.2 Antibody optimisation 
Optimisation for the most appropriate antibody concentration (neat through to 1 in 
1000 dilutions) and incubation times (overnight, 1 hour) was carried out. 
The dewaxed, rehydrated +/- heat treated slides were loaded onto a Sequenza clip 
and immersed in phosphate buffered saline (PBS) in a Sequenza rack for further 
analysis (Figure 5-1). The use of a Sequenza rack minimises reagent waste and 
allows uniform application of reagent over the tissue section. The bottom of the 
slide was placed on the bottom projections of the clip, and the section side of the 
slide gradually apposed to the smooth surface of the clip, between the lateral 
projections. An unbroken film of PBS was held between the clip and the slide. The 
clip and slide were held together with the spring of the clip and inserted into a 
Sequenza rack. To check that all slides were correctly inserted between the 
165 
 
projections of the clip, the troughs were partially filled with PBS and watched to 
ensure the rate of flow of PBS through the slide was neither too fast nor too slow. 
The Sequenza rack was kept covered to avoid evaporation. 100l Power Block® 
(Biogenex, San Ramon, CA, USA) was applied to the slides and left to stand for 
five minutes. The Power Block
®
 is known to reduce non-specific binding. 100l of 
primary antibody was then applied neat, 1 in 50, 1 in 100, 1 in 200 to two slides 
each in the first two assays and later in 1 in 400, 1 in 600, 1 in 800 and 1 in 1000 
dilutions in the subsequent two assays. 100ul PBS was applied to a further two 
slides as negative control.  
During optimisation, the sections were first incubated overnight in the initial 
optimisation assay, followed by incubation for one hour in subsequent assays. The 
slides were then rinsed three times with 0.01M PBS with Tween and 100l Super 
Enhancer
®
 (Ready to use, Biogenex, San Ramon, CA, USA) applied. The slides 
were incubated in the Super Enhancer at room temp for 20 minutes and then rinsed 
three times with PBS/Tween. 100l poly-HRP® (Ready to use, Biogenex, San 
Ramon, CA, USA), was then applied and the slides incubated at room temperature 
for a further 30 minutes. The slides were then once again rinsed three times with 
PBS/Tween and then removed from the Sequenza. Excess PBS was wiped from 
slides and a line was drawn around the tissue section using a water-repellent 
paraffin pen to prevent spreading of the chromogen diaminobenzidine (DAB).  
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A       B 
 
 
 
 
 
C  
       D                                   E  
Figure 5-1: Equipment used for IHC  
Sequenza clip (A). The Sequenza clips were immersed in phosphate buffered saline 
in a Sequenza rack (B). Schematic representation of slide and Sequenza clip with 
buffer (C); Addition of reagent causes displacement of buffer (D); Subsequent 
addition of buffer, washes off reagent and rinses slide (E). (Reproduced from 
http://www.cellab.se/pdfbroschyr/inkubation). 
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5.3.1.3 Chromogen incubation time optimisation 
Optimisation for ideal chromogen exposure times (2 – 15 min) was carried out. 
Slides processed as above were placed into Petri dishes and the tissue sections 
covered in DAB solution (1 drop of DAB mixed with 1ml of substrate buffer from 
the DAB kit, Biogenex, San Ramon, CA, USA) and left to incubate. During 
optimisation, the slides were incubated for varying lengths of time (2, 5, 10 and 15 
minutes) to establish the optimal incubation time.  
5.3.1.4 Mounting and preparation for analysis 
The slides were finally rinsed in tap water. The sections were counterstained by 
immersing in Coles Haematoxylin for 10 seconds and rinsed in tap water. Finally 
the slides were dehydrated by immersing them in one change of 70% alcohol, three 
changes of 74 OP alcohol and three changes of xylene for 2 minutes each. The 
slides were then mounted using Pertex
®
 mounting medium and a Leica 
Coverslipper
®
 place on the section. The prepared slides were then examined under 
a microscope. 
5.3.1.5 Optimisation of CART and Cg A double IHC assay 
This technique enables visualisation of CART-IR and Cg A-IR in the same tissue 
section by simultaneous detection of the two antigens using two contrasting 
chromogens. The primary antibody for Cg A was a mouse monoclonal antibody 
raised to human phaeochromocytoma tissue (LK2H10, anti-chromogranin A, 
Biogenex, CA, USA). This antibody is routinely used for Cg A IHC by the ICHNT 
histopathology department. The antibody concentrations used are those 
recommended by the manufacturers (LK2H10, anti-chromogranin A, Biogenex, 
CA, USA). 
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5.3.1.6 Chromogen combination for double IHC 
 Enzymatic chromogens result in permanent staining of tissues and are routinely 
used in double IHC. A red and blue chromogen combination provides adequate 
contrast to enable visualisation using a traditional microscope and hence this 
combination was chosen. Secondary antibodies used for detecting CART and Cg A 
were labelled with two different enzymes, alkaline phosphatase (AP) and 
horseradish peroxidase (HRP). Cg A-IR was visualised as a blue stain obtained due 
to reaction of AP with Fast Blue BB/Napthhol-AS-MX-phosphate and CART-IR 
was visualised as a red stain due to reaction of HRP with 3-amino-9-ethylcarbazole 
(AEC) (Boorsma 1984; Van der Loos 1999). 
5.3.1.7 CART and Cg A IHC 
The sections to be stained were dewaxed, treated with 0.6% hydrogen peroxide and 
placed on a Sequenza rack as described in section 5.3.1.2. 100 µl normal goat 
serum diluted in PBS (1 in 20) was applied to the slides for 10 minutes to reduce 
nonspecific binding. Following this, primary Cg A antibody was applied as per 
manufacturer’s recommendation (LK2H10, anti-chromogranin A, Biogenex, CA, 
USA). The slides were incubated with the primary antibody for 1 hour. The slides 
were then rinsed three times with PBS/Tween (5 ml Tween 20 per 1 L of PBS) for 
5 minutes. 100 µl of biotinylated goat anti-mouse secondary antibody diluted 1 in 
250 in 0.01 M PBS containing 0.1% sodium azide and 0.1% BSA was applied to 
the slides and left to incubate for 30 minutes. The slides were then rinsed three 
times with PBS/Tween (5 ml Tween 20 per 1 L of PBS) for 5 minutes.100 µL 
streptividin alkaline phosphatase (1 in 100 diluted with diluent supplied with the 
streptividin alkaline phosphatase) was then applied to the slides. The slides were 
rinsed three times with PBS/Tween (5 ml Tween 20 per 1 L of PBS) after 
incubation for 30 minutes. The slides were removed from the Sequenza racks and 
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Fast Blue solution applied to each slide. The blue colour for Cg A-IR visualisation 
was allowed to develop for 20 minutes. The slides were then rinsed thoroughly 
with tap water to terminate the reaction.  
The slides were then stacked onto a plastic rack and antigen retrieval for CART 
performed by the heat retrieval method (section 5.3.1.1). The slides were then 
processed as described in section 5.3.1.2 using mouse monoclonal CART antibody 
in 1 in 800 dilution diluted in 0.01 M PBS containing 0.1% sodium azide and 0.1% 
BSA.  
The red stain for CART-IR visualisation was developed using the AEC Biogenex 
kit (Biogenex, CA, USA). 0.5 ml hydrogen peroxide substrate and 1 drop of AEC 
solution was added to 2 ml of distilled water and mixed. The mixture was applied 
to sections and each section incubated for 10 minutes to allow the colour to 
develop. The slides were rinsed with water to terminate the reaction. The slides 
were then mounted in an aqueous mountant, allowed to dry at 37ºC and then 
mounted in Pertex. 
5.3.2 Tissue microarray (TMA) construction 
Routine histopathology paraffin wax blocks (ICHNT) were used to source tissue 
for construction of TMAs. Paraffin blocks of NENs and their corresponding 
haematoxylin and eosin (H & E) slides were identified through the ICHNT 
histopathology laboratory information system and retrieved from the pathology 
archives. 
H & E slides for each of the tumour blocks were examined in the presence of a 
histopathologist with expertise in NENs. Areas of the tumour block that were most 
representative of the NEN were considered suitable for placement into the TMA 
and were identified and highlighted. The corresponding areas on the paraffin blocks 
were then marked. Each TMA was assembled using a manual tissue arrayer 
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(Mitogen MTA1, Beecher instruments, WI, USA). The instrument consists of a 
thin walled stainless steel biopsy needle with an internal diameter of 1 mm and a 
stylet that is used to transfer the contents of the biopsy needle into the TMA block. 
Thus small tumour cores were retrieved from the donor paraffin blocks and placed 
onto new recipient blocks. The cores were positioned using an X-Y position guide 
that could be manually adjusted using a micrometer. Three cores were taken from 
each tumour block to allow adequate representation of the tumour. The tissue cores 
were 1 mm in diameter and the depth varied depending on the depth of the donor 
block. The position of each core was noted by constructing a tabulated grid 
containing a unique identifier and place code for each core. A core from a paraffin 
block of normal placenta was used as an orientation core and placed at the bottom 
left hand corner position of each block to enable orientation of the other cores in 
the TMA block. Each TMA block had a maximum of 90 cores.  Fifty two 
micrometre sections of the TMA blocks were cut using a microtome and placed 
onto glass slides, ready for IHC. Every fifteenth section was stained with H & E 
and reviewed to confirm the quality of the sections at different depths of the TMA 
blocks (Figure 5-2). 
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Figure 5-2: A representative slide showing 101 H & E stained cores in a section 
cut from a TMA  
5.3.2.1 Construction of NEN TMAs 
The primary aim of the study was to evaluate CART-IR in 
paragangliomas/phaeochromocytomas and NENs. Therefore, a consecutive cases 
TMA was constructed, including all available NENs from patients who had 
undergone surgery between 1982 and 2011 at ICHNT hospitals. 
Eight TMA blocks were constructed using three cores each from paraffin blocks of 
87 patients with paragangliomas/phaeochromocytomas. In addition, two TMAs 
were constructed from paraffin blocks containing 20 normal adrenal and used as 
controls. 
Five TMA blocks were constructed using conventional paraffin blocks from 44 
patients with pancreatic NENs [(23 insulinomas (2 blocks), 7 gastrinomas (1 block) 
and 14 non-functioning NENs (2 blocks)] using the methods as previously 
described in section 5.1.7.1  
Islets are scattered as very small clusters in the pancreas. Therefore, it was not 
possible to obtain TMA cores which would have representative islet cells 
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throughout the depth of the core. Hence sections cut from conventional paraffin 
blocks of healthy normal pancreas were used as controls. Staining was specifically 
assessed in the islet cells of these control samples. 
5.3.3 Retrieval of clinical information 
Clinical details including age of diagnosis, date of surgery, date of last follow-
up/death, and presence or absence of metastases were collated from archived 
clinical notes, hospital and laboratory information systems.  
Details of the secretory status of these tumours and patterns of secretion where 
possible were retrieved from patient clinical records and the laboratory information 
systems. 
Original histopathology reports were reviewed to retrieve information regarding 
presence or absence of vascular invasion, capsular invasion and necrosis within the 
NENs selected. 
5.3.4 IHC of TMA blocks 
In order to minimise inter- and intra- assay variation, all TMA sections were single 
stained for CART, Cg A and Ki 67 on a fully automated platform (Bond Max 
autostainer, Leica systems) in a single assay. The optimised protocol (section 5.3.1) 
was used for CART IHC. Cg A and Ki 67 were stained as per routine laboratory 
protocols. 
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5.3.5 Quantification of IR in TMAs 
The TMA blocks were scored manually. A preliminary analysis of the stained 
TMA slides for CART-IR revealed considerable variability in cell staining within a 
single core (175). Therefore, in addition to a score based on semi-quantitative 
evaluation of the intensity of scoring (0 = no staining, 1 = weak staining, 2 = 
moderate staining and 3 = strong staining), the TMAs were also given a score of 0, 
1, 2 or 3 based on the percentage of stained cells with each core (0 - 24%, 25 - 
49%, 50 - 74%, 75 - 100%). An IHC score for each core was then obtained by 
multiplying the intensity of staining with the percentage of cells staining positive. 
Thus the IHC score for a core in which 100% of cells were strongly stained (3) 
would be 300, and the score for a core where 50% of cells were weakly staining (1) 
would be 50. The average of the scores obtained from the three cores from a single 
NEN was taken as the final score for that sample. This final score was used for 
analysis. The specific site of staining (cytoplasmic, nuclear or membranous) was 
also recorded. The TMAs were scored independently by two observers. The TMA 
slides for Cg A were scored in a similar manner. Ki 67 index was calculated as the 
percentage of cells staining positive for Ki 67 per high power field. Three high 
power fields were examined and the average was assigned as the Ki 67 index for 
the core. The Ki 67 index for each core of a tumour were analysed and the highest 
score obtained was used as the score for the tumour for analysis. The Ki 67 index 
was used to grade the tumours as grade 1(<2%), grade 2 (2 – 20%) and grade 3 (> 
20%) (161). 
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5.4 Statistics 
The Fisher’s exact test was used to assess: 
1. the frequency and intensity of CART-IR and Cg A-IR in 
paraganglioma/phaeochromocytomas.   
2. the association between catecholamine secretion and CART – IR in 
paraganglioma/phaeochromocytomas.  
3. the prognostic significance of CART-IR and Cg A - IR in 
paraganglioma/phaeochromocytomas by comparing the numbers of 
paraganglioma/phaeochromocytoma tissues with and without features of 
poor prognosis with CART-IR and Cg A- IR IHC scores of 0 and >0, < 100 
and ≥ 100, <200 and ≥ 200, <300 and 300 scores. The prognostic features 
considered were death and metastatic disease and vascular invasion, 
capsular invasion, necrosis and Ki 67 index on histology. 
4. the frequency and intensity of CART-IR and Cg A –IR in pancreatic NEN 
vs. normal pancreatic tissue and the distribution of CART and Cg A IR 
across different sub-types of pancreatic NENs 
(insulinomas/gastrinomas/non-functioning NENs). 
5. the prognostic significance of CART-IR and Cg A-IR in pancreatic NENs 
by comparing the proportions of pancreatic NENs with and without features 
of poor prognosis with CART and Cg A IR IHC scores of 0 and >0, < 100 
and ≥ 100, <200 and ≥ 200, <300 and 300 scores. The prognostic features 
considered were death, metastatic disease and Ki 67 index on histology.  
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5.5 Results 
5.5.1 Optimisation of CART IHC assay 
Heat mediated antigen retrieval provided better CART-IR visualisation compared to when 
no antigen retrieval technique was used. IHC using mouse monoclonal CART antibody in 
a 1 in 800 dilution resulted in the most optimal staining with minimal background 
interference (Figure 5-3A). Therefore, all subsequent studies of CART-IR were performed 
using this antibody dilution.  
Double staining of normal adrenal medulla with Cg A and CART confirmed co-
localisation of Cg A and CART in the adrenal medulla (Figure 5-3B). While some cells 
expressed both Cg A and CART -IR (purple colour), others showed only Cg A (blue) or 
CART (red) expression. 
Representative images of IHC slides showing no staining (Figure 5-4A), intense 
cytoplasmic staining (Figure 5-4B) and intense nuclear staining (Figure 5-4C), for CART-
IR are shown.  
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Figure 5-3: IHC for CART and Cg A in normal adrenal medulla 
A: Single stain IHC for CART using a mouse monoclonal CART antibody (1 in 800 
dilution) and DAB as chromogen (brown). Cytoplasmic staining of the cells is 
confined to the adrenal medulla, with the adrenal cortex showing no CART-IR (X 
40 magnification).  
B: Double stain IHC for CART and Cg A, using a mouse monoclonal CART 
antibody in 1 in 800 dilution and commercial LK2H10 anti Cg A antibody 
(Biogenex) demonstrating cytoplasmic staining of adrenal medullary cells. Cells 
expressed either Cg A-IR (blue) or CART-IR (red) or both (purple). (X 400 
magnification) 
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Figure 5-4: CART IHC in NEN 
A: Pancreatic NEN showing negative staining for CART-IR (X 400magnification) 
B: Phaeochromocytoma showing intense cytoplasmic CART-IR (DAB, X 600 
magnification)  
C: Gastrinoma showing nuclear staining for CART-IR (X 400magnification) 
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5.5.2 Phaeochromocytomas/paragangliomas 
5.5.2.1 Demographics 
5.5.2.1.1 Clinical and biochemical details 
The site of tumour was known for 79/87 patients (55 adrenal phaeochromocytomas, 
24 paragangliomas). Information on presence or absence of metastases was 
available on 74/87 patients (9 metastatic, 65 non-metastatic). Mortality data was 
available for 86 patients (13 dead, 73 alive). Median survival was 3 years (range 1 
– 16 years).  
Details of secretory status of phaeochromocytoma/paragangliomas were available 
for 78 patients. The majority (83%) of patients secreted catecholamines (13 non-
secretory and 65 secretory) and noradrenaline was the most frequently secreted 
catecholamine (23/65 secreted only noradrenaline, 5/65 only adrenaline and 1/65 
only dopamine. 14/65 secreted noradrenaline and adrenaline, 3/65 secreted 
noradrenalin and dopamine, 1/65 secreted adrenalin and dopamine and 2/65 
secreted all three). Details of urine catecholamine secretion products was not 
known for 5/65 patients. 
5.5.2.1.3 Histology 
Details regarding presence or absence of necrosis, vascular invasion and capsular 
invasion (markers of poor prognosis) in the phaeochromocytoma/paragangliomas 
tissues were available in 69/87 patient samples. Most of the tissue samples were 
benign in appearance and expressed none of these sinister features 71% (48/69). 
Only 7% (5/69) expressed more than one of these markers of poor prognosis.  
All TMA blocks were scored for Ki 67. No phaeochromocytoma/paraganglioma 
had a Ki 67 score of > 2% per high power field (x 400 magnification). 
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5.5.2.2 CART-IR in phaeochromocytomas/paragangliomas 
CART and Cg A - IR IHC scores from control cores and 
phaeochromocytomas/paraganglioma cores are detailed in Tables 5-1 and 5-2 
respectively. No control cores (0%) had a CART IHC score of < 200 or a Cg A-IR 
IHC score of <100. In contrast, a significantly higher proportion of 
phaeochromocytomas/paragangliomas had lower IHC scores for CART (< 200: 
41%, n = 36/87, p<0.0001 vs. controls) and Cg A (< 100: 19%, n=14/87, p = 0.002 
vs. controls). These results suggest that Cg A- IR, and more frequently CART - IR 
is decreased in phaeochromocytomas/paragangliomas when compared to controls.  
There was no significant difference in distribution of secretory and non-secretory 
tumours across the Cg A-IR IHC score spectrum. However, there was a significant 
difference in the proportion of secretory and non-secretory 
phaeochromocytomas/paragangliomas with a CART IHC score of 0 [secretory 4/55 
(7%) vs. non-secretory 4/13 (31%)] and > 0 [secretory 51/55 (93%) vs. non-
secretory 9/13 (69 %)], < 200 [secretory 18/55 (33%) vs. non-secretory 9/13 (69%)] 
and > 200 [secretory 37/55 (67%) vs. non-secretory 4/13 (31%)]. However, there 
was no significant association between the profile of secretory products 
(adrenaline/noradrenaline/dopamine) and CART-IR. 
A Ki 67 index of > 2% is associated with poor prognosis (178). Hence 2% was 
chosen as a prognostic cut-off. All of the cases had a Ki 67 index < 2%. Therefore 
it was not possible to investigate an association between Ki 67 index and CART-IR 
IHC score. There was no significant association between histological markers of 
poor prognosis (vascular invasion/capsular invasion/necrosis) and CART-IR IHC 
score (Table 5-1) or Cg A-IR IHC score (Table 5-2). 
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Table 5-1: CART IHC score in phaeochromocytoma/paraganglioma (Ph/PG)   
 
Rows 1 & 2 (italics) show the number (percentage) of controls vs. Ph/PG with CART-IR IHC scores of 0 & >0, <100& >100, 
<200 & >200 and <300 & 300. Rows 3-10 show number (percentage) of metastatic vs. non-metastatic Ph/PGs, patients dead vs. 
alive, secretory vs. non-secretory Ph/PGs, Ph/PGs with or without markers of poor prognostic factors on histology (VI/CI/N) 
with CART IHC score of 0 & >0, <100& >100, <200 & >200 and <300 & 300. VI = vascular invasion; CI = capsular invasion; 
N = necrosis; * <0.05; ** <0.005; *** <0.0001 vs. controls. 
 
 
CART IHC score 
 
0 
n (%) 
> 0 
n (%) 
< 100 
n (%) 
≥ 100 
n (%) 
< 200 
n (%) 
≥ 200 
n (%) 
< 300 
n (%) 
300 
n (%) 
Controls (n = 43 cores) 0 (0%) 43 (100%) 0 (0%)
 
43 (100%)
 
0 (0%)
 
43 (100%)
 
9 (21%)
 
34 (79%)
 
Ph/PGs (n = 87) 13 (15%) 74(85%) 21(24%)
** 
66(76%)
** 
36 (41%)
*** 
51(59%)
*** 
74(85%)
*** 
13(15%)
*** 
Ph/PGs 
Metastatic (n = 9) 2 (22%) 7(78%) 2 (22%) 7 (78%) 5 (56%) 4 (48%) 9 (100%) 0 (0%) 
Non-metastatic (n = 65) 7 (11%) 58(89%) 16(25%) 49(75%) 23 (35%) 42 (65%) 54(83%) 11(7%) 
Dead (n = 13) 3 (23%) 10 (77%) 5 (38%) 8 (62%) 7 (54%) 6 (46%) 11 (85%) 2 (15%) 
Alive (n = 73) 10 (14%) 63 (86%) 16 (22%) 57 (78%) 29 (40%) 44 (60%) 63 (86%) 10 (14%) 
Secretory (n = 55) 4 (7%)
 
51 (93%)
 
10 (18%) 45 (82%) 18 (33%)
 
37 (67%)
 
46 (84%) 9 (16%) 
Non-secretory (n = 13) 4 (31%)
* 
9 (69%)
* 6 (46%) 7 (54%) 9 (69%)
* 
4 (31%)
* 12 (92%) 1 (8%) 
No VI/CI/N (n = 48) 6 (13%) 42 (87%) 13 (27%) 35 (73%) 19 (40%) 29 (60%) 37 (77%) 11 (23%) 
VI/CI/N (n = 20) 1 (5%) 19 (95%) 3 (15%) 17 (85%) 8 (40%) 12 (60%) 19 (95%) 1 (5%) 
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Table 5-2: Cg A IHC score in phaeochromocytoma/paraganglioma (Ph/PG)   
Rows 1 & 2 (italics) show the number (percentage) of controls vs. phaeochromocytoma/paraganglioma (Ph/PG) with Cg A-IR 
IHC scores of 0 & >0, <100& >100, <200 & >200 and <300 & 300. Rows 3-10 show number (percentage) of metastatic vs. 
non-metastatic Ph/PGs, patients dead vs. alive, secretory vs. non-secretory Ph/PGs, Ph/PGs with or without markers of poor 
prognostic factors on histology (VI/CI/N) with Cg A IHC score of 0 & >0, <100& >100, <200 & >200 and <300 & 300. VI = 
vascular invasion; CI = capsular invasion; N = necrosis; * <0.05; ** <0.005; *** <0.0001 vs. controls. 
 Cg A IHC score 
 
0 
n (%) 
> 0 
n (%) 
< 100 
n (%) 
≥ 100 
n (%) 
< 200 
n (%) 
≥ 200 
n (%) 
< 300 
n (%) 
300 
n (%) 
Controls (n = 43 cores) 0 (0%) 43 (100%) 0 (0%)
 
43 (100%)
 
5 (13%) 39 (87%) 21 (48%) 23 (52%) 
Ph/PGs (n = 87) 7 (8%) 80 (92%) 14(19%)
** 
73 (81%)
** 22 (25%) 65 (75%) 49 (56%) 38 (44%) 
Ph/PGs 
Metastatic (n = 9) 1 (11%) 8 (89%) 2 (22%) 7 (78%) 2 (22%) 7 (78%) 8 (89%) 1 (11%) 
Non-metastatic (n = 65) 2 (3%) 63 (97%) 8 (15%) 57 (85%) 15 (23%) 50 (77%) 33 (51%) 32 (49%) 
Dead (n=13) 2 (15%) 11(85%) 4(31%) 9(69%) 4(31%) 9(69%) 8(62%) 5(38%) 
Alive (n=73) 5 (7%) 68 (93%) 10 (14%) 63 (86%) 18 (25%) 55 (75%) 41 (56%) 32 (44%)  
Secretory (n = 55) 4 (7%) 51 (83%) 6 (11%) 49 (89%) 11 (20%) 44 (80%) 29 (53%) 26 (47%) 
Non-secretory (n = 13) 1 (8%) 12 (92%) 4 (31%) 9 (69%) 6 (46%) 7 (54%) 11 (85%) 2 (15%) 
No VI/CI/N (n = 48) 1 (2%) 47 (98%) 6 (13%) 42 (87%) 13 (27%) 35 (73%) 26 (54%) 22 (46%) 
VI/CI/N (n = 20) 1 (5%) 19 (95%) 2 (10%) 18 (80%) 3 (15%) 17 (85%) 10 (50%) 10 (50%) 
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5.5.3 Pancreatic NENs 
5.5.3.1 Demographics 
5.5.3.1.1 Clinical and biochemical details 
Twenty nine of the 43 pancreatic NENs were functioning pancreatic NENs (22 insulinomas, 
7 gastrinomas). Data on presence or absence of metastatic disease were available on 40/43 
patients. Eleven patients had metastatic disease (1/22 insulinoma, 3/7 gastrinomas and 7/14 
non-functioning pancreatic NENs). Mortality data was available on 40/43 pancreatic NENs. 
Four out of 40 patients were dead [mean survival (years): 13 (0.5 - 16)] and 34 out of 40 
patients [mean survival (years): 13 (0.5 - 16)] were alive at the time of analysis. Two patients 
died of unrelated causes. 
5.5.3.1.2 Histology 
Ki 67 expression was scored in 40/43 pancreatic NENs. Ki 67 index scores were [Grade 1 
(<2%); n = 35 (10 non-functioning NENs, 22 insulinomas, 3 gastrinomas); Grade 2 (3 – 20%) 
n = 4 (4 non-functioning NENs); Grade 3 (≥ 20%) n = 1 (1 gastrinoma)].  
5.5.3.2 CART-IR in pancreatic NENs 
CART-IR was not detectable in normal pancreatic islets. The number of pancreatic NENs 
with CART-IR and Cg A- IR IHC scores of 0 and >0, < 100 and ≥ 100, <200 and ≥ 200, 
<300 and 300 are detailed in Tables 5-3 and 5-4 respectively. 
Eighty eight percent (33/43) of pancreatic NENs expressed Cg A [80% (11/14) non-
functioning NENs, 90% (20/22) insulinomas and 100% (7/7) gastrinomas]. By contrast, only 
30% [43% (6/14) non-functioning NENs, 31% (7/22) insulinomas and 0% (0/6) gastrinomas] 
expressed CART IR. 1/7 gastrinomas showed strong nuclear expression of CART-IR.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
No pancreatic NEN had a CART IHC score of > 100. There was no advantage to using 
CART IHC in addition to Cg A, as in all pancreatic NENs with undetectable Cg A-IR 
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expression CART-IR was also absent. There was no significant association between 
histological markers of poor prognosis (metastatic disease, death, Ki 67) and CART or Cg A 
- IR in pancreatic NENs. 
In keeping with localisation within normal neuroendocrine cells (179), Cg A-IR in all 
pancreatic NENs and CART-IR in 42/43 pancreatic NEN was cytoplasmic. One NEN 
(gastrinoma) showed strong nuclear staining for CART-IR (100% of cells) (Figure 5-4C), 
whereas in this tumour Cg A-IR was localised to the cytoplasm.   
5.5.3.3 Comparison of circulating CART levels with CART-IR in Pancreatic NENs 
Pre-operative circulating Cg A and CART levels were available for twelve patients (5 non-
functioning NENs, 3 insulinomas, 4 gastrinomas) and were Cg A (median 122 pmol/L, range 
16 – >1000 pmol/L) and CART (median 64 pmol/L, range 36 – >1000 pmol/L).  
Circulating CART levels were above the reference range in 3/12 pancreatic NEN (2 non-
functioning NENs, 1 gastrinoma). None of these tumours displayed CART-IR on IHC. Of the 
patients with circulating CART levels within the reference range, CART-IR was undetectable 
in five tumours and in four tumours there was weak CART-IR (IHC score <100). Circulating 
Cg A levels were above the reference range in 8/12 patients (4 non-functioning NENs, 3 
gastrinomas and 1 insulinoma). Cg A-IR was variable in these tumours (median 106, range 0 
- 300). There was no significant association between circulating levels of Cg A and CART 
and tissue expression. 
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 CART IHC score 
 
0 
n (%) 
> 0 
n (%) 
< 100 
n (%) 
≥ 100 
n (%) 
< 200 
n (%) 
≥ 200 
n (%) 
< 300 
n (%) 
300 
n (%) 
Grade 1 (n = 35) 23 (68%) 8 (32%) 35 (100%) 0 (0%) 35(100%) 0(0%) 35(100%) 0 (0%) 
Grade 2 (n = 4) 2 (50%) 2(50%) 4 (100%) 0 (0%) 4 (100%) 0(0%) 3 (100%) 0 (0%) 
Grade 3 (n = 1) 1 (100%) 0 (0%) 1 (100%) 0 (0%) 1 (100%) 0 (0%) 1 (100%) 0 (0%) 
Metastatic (n = 11) 9 (82%)  
 
 
2 (18%) 11 (100%) 0 (0%) 11 (100%) 0 (0%) 11 (100%) 0 (0%) 
Non-metastatic (n = 31) 20 (65%) 11 (35%) 31 (100%) 0 (0%) 31 (100%) 0 (0%) 31 (100%) 0 (0%) 
Dead (n=4) 3 (75%) 1 (25%) 4 (100%) 0 (0%) 4 (100%) 0 (0%) 4 (100%) 0 (0%) 
Alive (n=34) 24 (71%) 10 (29%) 34 (100%) 0 (0%) 34 (100%) 0 (0%) 34 (100%) 0 (0%) 
 
 Table 5-3: CART IHC score in pancreatic NENs   
Shows the proportion (percentage) of grade 1- 3 pancreatic NENs [Grade 1 (<2%), Grade 2 (3 – 20%), Grade 3 (≥ 20%)], 
metastatic vs. non-metastatic pancreatic NENs, patients dead vs. alive with CART IHC score of 0 & >0, <100& >100, <200 & 
>200 and <300 & 300.   
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Table 5-4: Cg A IHC score in pancreatic NENs 
 
Shows the proportion (percentage) of grade 1- 3 pancreatic NENs [Grade 1 (<2%), Grade 2 (3 – 20%), Grade 3 (≥ 20%)], metastatic vs. non-
metastatic pancreatic NENs, patients dead vs. alive with Cg A IHC score of 0 & >0, <100& >100, <200 & >200 and <300 & 300.  
 Cg A IHC score 
 
0 
n (%) 
> 0 
n (%) 
< 100 
n (%) 
≥ 100 
n (%) 
< 200 
n (%) 
≥ 200 
n (%) 
< 300 
n (%) 
300 
n (%) 
Grade 1 (n = 35) 4(11%) 31(88%) 13(37%) 22(63%) 18(51%) 17(49%) 24(69%) 11(31%) 
Grade 2 (n = 4) 1(25%) 3(75%) 1(25%) 3(75%) 1(25%) 3(75%) 3(75%) 1(25%) 
Grade 3 (n = 1) 0(0%) 1(100%) 1(100%) 0(0%) 1(100%) 0(0%) 1(100%) 0(0%) 
Metastatic (n = 11) 1(9%) 10(81%) 3(27%) 8(73%) 4(36%) 7(64%) 7(64%) 4(36%) 
Non-metastatic (n = 31) 4(11%) 27(89%) 12(39%) 19(61%) 17(55%) 14(45%) 22(63%) 9(37%) 
Dead (n=4) 1(25%) 3(75%) 2(50%) 2(50%) 3(75%) 1(25%) 3(75%) 1(25%) 
Alive (n=35) 4(11%) 31(89%) 13(37%) 22(63%) 18(51%) 17 (49%) 23(66%) 12(34%) 
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5.6 Discussion 
CART expression has been demonstrated in a number of neuroendocrine cells including the 
adrenal medulla and pre-ganglionic sympathetic neurones. Consistent with published 
literature, the work described in this chapter demonstrates strong CART-IR in normal adrenal 
medullary tissue. While CART-IR co-localised with Cg A-IR in some cell populations, other 
CART-IR expressing cells were devoid of Cg A-IR and vice versa. This pattern suggests 
variable CART and Cg A expression in different populations of adrenal medullary cells. The 
adrenal medulla is composed of a number of different cell populations including distinct 
adrenergic, noradrenergic and small chromaffin cells and other tissue components such as 
ganglionic neurones, sustentacular cells, nerve fibres and blood vessels. While Cg A 
expression has been localised to both adrenergic and noradrenergic chromaffin cells (180), 
reports relating to CART-IR in chromaffin cells are scarce and conflicting. Presence of 
CART-IR in phenylethanolamine-N-methyltransferase (PNMT) staining adrenergic cells has 
been reported (164). Another study has described co-localisation of CART with NPY in 
noradrenergic cells only (167). Future studies are needed to confirm the distribution and 
ultra-structural localisation of CART-IR within the different populations of adrenal medullary 
cells. 
CART peptide has been previously shown to be expressed in phaeochromocytoma cell lines 
(55). CART peptide expression in human phaeochromocytomas has not been previously 
studied. The current study found variable CART-IR expression in 
phaeochromocytoma/paragangliomas. While normal adrenal medullary controls were 
strongly immunoreactive for CART (CART-IR IHC score >200), a significant proportion 
(42%) of phaeochromocytoma/paragangliomas had a CART-IR IHC score of <200. 
Similarly, all normal medullary tissue cores demonstrated a Cg A IHC score of >100, yet 
14% of phaeochromocytoma/paragangliomas had a Cg A-IR IHC score of <100. Patients 
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with CART-IR IHC scores of <200 or Cg A-IR IHC scores of <100 were more likely to have 
neoplastic disease.  
Consistent with the reported co-expression of CART-IR with enzymes involved in 
catecholamine secretion(164), a significantly greater proportion of secretory 
phaeochromocytoma/paraganglioma tissues had a CART-IR IHC score of > 200 (67% 
secretory vs. 31% non-secretory). However, no definite association between type of secretory 
products and CART-IR was observed. Information regarding secretory or non-secretory 
status of cases for this study was collected as a categorical variable. These results are 
interesting and further studies following retrieval of absolute pre-operative urine 
catecholamine levels from the clinical and pathology archives will further elucidate the 
significance of CART-IR in secretory and non-secretory 
phaeochromocytomas/paragangliomas. 
There was no association between CART-IR and the routinely used markers of poor 
prognosis; vascular invasion, capsular invasion or necrosis. Of note, although the above 
mentioned markers are used routinely, none of these are considered either sensitive or 
specific enough to reliably predict malignant behaviour (181). Malignant potential of a 
phaeochromocytoma/paragangliomas can only be reliably confirmed in the presence of 
metastases. Similarly the current work does not demonstrate a significant association between 
presence or absence of metastases/mortality and CART-IR. This is in contrast to circulating 
CART, which was, significantly higher in patients with metastatic/progressive 
phaeochromocytomas/paragangliomas.  
The current study was primarily designed to study the frequency and intensity of CART-IR in 
phaeochromocytoma/paragangliomas. Therefore a consecutive case TMA was built, using all 
available cases. Ninety percent of phaeochromocytomas and seventy percent of 
paragangliomas are benign/non-metastatic (182). Consistent with this reported incidence, the 
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majority of phaeochromocytoma/paragangliomas studied using TMAs were non-metastatic 
(88%). It is possible that any significant difference in CART-IR and Cg A-IR distribution 
was not detected due to the relatively small number of metastatic 
phaeochromocytoma/paragangliomas in the current study. A further larger study using 
progression or outcome based TMAs with comparable numbers of metastatic and non-
metastatic phaeochromocytoma/paragangliomas will enable more robust analysis of the 
association between CART-IR and prognosis.  
CART peptide is widely expressed in almost all types of pancreatic islet cells in rodent, 
porcine, bovine and human foetal pancreatic tissue (54). However, this expression declines 
rapidly post-partum and is virtually absent in all but a few scattered delta cells in the adult 
rodent pancreas (54). Although published literature describing CART peptide expression in 
the adult human pancreas is scarce, CART may be absent in the adult human pancreas (54). 
The results of my studies are consistent with this report, in that no CART-IR was detected in 
adult human pancreatic islet cells.  
It is interesting that circulating CART levels are increased in progressive and metastatic 
pancreatic NENs in the absence of CART-IR in normal pancreatic islets. A number of 
routinely used cancer biomarkers are onco-foetal proteins. These are expressed in neoplastic 
and foetal tissues, but not in normal healthy adult tissues. For example, CEA and βHCG are 
expressed only in foetal tissues and increased in the adult colorectal and germ cell cancers 
respectively (183). Onco-foetal proteins usually have a significant role in promoting cell 
growth, survival and/or differentiation in foetal tissues. Higher expression of these proteins in 
neoplastic tissues is a surrogate marker for greater de-differentiation and hence poorer 
prognosis (183). Increased circulating levels of CART in progressive and metastatic 
pancreatic NENs and the absence of CART expression in normal pancreatic islets, suggests 
that CART may be an onco-foetal protein. 
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Consistent with this proposal, a previous study has described absence of CART peptide 
expression in normal adult pancreatic islets, yet presence in foetal pancreatic islets and in 
pancreatic NENs (172). Of the nine pancreatic NENs analysed in the current study, three 
showed strong CART-IR [> 100 cells per visual field (x 250)], three showed no CART-IR 
and a further three showed weak CART-IR expression [<10 cells per visual field (x 250)]. 
The numbers used in this study were small and therefore, the diagnostic, prognostic or 
functional significance of CART-IR in pancreatic NENs remains unclear. Contrary to results 
from this previous study (172), none of the pancreatic NENs in my study expressed strong 
CART-IR. Only 30% of NENs showed weak (CART-IR IHC score <100) cytoplasmic CART 
staining. No CART-IR was detected in pancreatic NEN tissue even from patients with known 
raised circulating CART levels.  
There are several possible reasons for absent/weak CART-IR in all pancreatic NENs and a 
proportion of phaeochromocytomas/paragangliomas. It is possible that the form of CART 
present in the pancreatic NENs is not recognised by the CART mouse monoclonal antibody 
used for the CART IHC study. Secondly, due to deregulation of secretory granule formation, 
NEN cells may become incapable of forming secretory granules and hence storing CART 
within them. This would result in any CART synthesised being secreted directly into the 
circulation, leaving little CART within the neuroendocrine cell to facilitate positive 
expression of CART-IR on IHC. 
CART-IR has been reported in pancreatic NENs within single cells or as small cell clusters 
randomly scattered within the tumour (172). Although at least three cores most representative 
of the tumour were included in the TMA from each NEN, CART-IR cells may have been 
absent in the areas chosen for the TMA.  Although this may explain lack of CART-IR in a 
proportion of NEN cores, it cannot account for the absent or weak staining in all cores from 
pancreatic NENs. Further, several studies comparing IHC scoring in conventional slides and 
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TMAs have reported good correlation between TMAs and conventional histology slides 
(175). There is evidence to suggest that a TMA with three or more cores of a tumour provides 
immunohistochemical data that is more representative of the whole tumour than a single 
conventional slide. Weak or scattered antigen staining on a conventional slide is more 
susceptible to over or underestimation (175).  
Since CART-IR was absent in pancreatic NEN tissue, despite the high circulating CART 
levels in patients with pancreatic NENs shown in the previous chapter, it is possible that 
raised circulating CART in these patients is derived from non-tumour sources (184). CART 
peptide expression has been demonstrated in the hypothalamus, pituitary and adrenals 
(54,164,166). CART may play a role in catecholamine and glucocorticoid synthesis and the 
metabolic stress response. Raised plasma CART may reflect stimulation of CART release 
secondary to HPA axis activation following tumour related metabolic stress. This may also 
explain the particularly high circulating CART levels in progressive pancreatic NENs despite 
absence of any evidence of CART-IR in these tumours.  
Although the intracellular location of CART-IR in previous studies is poorly documented 
(48), electron microscopic studies have localised CART to cytoplasmic secretory granules 
(48). Consistent with this, all phaeochromocytomas/paragangliomas and the majority of 
pancreatic NENs which expressed CART-IR, demonstrated CART localised to the 
cytoplasm. However, tissue from one gastrinoma patient exhibited strong nuclear CART-IR 
staining. There are no current reports of nuclear expression of CART-IR. It is not possible to 
draw any conclusions based on a single tissue sample exhibiting nuclear CART-IR. This 
nuclear staining may be an artefact due to non-specific IR in a16 year old formalin fixed 
paraffin block of tissue or may reflect cross-reactivity of another peptide with the CART 
antibody used for IHC. Further histological and IHC analysis of this sample may yield more 
information. 
191 
 
With 70% of pancreatic NENs having undetectable CART-IR, CART is unlikely to be a good 
diagnostic IHC marker for pancreatic NENs. In contrast, consistent with its role as the current 
gold standard NEN IHC diagnostic marker, Cg A was expressed in most pancreatic NEN 
tissues. However, there was no significant association between frequency and intensity of Cg 
A-IR and other established prognostic factors such as grade of tumour, presence or absence 
of metastasis or mortality.  
In conclusion, the results of the work in this chapter suggest that a significant proportion of 
phaeochromocytomas/paragangliomas show decreased CART-IR, and chromaffin tissue with 
CART-IR < 200 is more likely to be neoplastic. A significantly larger proportion of secretory 
compared to non-secretory phaeochromocytomas/paragangliomas exhibit strong CART-IR. A 
further study using an outcome or progression based TMA is needed to evaluate the 
significance of absent CART-IR in patients with phaeochromocytomas. In contrast, CART-
IR is virtually absent from pancreatic NENs and hence is not a useful IHC marker for these 
tumours. 
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Chapter 6 : Final Discussion 
The incidence of NENs has trebled in the last three decades, largely as a result of improved 
diagnostic modalities. Despite this, although the five year survival in early localised disease 
is above 90%, five year survival rates in metastatic disease have shown very little 
improvement in the last three decades. These statistics highlight the importance of early NEN 
diagnosis.  This work focuses on assessing the utility of established and novel NEN 
biomarkers.  
Cg A is the best available NEN biomarker. However, lack of standardisation between Cg A 
assays, makes direct comparison between them difficult. My work comparing the diagnostic 
accuracy of four commonly used Cg A assays showed no significant difference in diagnostic 
accuracy between these assays for investigating NEN patients. Any reported differences in 
sensitivities and specificities between the assays are likely to be secondary to choice of 
diagnostic cut-offs. These results highlight the need for consensus regarding desirable 
sensitivities and specificities. Furthermore, these findings also question the validity of 
interpreting results in terms of a single diagnostic cut-off point. A low cut-off designed to be 
very sensitive is likely to increase the number of false positives. In contrast, a cut-off placed 
high will decrease the number of false positives but is likely to result in a rise in false 
negatives. Sensitivity and specificity relate to a single pre-determined Cg A level (the chosen 
diagnostic cut-off). They do not make a distinction between a patient with Cg A levels just 
above this diagnostic cut-off and a patient with Cg A levels several times the upper limit of 
reference range. An alternative method of reporting is to express these results as likelihood 
ratios. This describes the likelihood that a given concentration of Cg A would occur in a 
patient with a NEN when compared to the likelihood of the same result being found in an 
individual without a NEN. Thus, likelihood ratios can be determined specifically for the 
patient’s Cg A level (185), giving the clinician a better indication of an individual patient’s 
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risk of having a NEN. This could then be interpreted in the context of the clinical index of 
suspicion (pre-test likelihood) for NEN and used to estimate the overall likelihood of a 
diagnosis of NEN for that particular patient (185).  
The other issue highlighted by my Cg A study was the variable concordance between the 
commonly available assays. This is not surprising as all the Cg A assays use antibodies raised 
to different epitopes. Post translational processing is often impaired in NENs, resulting in 
many different forms of Cg A in circulation. The concentration of Cg A detected by 
individual assays in a particular patient depends on the circulating forms of Cg A and the 
epitopes recognised by that assay. This problem is not specific to Cg A. In fact these 
limitations in determining the circulating antigen concentrations extend to most peptide 
tumour markers including calcitonin. In an attempt to improve concordance between 
calcitonin assays, the National Association of Clinical Biochemists (NACB, USA) 
recommended that assays for diagnosis of MTC only use antibodies specific for the mature 
form of calcitonin (139). This is contrary to NACB’s recommendation to use a combination 
of antibodies to detect as many of the clinically relevant forms of peptide marker as possible, 
such as in cancers like prostate cancer and gestational trophoblastic tumours (139). I have 
demonstrated that a combination of discordant Cg A assays improves diagnostic accuracy by 
detecting a larger number of patients with NENs. This provides further evidence for using an 
antibody combination to detect as many clinically significant Cg A epitopes as possible.  
Establishment of laboratory specific reference limits for assays allows a better assessment of 
the utility of the assays in the local clinical setting. This is supported by my work comparing 
Cg A assays. Decision limits suggested by the manufacturers for several Cg A assays 
evaluated fell at very different percentile positions and would not have necessarily provided 
the sensitivity and specificity desired by local clinicians. Establishing reference ranges locally 
allows the use decision limits that set according to local preferences and will thus enable 
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better interpretation of results. However, using different decision limits may pose difficulties 
when comparing biomarker levels in multi-centre studies. Expressing the results as multiples 
of the upper reference limit, 95
th
 percentile of reference population, may help standardise 
reporting and allow comparison of biomarker levels on patients from different centres. 
Despite most current calcitonin assays now using antibodies specifically directed against 
mature calcitonin, the assays are not equivalent and not directly comparable.  Matrix effects 
and differences in antibody affinity and avidity may account for the differences between the 
available calcitonin assays. This was highlighted in my study of the DiaSorin
®
 calcitonin 
assay, where, despite standardisation of antisera specificities and the use of a standardised 
calibrant, diagnostic cut-offs from the Nichols
®
 assays could not be extrapolated to the 
calcitonin assay.  Development of more specific antibodies, higher order international 
calibrants and reference standards that behave analytically in the same way as patient 
samples, may improve comparability between assays.  
CART is a novel NEN biomarker and my work has demonstrated that circulating CART 
levels were higher in pancreatic NENs and phaeochromocytomas/paragangliomas with 
progressive disease. CART was a better marker of disease progression than any of the 
existing NEN biomarkers. Serial CART measurements in all pancreatic NENs patients who 
died within 12 months of follow-up showed a significant rise in CART levels before death. 
This suggests that CART may be a particularly useful prognostic marker in patients with 
pancreatic NENs. It was on the basis of these results that CART has now been introduced as a 
NEN biomarker into routine clinical practice at the ICHNT Gut hormone SAS laboratory. It 
will be interesting to perform further long-term longitudinal studies to assess the prognostic 
significance of a raised plasma CART level at diagnosis in patients diagnosed with pancreatic 
NENs. Patients with phaeochromocytomas/paragangliomas who had raised plasma CART 
levels at diagnosis, showed a fall in levels to below the diagnostic cut-off after complete 
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excision of the tumours. Further long-term follow-up of these patients looking at changes in 
plasma CART levels in those with recurrent disease will be useful to assess the utility of 
CART as a surveillance marker in phaeochromocytomas/paragangliomas patients. A single 
plasma biomarker detecting recurrence will be particularly useful in this cohort of patients as 
currently the only alternative available for biochemical diagnosis are urine catecholamine and 
metanephrine measurements. Currently, these require 24 hour urine collections that are often 
inconvenient for the patients.  
While CART peptide expression has been reported in a number of foetal pancreatic 
neuroendocrine tissues and in some neuroendocrine tumour tissues, no CART peptide 
expression has been found in adult pancreatic neuroendocrine cells (54). The higher 
circulating CART levels in progressive tumours in my study raised the possibility of onco-
foetal expression of CART, with the more de-differentiated aggressive pancreatic NENs 
showing increased CART peptide expression. However, my IHC work did not demonstrate 
any significant CART expression in pancreatic NENs. This discordance between high 
circulating CART and absent CART tissue expression in pancreatic NENs may reflect direct 
secretion of CART into circulation soon after synthesis due to defective secretory granule 
formation and storage (153). However, both CART and Cg A are stored within the secretory 
granules and the pancreatic tumours which were negative for CART-IR were positive for Cg 
A-IR. It is possible that the CART and Cg A have different intra-cellular locations and are 
processed differently. Further electron microscopy studies to define the exact intra-cellular 
location of CART would help to elucidate this. Another explanation could be that the form of 
CART peptide expressed in the pancreatic NENs is not recognised by the monoclonal 
antibody used in IHC studies of CART peptide expression but is recognised by the polyclonal 
antibody used to detect circulating CART. Further studies using a different antibody could 
elucidate this further.  
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In direct contrast to pancreatic NENs, both normal adrenal medulla and 
phaeochromocytoma/paraganglioma tissue showed significant CART peptide expression. 
While there was no significant difference in CART expression between benign and malignant 
tumours, functional tumours showed significantly higher CART peptide expression, but not 
Cg A peptide expression, when compared to non-functional tumours. Interestingly, previous 
studies of CART and Cg A peptide expression suggested that both Cg A and CART may be 
expressed in different populations of adrenal medullary cells (167,180). This may explain the 
observed differences in prognostic significance between these two peptides in my studies. 
Future studies to identify the specific cell types within the adrenal medulla expressing CART 
peptide will be help to further evaluate the role of CART as 
phaeochromocytoma/paraganglioma biomarker, and to characterise its function within 
normal adrenal medulla.  
The work described in this thesis highlights the limitations of the currently available NEN 
biomarkers and evaluates the role of CART, a novel prognostic NEN biomarker. None of the 
currently available NEN biomarkers including CART are sufficiently sensitive or specific to 
be used as a single biomarker. A number of conditions other than NENs can cause elevations 
in circulating levels of NEN biomarkers. This was highlighted by my study which showed 
increased circulating concentrations of biomarkers in patients with renal impairment despite 
there being no evidence for the presence of a NEN. Circulating concentrations of biomarkers 
are not all equally affected by non-NEN causes. Renal impairment had a greater impact on 
Cg A than on CART or Cg B levels. Therefore using a panel of biomarkers significantly 
improves diagnostic and prognostic accuracy, both in terms of specificity and sensitivity and 
this may be the best future approach for the diagnosis and surveillance of these tumours. 
However, a thorough understanding of the strengths and limitations of individual biomarker 
assays is paramount for accurate and clinically relevant interpretation of results.  
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Appendix I – RIAs used in the thesis 
 
GENERAL PRINCIPLE OF A COMPETETIVE RADIOIMMUNOASSAY 
The specificity and affinity of antibodies for specific antigens along with the ability of 
antibodies to form cross-links with antigens enables the identification and quantification of 
specific antigens using immunoassays. In a typical immunoassay an antibody is used as a 
reagent to detect an analyte (antigen) of interest. In a competitive immunoassay, labelled 
antigen (added to the reaction mixture as reagent) and unlabelled antigen (native to the 
sample being analysed) compete for binding to the antibody. The technique assumes that the 
antibody binds to the labelled and unlabelled antigens with equal avidity and hence the 
probability of the antibody binding to the labelled antigen is inversely proportional to the 
concentration of the native unlabelled antigen in the sample. A fixed amount of labelled 
antigen and antibody are added to each sample to be analysed.  The greater the concentration 
of native unlabelled antigen in a sample, the fewer the antibody binding sites are available for 
binding of unlabelled antigen. Bound and unbound antigens are separated after appropriate 
incubation.  The radioactivity of both fractions is then measured in a gamma counter. 
Unlabelled antigens of known concentrations (standards) are used to construct a standard 
curve. The concentration of the unlabelled antigen in the sample is then extrapolated from the 
standard curve. 
 A competitive RIA is a competitive immunoassay where the antigen is labelled with a 
radioactive substance, most commonly 
125
I.  Both poly and monoclonal antibodies may be 
used. Polyclonal antibodies are usually obtained by immunising rabbits with antigen in the 
presence of adjuvant.  However, polyclonal antibodies derived from species other than rabbit 
may sometimes be used.  All RIAs described in this thesis use antibodies polyclonal raised in 
rabbits. It is essential that the assays are performed under optimal conditions in terms of 
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buffer, volume, antibody titre, incubation time, incubation temperature and separation 
method.  There are several methods by which the bound and unbound fractions of the 
antigens can be separated. The most widely used methods are precipitation and adsorption. In 
the adsorption method, the unbound fractions are adsorbed onto activated or dextran coated 
charcoal suspension (Cg B and CART assays). The dextran in the charcoal suspension blocks 
the larger holes in the porous charcoal.  The suspension is then added to the reaction mixture, 
where it traps both labelled and unlabelled free antigen.  After centrifugation, the carbon 
pellet, containing free antigen, and the supernatant, containing bound antigen-antibody 
complex, are separated by aspiration with a Pasteur pipette.  An alternative to adsorption is 
precipitation of the bound fraction by adding a second precipitating antibody (Cg A assay). If 
the primary antibody is a rabbit antibody, the precipitating antibody would be an anti-rabbit 
antibody raised in an animal of another species (e.g. sheep, goat).  In contrast to charcoal 
adsorption, this method results in the bound antigen-antibody complex being trapped within 
the pellet, with the unbound antigen remaining in the supernatant.   
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Tube Tube contents Description 
 Buffer Label Antibody  
Blank    for assessing non-specific binding of 
label 
½×  half 
concentration 
 for assessing whether greater sensitivity 
could have been achieved with a lower 
concentration of label 
2×  double 
concentration 
 for assessing the sensitivity of the assay 
to the amount of label added, and for 
calculating specific activity of label 
Zero    placed at regular intervals throughout 
the assay, for assessing baseline drift 
Excess   in excess for assessing the immunological 
integrity of the label 
Table A1:  Details of tubes for evaluation of RIA performance.  Ticks and crosses 
indicate the presence or absence, respectively, of that component of the assay.   
In addition to the tubes listed in table A1, aliquots of quality control (QC) samples are run to 
allow comparison between assays.  QC is essential in RIA (Sarson, 1982).  A number of 
tubes are therefore included in each assay to evaluate internal performance and to allow 
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between-assay comparison.  These are detailed in table A1. QCs for the RIAs described in 
this thesis were prepared by using charcoal adsorption to remove endogenous hormone from 
a large pool of plasma.  The hormone-stripped plasma was then spiked with known quantities 
of synthetic hormone and aliquoted for freezing at -80ºC.  Two or more QCs are prepared, 
with peptide concentrations spanning the range relevant to the assay, and an aliquot of each is 
included in every assay.    
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GENERAL PROCEDURE FOR LABELLING OF PEPTIDES 
Reagents were supplied by Sigma (Poole, UK) or VWR International (Lutterworth, UK).  
Except where stated, peptides were iodinated and purified by Professor Mohammad Ghatei 
(Department of Investigative Medicine, Imperial College London).  Labelled antigen was 
separated from free iodine and unlabelled antigen by High Pressure Liquid Chromatography 
(HPLC) using a C18 column (Waters, Massachusetts, USA).  The solvents were acetonitrile 
and water with 0.05% (v/v) trifluoroacetic acid (TFA).  Solvents were passed through 0.2 μm 
disc filters under vacuum prior to use.  HPLC was performed with a flow rate of 1 ml/min.  
The column was equilibrated with 15% (v/v) acetonitrile before addition of the iodinated 
reaction mixture.  The acetonitrile concentration was maintained at 15% for the first 10 
minutes, before being gradually increased to 45% over 90 minutes.  1.5 ml fractions were 
collected into a 1 ml solution of 20 mM HEPES, pH 11 (to neutralise the acidity of collected 
fractions resulting from TFA), with 0.3% bovine serum albumin (BSA) (First Link UK Ltd, 
Birmingham, UK), before testing by RIA.   
GENERAL ASSAY PROTOCOL 
The general structure of assays is shown in table A2.  Except where indicated, the standard 
curve for each assay was prepared with synthetic peptide made up to varying concentrations 
in assay buffer and added in duplicate at volumes of 1, 2, 3, 5, 10, 15, 20, 30, 50 and 100 μl. 
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Tube number Designation 
1 – 2 Blank 
3 – 4 ½× 
5 – 6 2× 
7 – 8 Zero 
9 – 10 Zero 
11 – 12 Standard 1 μl 
13 – 14 Standard 2 μl 
15 – 16 Standard 3 μl 
17 – 18 Standard 5 μl 
19 – 20 Standard 10 μl 
21 – 22 Standard 15 μl 
23 – 24 Standard 20 μl 
25 – 26 Standard 30 μl 
27 – 28 Standard 50 μl 
29 – 30 Standard 100 μl 
31 – 32 Zero 
33 – 34 QC low 
35 – 36 QC medium 
37 – 38 QC high 
39 – 40 Zero 
41 – … Samples 
Every 50 samples Two zeroes 
Every 400 samples and at end Standard curve as above 
Final 2 tubes Excess 
 
Table A2:  General structure of a manual competitive Cg A, CART and Cg B RIA.    
½× = half concentration; 2× = double concentration. 
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SEPARATION AND COUNTING OF ASSAYS 
For assays requiring charcoal adsorption, 500 μl chilled (4°C) charcoal/dextran suspension 
was added to each tube.  Immediately afterwards, the tubes were centrifuged at 1500 g for 20 
minutes at 4°C.   Separation of supernatant from pellet was performed immediately after 
centrifugation, by aspiration using a Pasteur pipette.   
For assays requiring immunoprecipitation (Cg A assay), 100 μl sheep anti-rabbit secondary 
antibody (Pharmacia Diagnostics, Uppsala, Sweden) was added to each tube. Following a 
30–60 minute incubation at room temperature, 500 μl of 0.01 % Triton-X-100 solution 
(Sigma, Poole, UK) was added.  Immediately afterwards, the samples were centrifuged at 
1500 g for 20 minutes at 4°C.  Separation of supernatant from pellet was performed 
immediately after centrifugation, by aspiration using a Pasteur pipette.   
After separation by either method, the tubes containing supernatant were sealed by addition 
of a small quantity of low melting-point (45°C) wax (SER Wax Industry, Turin, Italy), to 
prevent radioactive contamination of equipment.  Counting of radioactivity in the supernatant 
and pellet was with four 16-well gamma counters (Nuclear Enterprises Technology, 
Edinburgh, UK) linked to a computer for automated data collection.  A non-linear plot was 
used for construction of the standard curve and calculation of sample peptide concentrations 
(RIA software, Nuclear Enterprises Technology, Edinburgh, UK).   
CHROMOGRANIN A (SAS) ASSAY PROTOCOL 
The SAS assay is a competitive radioimmunoassay utilising polyclonal antisera raised against 
porcine pancreastatin amide (Peninsula, CA, USA), which is a 49-amino acid fragment 
produced by dibasic cleavage of the Cg A peptide{{245 Bech,P. 2008; }}. It had full cross 
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reactivity with human pancreastatin {{454 Sekiya,K. 1988; }}. The antiserum was used at a 
final dilution of 1:79000.  
Plasma volume of 100 μl was used and all tubes were buffered to a total volume of 700 μl in 
0.06M phosphate buffer with 0.3% BSA and 0.02% Tween-20. The top standard was made at 
a concentration of 1pmol/ml (1 pmol of synthetic pancreastatin was dissolved in 1 ml of 
buffer). The range of the assay was 1 - 1000 pmol/L 
One hundred ml of time expired plasma (First link UK Ltd) was seeded with 40 pmol, 
15pmol/L and 5 pmol/L of synthetic pancreastatin (1 – 49) to get high, medium and low QCs 
with an approximate concentration of 500 pmol/L, 200 pmol/L and 60 pmol/L. The inter 
assay variation for high, medium and low QCs were 10%, 8.6% and 8.1% respectively. 
CART ASSAY PROTOCOL 
Concentrations of CART in plasma were measured by specific and sensitive RIA (Stanley et 
al, 2004).  
125
I-labelled CART55-102 was prepared by the iodogen method (Wood et al, 1981) 
and purified by HPLC.  The antiserum was raised in a rabbit by immunisation with CART55-
102 conjugated to BSA by glutaraldehyde and detects CART fully but does not cross-react 
with other known neuropeptides (Stanley et al, 2004).  Plasma volume of 100 μl was used 
and all tubes were buffered to a total volume of 700 μl in 0.06M phosphate buffer with 0.3% 
BSA and 0.02% Tween-20.  A standard concentration of 1 pmol/ml was used and the 
antiserum was used at a final dilution of 1:80000.  The assay was incubated for three days at 
4°C before separation by charcoal adsorption.  One hundred ml of time expired plasma (First 
link UK Ltd) was seeded with 40 pmol, 15pmol/L and 5 pmol/L of synthetic CART (55 – 
102) to get high, medium and low QCs with an approximate concentration of 500 pmol/L, 
200 pmol/L and 60 pmol/L. The inter assay variation for high, medium and low QCs were 5 
% ± 1.1, 7 % ± 1.4 and 8 % ± 2% respectively. 
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SOLUTIONS FOR RIA 
0.06M Phosphate buffer 
Boil 5 litres distilled water, allow to cool, then add Na2HPO4.2H2O (48.0 g), KH2HPO4 (4.13 
g), Ethylenediaminetetraacetic acid (EDTA) (18.61 g) NaN3 (2.50 g), then adjust pH to 7.4 
with concentrated NaOH added drop wise.   
0.06M Phosphate buffer with gel 
Prepared as for 0.06M Phosphate buffer, as above, except that 12.5 g gelatine is added to the 
distilled water prior to cooling.   
Dextran-coated charcoal 
To each 100 ml assay buffer, add 2.4 g Norit OL activated charcoal (Hopkin and Williams, 
Chadwell Heath, Essex, UK) and 0.24 g clinical grade dextran of average molecular weight 
70 kDa (Sigma, St. Louis, Montana USA).   
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Appendix II: Production of CART monoclonal antibody for IHC 
 
MOUSE MONOCLONAL ANTI-CART (55 – 102) ANTIBODY 
The mouse monoclonal anti-CART antibody was produced in house by Dr Sarah Darch. 
Balb/c mice were immunised with Rat CART peptide (55–102) conjugated to BSA via 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide. Spleen cells from a CART antibody positive 
mouse were fused with Sp2/o-Ag14 myeloma cell line. Supernatants from the resulting 
hybridoma lines were screened in a RIA by using 
125
I CART (55–102). Positive hybridoma 
lines were cloned by limiting dilution.  
The monoclonal antibody (from clone CART G3 G1 A9 F8 H12) was purified using Hitrap 
protein G affinity chromatography. Purified IgG was dialysed in Sodium Bicarbonate pH8.0 
and concentrated by ultracentrifugation to 1mg/ml and stored at -20
o
C. 
The mouse monoclonal antibody is immunoglobulin G class and subclass 1, light chain kappa 
(IgG1κ) (using isotype analysis).  
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Neuroendocrine neoplasia (NEN) account for 2% of all malignancies (1). Patients with NEN 
often present with non-specific symptoms, and thus represent a major diagnostic challenge. 
There are several circulating NEN biomarkers. Chromogranin A (Cg A) is regarded as the 
gold standard (2). Chromogranin B (CgB) has been found to be a useful diagnostic addition 
to Cg A measurements (3). The peptide product of cocaine- and amphetamine-regulated 
transcript (CART) is also increased in patients with NENs, particularly pancreatic NENs (4).  
Renal impairment or failure can increase circulating concentrations of Cg A (2) and CART 
(4). However,  CgB may be unaffected by mild renal impairment and is only increased in 
severe renal failure (3). The population most likely to be affected by NEN are also 
susceptible to renal impairment; chronic kidney disease (CKD) occurs in approximately 10% 
of the population aged 50–60 and the mean age of patients diagnosed with a NEN is 61 years 
(1;5). We therefore examined the effect of varying degrees of renal impairment/failure on 
plasma concentrations of Cg A, CgB and CART in patients without NEN.  
Ethical approval was obtained from the Hammersmith and Queen Charlotte's & Chelsea 
Hospitals Research Ethics Committee (04/Q0406/80). Following informed consent, five ml of 
blood was collected from forty healthy volunteers. In addition, samples from 107 patients 
with different stages of renal impairment were obtained and irreversibly annonymized as per 
Royal College of Pathology, UK guidelines (D035, Sept 2007).  All samples were collected 
in an EDTA tube, spun within 15 minutes of collection at 10,000g for 10 minutes. Plasma 
was then stored at -20ºC until analysis. Cg A, CgB and CART concentrations were measured 
using an in-house radioimmunoassay (4)  at the National Gut Hormone Specialist Assay and 
Advisory Laboratory, ICHNT, UK.  
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The data was analysed by Kruskal-Wallis one-way ANOVA using Dunn’s multiple 
comparison test to examine for significant differences between healthy volunteers and 
different CKD stages (Figure 1).  
Median (range) concentrations for the healthy control group were: Cg A-immunoreactivity 
(IR) =29pmol/L (22-47), CgB-IR =70pmol/L (55-111), and CART-IR =56pmol/L (22-84). 
Patients were divided into CKD stage groups using their eGFR value: ≥60ml/min/1.73m2 
(stages I and II, n=17), 45-59 (stage IIIA, n=19), 30-44 (stage IIIB, n=22), 15-29 (stage IV, 
n=20), and <15 (stage V, n=29). For all three biomarkers, concentrations increased with 
decreasing eGFR, with highest median concentrations detected in patients with eGFR <15 
(Figure 1).  
Forty percent of patients with eGFR ≥60 had increased Cg A-IR, a percentage that rose to 
100% with an eGFR of less than 29. The highest plasma concentration of Cg A-IR measured 
was 489pmol/L (normal range <60pmol/L).   
CgB-IR concentrations were less affected by renal function than Cg A-IR concentrations. 
With eGFR values between 29-16, only 16% of patients had increased concentrations, which 
rose to 84% of patients with eGFR of <15.  The highest concentration of CgB-IR measured 
was 232pmol/L (normal range <150pmol/L).  
Plasma CART-IR concentrations were normal in patients with eGFR ≥60, but were increased 
in 80% of patients with eGFR of <15. The highest concentration of CART-IR measured was 
494pmol/L (normal range <125pmol/L).  
The accuracy of GFR estimation decreases at near-normal levels of kidney function. Hence, 
consistent with common practice, eGFR is reported as ≥60ml/ min1.73m2 in our laboratory. 
As a result, eGFR cannot be used to make a distinction between individuals with normal renal 
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function and those with CKD stages I and II. Therefore, the eGFR ≥60ml group in our study 
included patients with mild renal impairment (CKD stages I and II). While there was no 
significant difference in CgB-IR (P=0.701) and CART-IR (P=0.858), Cg A-IR was 
significantly increased (P=0.0358) in patients in the eGFR ≥60ml compared to healthy 
volunteers. These results are interesting because they suggest that while all three peptides are 
affected to varying degrees by renal failure, Cg A-IR may rise even with mild renal 
impairment (eGFR ≥60ml). Thus, CgB-IR may be a more reliable marker than Cg A-IR in 
patients with mild renal impairment (eGFR>45).    CgB is larger than both Cg A and CART 
and therefore may not be as dependent on glomerular filtration, which may explain the fewer 
increased concentrations of CgB-IR in patients with renal disease. 
Interestingly, no patients with renal failure had Cg A-IR or CART-IR concentrations above 
500pmol/L or CgB-IR concentrations above 250pmol/L. Therefore, at these higher cut-offs, 
although the diagnostic sensitivity of these NEN markers is low (Cg A-IR 20% at 500 
pmol/L; CART-IR 17% at 500pmol/L; CgB-IR 12% at 250pmol/L), the diagnostic specificity 
for NEN diagnosis is very high (100% for all three biomarkers) and patients with 
concentrations above these cut-offs must be investigated for NENs, even in the presence of 
renal failure.  Our results indicate the need for additional studies to determine the diagnostic 
cut-offs with optimal sensitivity and specificity for the neuroendocrine biomarkers to enable 
NEN diagnosis in renally impaired patients.  
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Figure 1: Plasma levels of chromogranin A (Cg A-IR), chromogranin B (CgB-IR) and CART 
(CART-IR) increase with decreasing estimated glomerular filtrate (eGFR).  
Anonymized patient samples (107) were categorized according to their eGFR ml/min/1.73m2 
value: 90-60 (CKD stage 1+II, n=17), 45-59 (CKD stage IIIA, n=19), 30-44 (CKD stage IIIB, n=22), 
15-29 (CKD stage IV, n=20), <15 (CKD stage V, n=29), control indicates healthy subject group 
(n=40). A one-way ANOVA with Dun’s post test compares CKD stage groups against healthy 
volunteers for each biomarker; ns=not significant (P>0.05); *= P<0.05; ***= P<0.001. Dashed line 
indicates normal upper limit for each biomarker. 
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